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Abstract 
Ankylosing Spondylitis (AS) is a chronic inflammatory disorder of the spine which 
leads to progressive spinal fusion and deformity. With improvements in MRI, this 
condition is now being recognized earlier. The treatment of this condition so far is 
limited to physiotherapy, NSAIDs and anti-TNF therapy. The assessment of response 
to therapy is largely subjective using clinical outcome measures such as the Bath 
Ankylosing Spondylitis disease activity index (BASDAI). This thesis describes the 
search for an objective measure of response to therapy in AS. It does so by studying 
two separate patient cohorts- one receiving anti-TNF therapy and the other receiving a 
novel oral phosphodiesterase-4 inhibitor, apremilast, in a clinical trial setting.  In 
addition to various clinical outcome measures and laboratory biomarkers, it also 
explores novel volumetric analysis of bone oedema lesions on MRI and its correlation 
to clinical indices. The results of this study indicate that apremilast improves clinical 
indices of response in AS and also modulates bone biomarkers. However, it may do 
so differently to anti-TNF agents with plasma sclerostin and RANKL: OPG possibly 
playing important roles in its mechanism of action. This study highlights the fact that 
different laboratory biomarkers may be modulated differently by different drugs. The 
novel volumetric analysis developed using Dynamika software showed promise with 
good correlation to established methods of scoring scans such as Berlin scoring. In 
particular, a novel biomarker, the product of the volume of the lesion and its intensity 
correlated well with changes in BASDAI in the anti-TNF cohort. However, there are a 
number of issues, notably inter-observer variability as well as time required to carry 
out the analysis, that need to be resolved. This could be done by developing 
automated regions of interest using this software on the basis of intensity of the 
lesions, hence providing an objective measure of response to therapy in AS.  
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1.1 Ankylosing Spondylitis: Clinical features and diagnosis 
Ankylosing Spondylitis (AS) is a chronic inflammatory arthritis affecting the spine 
and sacroiliac joints. It has a prevalence of 0.1-0.5% world wide and affects young 
men more than women, presenting in their teens and early twenties leading to bony 
ankylosis of the spine. It is also known as Bechterew and Marie-Strumpell disease, 
after the clinicians who first described it in the 1890’s. 
 
AS was initially diagnosed only after patients developed the classical posture of 
exaggerated thoracic kyphosis and loss of lumbar lordosis associated with this 
condition. With the introduction of X-rays, the importance of radiographic sacroiliitis 
as a hallmark of AS was recognized. It became the basis of the modified New York 
criteria (1984) [1], which are still widely used today. According to these criteria, a 
patient is considered to have AS only if the patient has radiographic sacroiliitis in the 
presence of other clinical features such as inflammatory back pain, limitation of 
movement of the lumbar spine in both sagittal and frontal planes and limitation of 
chest expansion.  
 
Radiological sacroiliitis may not be evident early on in the disease leading to a delay 
of many years between the onset of symptoms and the diagnosis of AS [2]. Magnetic 
Resonance Imaging (MRI) helps in early diagnosis of AS by detecting bone oedema 
prior to any radiographic changes. MRI changes have now been included in the more 
recent Assessment of Spondyloarthritis international Society (ASAS) classification 
criteria [3].  
 
Ankylosing Spondylitis (AS) is thought to affect the cartilage/bone interface including 
the sites of insertion of tendons and ligaments to bone (enthesis). The disease tends to 
wax and wane with periods of flares characterized by increased pain and stiffness, 
followed by periods of remission. Uncontrolled disease progresses to ankylosis 
particularly of sacroiliac joints and spine. Involvement of the vertebral bodies leads to 
syndesmophyte formation, squaring and fusion of vertebrae. Spinal ankylosis which 
presents on X-rays as bamboo-spine appearance, leads to loss of spinal mobility and 
 18 
progressive thoracic kyphosis. Involvement of the costovertebral joints leads initially 
to chest pain and later to restriction of chest expansion. 
 
Peripheral arthritis and enthesitis is seen in 40-60% of AS patients. Commonly 
involved sites include the Achilles insertion, plantar fascia insertion and insertion of 
the patellar tendon. AS is associated with other HLA B27 related conditions. These 
include Psoriasis, Crohn’s disease, Ulcerative Colitis and uveitis. Amyloidosis may be 
a rare systemic complication in long standing disease. 
 
1.2 Pathogenesis of Ankylosing Spondylitis 
 
Genetic factors play a major role in susceptibility to AS [4]. HLA-B27, an allele of 
the HLA-B locus in the class I region of human major histocompatability complex 
(MHC), is thought to play a central role in disease pathogenesis. Although the exact 
pathogenesis is still not clear, a number of theories exist (Fig 1). 
 
The HLA-B27 complex has 3 components. The HLA heavy chain is associated with a 
light chain (β2 microglobulin) and a short peptide called the antigenic peptide. These 
antigenic peptides are generated in the cytosol but are trimmed further by amino 
peptidases in the endoplasmic reticulum. One such peptidase is encoded by 
endoplasmic reticulum aminopeptidase 1 (ERAP1), the gene for which has been 
found to be associated with AS [5-7]. A defective ERAP1 may cause a slower rate of 
folding of the HLA molecules. This may trigger an intracellular signalling response 
known as the unfolded protein response (UPR) [8]. UPR in macrophages may lead to 
generation of IL-23 which in turn can activate Th17 lymphocytes that produce the 
pro-inflammatory cytokine, IL-17 [9]. This theory is known as the UPR hypothesis. 
 
An older theory is the molecular mimicry hypothesis. HLA class I complexes engage 
the T-cell receptors (TCRs) of CD8+ T lymphocytes. This interaction is required to 
develop immunity to viruses by developing TCRs specific for viral peptides carried 
on HLA molecules. Normally, tolerance to self-peptides exists. This may however, be 
lost if an infectious pathogen activates the immune system through a peptide that 
mimics the self-peptide. 
 19 
 
When HLA B27 molecules reach the cell surface, the β2 microglobulin dissociates 
from the HLA heavy chain resulting in a free heavy chain. In this hypothesis, free 
chain homodimers engage killer cell immunoglobulin like receptors (KIRs) on natural 
killer (NK) cells and T lymphocytes leading to their activation. This is called the free 
heavy chain hypothesis [10]. 
 
Activation of inflammatory cells leads to production of pro-inflammatory cytokines 
including TNF-α along with anti-inflammatory cytokines. However, an imbalance in 
favour of pro-inflammatory signals leads to inflammation and subsequently to bone 
destruction and erosion. This is mediated by osteoclasts that express bone destructive 
enzymes such as cathepsin K and matrix metalloproteinases (MMP) [11]. In contrast 
to RA, repair in AS is characterized by new bone formation in the form of 
syndesmophytes (in vertebrae) and enthesophytes (at entheses). The early stages of 
bone formation are controlled by bone morphogenic proteins (BMPs). This process is 
negatively controlled by endogenous inhibitors including noggin [12] secreted by 
chrondrocytes and sclerostin [13] secreted by osteocytes. The later stage of bone 
formation is controlled by the wingless (Wnt) family of glycoproteins [14], which 
activate receptors on mesenchymal cells leading to increased intracellular β catenin. 
This process is negatively regulated by endogenous suppressors such as Dickkopf-
related protein 1 (Dkk-1) [15]. 
 
Hence, the proposed pathogenesis of AS consists of a number of different inter-related 
processes. Each of these is controlled by different pathways and factors. It is still not 
clear how each pathway interacts with the others. Evidence that inflammation may be 
uncoupled from bone formation is demonstrated by achievement of adequate control 
of inflammation with anti-TNF agents whilst failing to influence new bone formation. 
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With permission from: Tam, L.-S. et al. (2010) Pathogenesis of ankylosing 
spondylitis. Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2010.79 [16] 
 
Fig1.1: The different HLA-B27 structures and hypotheses as to how they induce 
disease processes in Ankylosing Spondylitis. The figure shows the 3 different 
theories of pathogenesis in AS.  
 The unfolded protein response leading to production of IL-23 and hence 
activation of Th17 cells. 
 The accumulation of free heavy chains on dissociation of β2 microglobulin 
leading to engagement of killer cell immunoglobulin like receptors (KIRs) 
on NK cells and lymphocytes leading to their activation.  
 The molecular mimicry theory where an infectious pathogen mimics self-
peptides and leads to binding of T cell Receptor on CD8 T lymphocytes. 
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1.3 Treatment of Ankylosing Spondylitis and the role of anti-TNF 
agents 
 
Treatment for AS in the early 20
th
 century involved the use of gold and thorium X. 
Spinal irradiation was made popular by Gilbert Scott and Hernaman-Johnson in the 
UK in the 1930s, but led to aplastic anaemia and leukemias in later life[17]. With the 
introduction of non-steroidal anti-inflammatory drugs (NSAIDs) in the 1950s, these 
drugs became the mainstay of treatment in AS along with physiotherapy. Sustained 
consistent use of NSAIDs as against intermittent use has been shown to retard 
radiographic progression [18]. Similarly, a recent study comparing high intake of 
NSAIDs (NSAID index>50) was associated with a lower likelihood of radiographic 
progression over 2 years [19]. However, it is still unclear as to whether this should be 
recommended to all patients. Disease modifying anti-rheumatic drugs (DMARDs) 
such as methotrexate and sulfasalazine are ineffective in spinal disease but may be 
effective in patients with peripheral arthritis [20, 21]. 
  
With the advent of anti-TNF therapy, treatment in AS was revolutionized. Etanercept, 
infliximab, adalimumab and more recently golimumab have been licensed for use in 
patients with AS who have failed at least 2 NSAIDs and continue to have symptoms 
suggestive of active disease. Clinical trials have shown that 50-70% of AS patients 
treated with anti-TNF agents show a 50% improvement in disease activity scores [22-
24]. Also failure or intolerance of one agent resulting in switching to another has also 
been shown to be effective [25].  However, anti-TNF therapy has so far failed to show 
inhibition of radiographic ankylosis [26-28]. This has led to a search for further novel 
agents that could modify outcome in AS. Neither rituximab [29], an anti-CD20 
antibody nor tocilizumab [30], an anti-IL 6 receptor antibody, have shown any 
significant clinical improvement. However, data from a recently conducted study 
using a humanized IL-17 antibody, secukinumab [31], has shown a significant 
response to treatment both clinically and on MRI.   
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1.4 Apremilast- a novel oral anti-inflammatory agent in the treatment 
of AS  
 
Apremilast (Fig 2) is an oral phosphpodiesterase (PDE) 4 inhibitor. PDE4 is one of 
the major phosphodiesterases expressed in leukocytes, endothelial cells, smooth 
muscle cells and keratinocytes.  Inhibitors of PDE4 cause accumulation of 
intracellular cyclic adenosine monophosphate (cAMP), which in turn activates protein 
kinase A and other downstream effectors, resulting in inhibition of pro-inflammatory 
cytokine transcription and other pro-inflammatory cellular responses such as 
neutrophil degranulation, chemotaxis, and adhesion to endothelial cells. In addition to 
inhibition of pro-inflammatory mediators via the NFκB pathway, PDE4 inhibition up 
regulates anti-inflammatory mediators such as IL-10 and TGFβ through the cAMP 
response element-binding (CREB) transcription factor (Fig 3) [32-34]. 
                                            
Fig 1.2: Chemical structure of apremilast, (S)-N-(2-[1-(3-ethoxy-4-
methoxyphenyl)-2-methanesulphonylethyl]-1, 3-dioxo-2, 3-dihydro-1H-isoindol-
4-yl) acetamide 
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cAMP= cyclic adenosine monophosphate; CREB=cAMP response binding 
element; IFN=interferon; IL=interleukin; NF-B=nuclear factor kappa-B; 
PDE4=phosphodiesterase 4; PKA=protein kinase A; TGF=transforming growth 
factor; TNF-α=tumour necrosis factor-α 
 
Fig 1.3: Apremilast inhibits Phosphodiesterase 4 which is required for the 
breakdown of Cyclic AMP to AMP. This leads to accumulation of cAMP which 
in turn leads to activation of Protein Kinase A (PKA). PKA in turn causes 
suppression of pro-inflammatory mediators including TNFα, IL-17, IL-23 and 
IFN-γ through the NF-κB pathway. It also causes activation of anti-
inflammatory mediators such as IL-10 and TGF-β through the cyclic-AMP 
response element binding. 
 
A recently published study showed that Apremilast inhibits spontaneous release of 
TNF alpha from human rheumatoid synovial membrane cultures [35]. In addition, it 
also showed that Apremilast significantly suppressed arthritis in both the collagen 
induced and monoclonal Abs-induced arthritis models. 
 Apremilast has also been shown to inhibit TNF α, IL-2, IL-12 and IL-23 mRNA 
levels in peripheral blood mononuclear cells (PBMCs) from healthy human donors. 
These cytokines play an important role in psoriasis and spondyloarthropathies. The 
cAMP 
AMP 
PDE4 Apremilast 
Immune Cell 
NF-κB 
CREB 
PKA 
Inhibits Pro-
inflammatory 
mediators 
(i.e., TNFα, 
IL-17, IL-23, 
IFNγ 
Increases Anti-
inflammatory 
mediators 
i.e., IL-10, 
TGF-β 
 24 
same study showed a significant reduction in epidermal thickness and proliferation in 
the mouse model of psoriasis [36]. Apremilast has recently been shown to be effective 
in the treatment of psoriasis [37] as well as psoriatic arthritis [38] in phase II studies. 
Phase III studies for these conditions are now ongoing. Prior to the work described in 
this thesis, now published, there have been no clinical trials with the use of PDE4 
inhibitors in AS. 
 
1.5 Biomarkers of Response to therapy in Ankylosing Spondylitis 
 
An National Institutes  of Health study group defines a biomarker as: "a characteristic 
that is objectively measured and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention."[39]. 
 
Assessing outcome using biomarkers in AS is particularly challenging as symptoms 
reflect not just the underlying inflammatory processes but also mechanical factors 
such as spinal fusion. Acute phase reactants such as ESR and CRP are not reliable 
markers of inflammation in AS. Also the slow nature of ankylosis in AS, makes it 
difficult to assess disease modifying potential of any new therapies [40]. At present, 
clinical assessment of disease activity is mainly through patient reported 
questionnaires which are subjective. The only objective assessment of disease is 
through measurement of spinal movements. Imaging biomarkers such as MRI play an 
important role in diagnosis but are not used for routine patient monitoring. There are 
still no established laboratory biomarkers of disease activity or response to treatment. 
 
1.5.1 Clinical Outcome measures in AS 
Clinical outcomes can be divided into those that assess disease activity, patient 
function, mobility and health related quality of life. There are a number of different 
indices described for each. Some of the commonly used ones are discussed below. 
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1.5.1.1 Disease Activity   
 
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [Appendix 1] 
was devised in 1994 by a multidisciplinary team in Bath with patient input [41]. The 
index consists of 6 visual analogue scales that measure fatigue, spinal and peripheral 
joint pain, localized tenderness and morning stiffness. A total score is obtained and 
divided by 5 to obtain the final BASDAI score. A score of ≥ 4 on 2 separate occasions 
3 months apart along with a spinal pain visual analogue score of >4, would merit anti-
TNF therapy as recommended by the National Institute of Clinical Excellence 
(NICE). A response to treatment requires a drop in the BASDAI to at least 50% of 
pretreatment value or a fall by 2 units [42].  However, a study investigating the 
minimal change in BASDAI that was clinically relevant, quotes this as 10mm (=1) or 
a change of BASDAI by 22.5% [43].  
 
The BASDAI has been shown to be both valid [44] and reproducible [45]. However, 
studies have shown that BASDAI scores in mechanical back pain patients are similar 
to those with inflammatory pathology [46, 47], suggesting that the BASDAI also 
measures mechanical symptoms and stiffness due to spinal fusion [40].  
 
1.5.1.2 Patient Function 
 
The Bath Ankylosing Spondylitis Functional Index (BASFI) 
 [Appendix 2] [48] is a questionnaire that consists of 8 questions regarding patient 
function and 2 that assess the patient’s ability to cope with AS. Each question is 
answered on a horizontal visual analogue scale of 0-10 cms. The results are then 
totaled and divided by 10 to obtain a final score. The BASFI has been shown to co-
relate well with other functional indices such as the Dougados Functional Index (DFI) 
as well as with disease activity and radiological damage [49]. Both have also been 
shown to have a good test- re-test reliability [50]. Other indices to assess function 
include the Health assessment questionnaire- Spondyloarthropathy (HAQ-S) [51] and 
the Revised Leeds Disability Questionnaire (RLDQ) [52].  
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1.5.1.3 Bath Ankylosing Spondylitis- Global scale (BAS-G) 
 
The BAS-G [Appendix 3] was developed in 1996 as a measure of effect of AS on the 
patient’s well being [53]. This was measured on a horizontal visual analogue scale 
from 0-10cms with the patient marking how he/she felt over the last week and also 
over the last 6 months. This was shown to correlate best with BASDAI (r=0.73) 
followed by BASFI (r=0.54). However, this has been found to be less reliably 
reproducible than BASDAI or BASFI [45]. 
 
 
1.5.1.4 Mobility 
 
Mobility in AS reflects a combination of disease activity as well as structural damage. 
The Bath Ankylosing Spondylitis Metrology Index (BASMI) 
 [Appendix 4] is a combination of 5 measurements of spinal mobility that reflect axial 
disease [54]. These include cervical rotation, tragus to wall distance, lateral lumbar 
flexion, modified Schoeber’s and intermalleolar distance. All 5 measurements were 
then scored as 0, 1 and 2 using defined cut-offs. Each score is then added to give a 
total score of 0-10. However, this was found to be less sensitive to change and was 
later modified to allow a score range of 0-10 for each measure [55]. A further 
modification to this converts the actual measurements into a linear scale of 0-10 called 
the BASMI-Linear [Appendix 5]. A comparison of all three scales showed the 
BASMI-Linear demonstrated the best sensitivity to change [56]. 
 
A recent small study of 30 Danish patients assessing reproducibility of BASMI [0-10] 
by comparing results between a trained physiotherapist and an untrained nurse who 
underwent a one hour training session with the physiotherapist, found good intra-
observer as well as inter-observer agreement [57]. 
 
The other instrument to measure spinal mobility is the Edmonton AS mobility index 
(EDASMI) [58]. This comprises of four measures- cervical rotation, chest expansion, 
lateral lumbar flexion and internal rotation of the hip. This has been shown to have 
similar validity and reliability to the BASMI.  
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Studies examining response of different mobility measures to physiotherapy have 
shown improvements in cervical rotation, finger to floor distance, cervical forward 
flexion, chest expansion and thoraco-lumbar rotation. However, only cervical rotation 
and lateral lumbar flexion have consistently been shown to be different between 
treatment groups in phase II placebo controlled trials with anti-TNF agents [59]. 
 
1.5.1.5 Health related Quality of Life (QoL) in AS 
 
Studies have confirmed that fatigue is a major symptom in AS particularly in those 
with more severe disease [60, 61]. This can be measured by question no.1 on the 
BASDAI which pertains to fatigue. A study of 812 patients comparing the single item 
fatigue question on BASDAI to the Multi-dimensional Fatigue Inventory (MFI) 
showed that either could be used effectively to measure fatigue in AS. Fatigue was 
associated with level of disease activity, functional ability, global well-being and 
mental health status [62]. Fatigue has a negative impact on different aspects of quality 
of life. 
 
There are a number of instruments measuring quality of life including the Short Form-
36 (SF-36) Health Survey [63] or Short-Form-12 (SF-12) [64] and the Functional 
Assessment of Chronic Illness Therapy (FACIT) questionnaires. There are also a 
number of AS specific tools such as the AS-QoL [65], EuroQoL, Patient Generated 
Index ( PGI) [66] and EASi-QoL [67]. 
  
FACIT [Appendix 6] was developed from the existing questionnaire- Functional 
Assessment of Cancer Therapy- General (FACT-G) used to assess quality of life in 
cancer patients [68]. The questions are divided into four quality of life domains- 
physical, social, emotional and functional well being. It is self-administered either on 
paper or directly on the computer and has been validated as a tool in a number of 
different conditions including rheumatoid arthritis. Scores are calculated as a 
summation of the four individual components. Higher scores on FACIT-F indicate an 
improvement in quality of life. 
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1.5.1.6 Criteria for improvement in AS 
 
The Assessment of Spondyloarthritis international Society (ASAS) first described 
criteria for improvement in AS in 2001. These covered 4 domains- 
Patient global as assessed by BAS-G 
Pain as assessed by a visual analogue scale measuring spinal pain 
Function as assessed by BASFI 
Inflammation as assessed by the mean of BASDAI questions 5 and 6 
 
The ASAS 20 improvement criteria [69] were defined as an improvement of ≥20% 
and ≥1 unit in at least 3 domains on a scale of 10 without any worsening of ≥ 20% and 
≥1 unit in the remaining domain. The ASAS partial remission criterion is based on the 
same 4 domains and was defined as a value not above 2 units in each of the domains 
on a scale of 10. 
 
In 2004, ASAS described the ASAS 40 improvement criteria [70] which used the 
same 4 domains but was defined as an improvement of ≥40% and ≥2 units in at least 3 
domains on a scale of 10 without any worsening in the remaining domain. They also 
described the ASAS 5/6 criteria which took into account 2 additional domains- CRP 
and spinal mobility as measured by lateral spinal flexion. An improvement of ≥20% 
was required in at least 5 domains to meet these criteria. 
 
More recently, ASAS developed a new AS disease activity score [ASDAS] [71] 
similar to the disease activity score (DAS) described for rheumatoid arthritis. Two 
versions have been introduced, so that the ASDAS can be calculated using either CRP 
or ESR. These are as follows: 
 
ASDAS calculated using CRP: 0.121x back pain + 0.058x duration of morning 
stiffness+ 0.110 x patient’s global assessment + 0.073x peripheral 
pain/swelling+0.579x Log (CRP+1) [Preferred] 
(When CRP is lower than minimum value, then half of minimum value used for 
calculation purposes. Highly sensitive CRP to be used where available) 
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ASDAS calculated using ESR : 0.113 x patient global +0.293x square root of 
ESR+0.086 x peripheral pain/swelling+ 0.069x duration of morning stiffness + 0.079x 
total back pain [alternative] 
 
The ASDAS demonstrates construct validity and high responsiveness when patients 
are treated with anti-TNF agents. Changes in ASDAS correlated with a change in 
BASDAI, CRP and MRI inflammation scores [72]. A recent study to determine 
clinically relevant cut-offs  for disease activity and improvement scores using ASDAS 
[73], concluded that a score of <1.3 could be classified as inactive disease, 1.3-2.1 as 
moderate disease activity, 2.1-3.5 as high disease activity and >3.5 as very high 
disease activity. A clinically important improvement in ASDAS was found to be ≥1.1, 
while an improvement of ≥2.0 on ASDAS was considered a major improvement. 
These cut offs need to be validated in further studies. One important criticism of 
ASDAS is the fact that it relies on acute phase reactants which are only elevated in 
40% of patients with AS. It also takes into account peripheral pain or swelling which 
is again seen only in a section of AS patients. Hence, the ASDAS is unlikely to 
represent true response in the absence of an elevated ESR/CRP or peripheral 
involvement. 
 
1.5.2 Imaging Biomarkers in AS 
 
In RA synovitis of joints is usually apparent on clinical examination. However, spinal 
inflammation in early stages of AS is only detectable on imaging. Hence imaging 
plays an important role in the diagnosis of AS and potentially in the assessment of 
response to therapy. MRI is the best modality to assess acute inflammation which 
presents as bone oedema or osteitis. Plain radiographs however, are more helpful in 
assessing damage in the form of new bone formation (syndesmophytes and ankylosis) 
in AS. The role of ultrasound (US) is largely restricted to assessment of peripheral 
joints and entheses. However, there have been a few reports examining the use of US 
in imaging sacroiliac and spinal blood flow. Scintigraphy and CT scans are less useful 
in AS.  
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1.5.2.1 Conventional Radiography 
 
The sacroiliac joints are usually the first to be affected in AS and hence radiographic 
sacroiliitis is considered the hallmark of AS. Early studies showed that almost 60% of 
patients with suspected AS but with normal radiographs went on to develop 
sacroiliitis after 10 years [74]. Subsequent studies have shown that men tend to have a 
more severe spinal disease than women and those with hip involvement, had a more 
severe form of spinal disease [75].  
 
A recent study of 769 patients showed that the lumbar spine was the segment 
predominantly involved in the first 20 years of the disease, but that with longer 
duration of disease the cervical and lumbar spine were involved with equal frequency. 
Complete fusion of the spine was seen in 27.9% of patients with disease duration over 
30 years and in 42.6% patients with disease duration over 40 years [76]. 
 
The modified New York Criteria describe grading of sacroiliitis from 0-4. A diagnosis 
of AS requires the presence of sacroiliitis grade ≥ 2 bilaterally or grade 3-4 
unilaterally. The grading is as follows: 
 
Grade 0: normal 
Grade 1: suspicious changes 
Grade 2: minimal abnormality—small localised areas with erosion or sclerosis, 
without alteration in the joint width. 
Grade 3: unequivocal abnormality—moderate or advanced sacroiliitis with one or 
more erosions, evidence of sclerosis, widening, narrowing, or partial ankylosis. 
Grade 4: severe abnormality—total ankylosis 
 
There are 3 methods of scoring spine radiographs in AS. The earliest described 
method is called the Stoke Ankylosing Spondylitis Spine Score (SASSS) [77]. This 
method scored the anterior and posterior site of vertebrae from the lower border of 
T12 to the upper border of S1 on a score of 0-3 on lateral spinal films (Fig). The 
modified SASSS (mSASSS) altered this to look at only the anterior site of the same 
vertebrae and included the cervical spine from the lower border of C2 to the upper 
border of T1 [78]. The Bath Ankylosing Spondylitis Radiology Index (BASRI) [75] 
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was developed later and encompasses the BASRI-spine and BASRI-hip scoring 
systems using a scale of 0-4. When added together, the BASRI total score is obtained.  
None of the scoring systems take into account the thoracic spine as this is difficult to 
visualize on plain X rays. The BASRI is the only method that allows assessment of 
the posterior elements as it requires antero-posterior in addition to lateral views.  
 
A study comparing the three radiographic scoring systems on radiographs of 133 
patients at baseline, 1 year, 2 years and 4 years, found the mSASSS to be the most 
appropriate method of scoring to assess disease progression and demonstrated better 
inter-observer reliability. [79]. However, the mSASSS does not include posterior 
elements and the thoracic spine, where changes are commonly seen in AS. The 
mSASSS failed to show any slowing of radiographic progression even after 2 years of 
treatment with infliximab [26], adalimumab [28] or etanercept [27]. Another study 
that compared X-rays at baseline to 4 years post- infliximab therapy showed that 
patients that did not show damage on mSASS score at baseline did not go on to 
develop any further damage at 4 years post-infliximab therapy but those that showed 
damage at baseline showed significant progression of changes at 4 year follow up 
[80]. The authors concluded from this small study of 33 patients that Infliximab may 
retard radiographic progression but does not inhibit this. 
 
 Given that X-rays only show chronic changes in the form of new bone formation and 
not inflammatory lesions, conventional radiography is not useful in assessing response 
to treatment over short periods. However, X-rays are more likely to pick up 
syndesmophytes than MRI scans [81] and hence conventional radiography remains 
quite important in assessing disease modification in the long term. 
 
1.5.2.2 Magnetic Resonance Imaging (MRI) 
MRI is a form of medical imaging that uses the property of nuclear magnetic 
resonance.  The strong magnetic field created by the scanner aligns the magnetization 
of nuclei within the body and radiofrequency magnetic fields are applied to alter this 
alignment, producing images of the scanned area. It is especially useful in visualizing 
different soft tissues. 
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The introduction of MRI has revolutionized both the diagnosis and management of 
AS. Not only are patients being diagnosed much earlier and consequently started on 
treatment earlier, but also there is now a way to objectively measure response to 
treatment in these patients on MRI scans. The biggest advantage of MRI scans is the 
lack of radiation involved, although the high cost, long imaging times and patient 
factors such as claustrophobia or contraindications such as pacemakers or recent metal 
implants are disadvantages that may limit its use.  
 
Although MRI allows for early diagnosis in AS, there may be disparities between the 
patient’s symptoms and imaging results. For example, some patients with few clinical 
symptoms may show extensive lesions on MRI, whilst others who are much more 
symptomatic may show very little by way of lesions on MRI scans.  
 
1.5.2.2.1 Different MRI sequences and what they show 
 
There are 2 main sequences used in imaging in AS- the T1 weighted (T1w) sequence 
and the Short Tau Inversion Recovery (STIR) sequence. T1 sequences show fat as a 
bright or hyper-intense signal and water as a dark (hypo intense) signal. STIR 
sequences show water as a bright signal and fat tissue as a hypo-intense signal. Hence, 
bone oedema representing acute inflammatory lesions appears as bright lesions on 
STIR while as hypo-intense lesions on T1w sequences. On the other hand chronic 
fatty change suggestive of previous inflammation appears bright on T1w sequence 
and hypo-intense on STIR sequences. The T1w sequences also show chronic changes 
in the form of erosions, syndesmophytes and bony ankylosis. 
 
 T1w post-contrast sequence, which also shows bone oedema, has the additional 
advantage of showing increased vascularity and synovitis in the SI joints. However, 
studies have shown that results of STIR and post-contrast T1w sequences are 
comparable. Since STIR sequences avoid using expensive contrast media and the 
associated low risk of renal impairment, only STIR sequences are now recommended 
for imaging in AS [82]. 
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1.5.2.2.2 Acute and chronic changes seen on MRI in AS and their significance 
 
The acute inflammatory lesions in AS commonly occur at the anterior corners of 
vertebral bodies. These give a shiny corner appearance on radiographs, also called 
Romanus lesions. These can also be present at the posterior corners of the vertebral 
body. Studies have shown that these can be present in patients with degenerative 
arthritis and healthy volunteers as well. However, when 3 or more Romanus lesions 
are present in a patient, it is highly diagnostic of spondyloarthropathy [83].   
 
Chronic lesions may appear as fatty changes at corners of bodies of vertebrae. These 
are referred to as fatty Romanus lesions (FRLs). A recent study showed that the 
presence of 5 or more FRLs increased the likelihood ratio of the diagnosis of 
spondyloarthropathy to 12.6 (a highly significant level) [84]..  
 
 In some patients, there is bone edema on either side of a vertebral end plate with 
involvement of the intervertebral disc. This is called spondylodiscitis or Anderson 
lesion. This can sometimes be associated with vertebral fractures and collapse. 
Similarly, chronic lesions can involve the entire breadth of the vertebral body leading 
to calcification of inter-vertebral disc and pseudo-arthrosis of adjacent vertebrae. 
 
Other sites of inflammation include the posterior elements- the pedicle, facet and 
costo-vertebral joints and spinous processes. Studies have shown that these are most 
commonly seen in the thoracic spine [85] and often involved in patients with shorter 
disease duration [86]. Another study showed that conventional MRI scanning 
protocols that do not scan beyond the body of the vertebra may miss up to 20% of 
lesions in lateral aspects of the thoracic vertebrae [87]. Hence MRI protocols need to 
be modified in order to look for lesions in the posterior elements. 
 
Active sacroiliitis on MRI scanning are identified on the basis of presence of 
subchondral bone marrow oedema/osteitis on STIR sequences [88]. If there is a single 
lesion, this is required to be present in at least 2 slices. If there are two lesions, a 
single slice is enough to make the diagnosis. Studies have shown that patients with 
shorter disease duration and those who were HLA-B27 positive showed more 
extensive sacroiliac inflammation [89].  
 34 
 
 
Fig 1.4(A): MRI STIR sequence of lumbar spine showing hyper-intense signal at L3-
4 intervertebral disc space suggestive of spondylodiscitis. 
 
 
 
Fig 1.4(B): MRI STIR sequence of the thoracic spine showing anterior and posterior 
corner inflammatory lesions as well as lesion involving the posterior elements. 
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Chronic change in the sacroiliac joints is also indicated by periarticular fat deposition, 
subchondral sclerosis, erosions and ankylosis of the sacroiliac joints.  
 
1.5.2.2.3 MRI scoring systems for the spine and SI joints in AS 
Various scoring systems have been devised to help assess the degree of disease 
activity on MRI and to study the effect of treatment on lesions present at baseline. 
There are a number of scoring systems currently available to assess disease activity 
and chronicity in AS. All scoring systems obtain sagittal T1w and STIR sequences of 
the spine and semi-coronal views of the sacro-iliac joints. Most systems score both the 
spine and sacro-iliac joints, although some systems have been devised only to score 
either the spine [90] or the sacro-iliac joints [91]. Most scoring systems score both 
active lesions and chronic changes on MRI, although some only address active lesions 
[92, 93]. 
 
Scoring systems for the spine divide the spine into disco-vertebral units by drawing an 
imaginary horizontal line through the centre of each vertebral body. A disco-vertebral 
unit is hence composed of the lower half of the upper vertebra, the inter-vertebral disc 
and the upper half of the lower vertebra. This hence divides the spine into 23 disco-
vertebral units extending from the lower border of C2 to the upper border of S1. In 
most scoring systems, all of these vertebral units are scored and the total score 
obtained. However, the Spondyloarthritis Research Consortium of Canada (SPARCC) 
method only takes into account the 6 most affected disco-vertebral units and divides 
each unit into 4 quadrants [94].  
 
In some scoring systems, active inflammatory lesions are scored as 1 or 0 indicating 
that they are either present or absent respectively (SPARCC method, Canada-
Denmark system). Others add points if the depth of the lesion is ≥ 1cm and another 
point for high intensity of the lesion (SPARCC). In the Leeds system, comparison is 
made between MRI scans pre and post treatment and scores reflect a difference in 
lesions in between scans.  
 
Other commonly used scoring methods score each disco-vertebral unit between 0-3 
depending on the extent of the lesion and express this out of a total score of 69 [93]. 
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In the Aarhus-Madsen scoring system, an extra 1 point is awarded for the involvement 
of cost-vertebral joints at the thoracic level bringing the total to 81 [95]. Similarly the 
SPARCC system has been modified to allow a dichotomous score for the posterior 
elements through out the whole spine [85]. 
 
Just as for the spine, a number of different systems exist for scoring active lesions in 
the sacro-iliac joints. In some, the entire joint is scored on a scale of 0-3 giving a total 
score of 0-6 [91]. Others divide each joint into halves [93] or further into quadrants 
[96]. The SPARCC system takes into account 6 consecutive semi-coronal slices 
giving points per quadrant and additional points for depth ≥ 1cm and intensity. The 
Leeds system also score each quadrant but then take into account the change in 
between scans to reach the final score.  
 
A study comparing the ASspiMRI-a method to the Berlin score and the SPARCC 
system found that all three systems performed equally well for scoring the spine [97]. 
Similarly, a study examining 5 different scoring systems for the sacro-iliac joints, 
found that they performed similarly but sensitivity to change was better in the 
SPARCC scoring system [91].  
 
1.5.2.2.4 MRI as a biomarker of response to therapy 
 
Initial studies examining the efficacy of anti-TNF agents showed that improvement in 
BASDAI scores correlated with improvement in MRI spine scores[90] [98]. However, 
no correlation with status scores was performed. Sieper et al studied the sustained 
effect of Infliximab on MRI lesions in AS over a 2 year period. The study found no 
correlation between MRI scores and BASDAI, BASMI, BASFI, ESR or CRP using 
the ASspiMRI-a score. However, there was a significant correlation between change 
in BASDAI and BASFI at 12 weeks and MRI score on STIR lesions. This correlation 
was not seen when MRI was repeated at 2 years [99]. 
 
Rudwaleit et al [100] studied MRI scans from AS patients participating in randomized 
controlled trials of anti-TNF therapy to correlate MRI findings with clinical and 
laboratory findings. They found that MRI scans of the spine or SI joints did not co-
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relate with BASDAI, BAS-G, ESR, CRP or morning stiffness. However, they found 
that patients with a shorter disease duration of <10 years who had an MRI spine score 
of ≥ 11 using the Berlin method and a CRP of ≥40 mg/l were more likely to achieve a 
50% improvement in BASDAI on treatment with anti-TNF agents.  
 
A more recent study co-relating ASDAS with MRI scores, showed only a weak co-
relation between MRI SIJ and total inflammation scores and ASDAS [72]. However, 
in this study MRI spine scans did not include the cervical and thoracic spine.  
 
Although there are a number of different scoring methods on MRI, they are all 
subjective and depend on the expertise of the clinician. The scoring systems have 
been developed using MRI scans of patients before and after anti-TNF therapy where 
there is a 40-50% improvement in bone oedema on scans. They are not sensitive to 
smaller changes as there is still no way of quantifying these lesions in order to be able 
to appreciate the difference before and after therapy. Further work needs to be done to 
study the role of MRI as a biomarker in AS. 
 
 
1.5.2.2.5 MRI as a biomarker of disease progression 
 
Recent studies have suggested that syndesmophytes are more likely to develop from a 
prior inflammatory lesion suggesting that inflammation may lead to ankylosis [101, 
102]. However, these same studies have also shown that new syndesmophytes 
developed more commonly in corners without prior Romanus lesions suggesting 
dissociation between inflammation and ankylosis. A recent publication by van der 
Heidje et al confirms this finding in a cohort of patients treated with Infliximab over a 
24 week period [103]. Others have shown that syndesmophytes appear at sites of 
previous fatty Romanus lesions [104]. It is also thought that lesions on MRI that 
resolve show an increased tendency to develop syndesmophytes compared to those 
that show persistent activity [105]. A similar trend was noticed in a recently published 
study by van der Heidje [103]. However, the numbers involved in the latter study 
were small and hence no concrete conclusions could be drawn. 
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1.5.2.3 Ultrasonography 
Ultrasound is a medical imaging technique that uses cyclic sound waves with a 
frequency above that audible to the human ear. Different tissues reflect sound waves 
differently which are captured to produce images. This technique is useful to visualize 
not only superficial structures like muscles and tendons but also internal organs. 
 
The use of ultrasound in AS has predominantly been for assessment of peripheral 
arthritis and enthesitis in AS. However, there have been a few studies looking at the 
role of ultrasound in visualizing inflammation within the sacroiliac joints using power 
Doppler ultrasound. There has also been some interest in studying spinal blood flow 
in AS and how it changes with treatment.  
 
1.5.2.3.1 Ultrasound in the assessment of enthesitis 
 
Enthesitis is the primary lesion in spondyloarthropathies. Grey-scale ultrasound was 
first used to show changes of enthesitis in the lower limbs by Lehtinen et al in 
1994[106]. The study described findings in 31 patients with spondyloarthropathies 
and found that ultrasound picked up abnormalities even when patients were clinically 
asymptomatic. Balint et al [107] also confirmed this in a study of 35 patients and 
devised a scoring system for abnormalities seen on grey scale imaging. This was 
called the Glasgow Ultrasound Enthesitis Scoring System (GUESS).  
 
Lesions seen on grey scale in enthesitis include loss of normal fibrillar pattern of 
tendon insertion which may or may not be associated with increased thickness of the 
tendon. Focal changes such as calcification, fibrosis and periosteal changes in the 
form of erosions or new bone formation in the form of enthesophytes are also seen. 
Additionally, there may be an associated bursitis adjacent to the enthesis.  
 
Power Doppler was first shown to be useful for imaging enthesitis by D’Agostino et 
al [108]. They compared enthesitis in patients with spondyloarthropathy versus 
patients with RA and mechanical back pain. Although enthesitis was seen in all 3 
patient groups, vascularity at the site of insertion of enthesis was only observed in 
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patients with spondyloarthropathies. However, studies have warned against the 
presence of Doppler artefacts at the site of enthesis due to the highly reflective 
cortical bone surface [109]. 
 
Apart from GUESS, there are now 3 other scoring systems for enthesitis. These 
include the D’Agostino scoring system [108], the Spanish Enthesitis Index (SEI) 
[110] and the Madrid Sonographic enthesitis index (MASEI) [111]. The first and last 
combine both the grey scale and Colour Doppler findings on US. There is still no 
consensus on which system is best and none have proved to be sensitive enough to 
detect changes following treatment. 
 
Recent studies have developed a 3 grade semi-quantitative scoring systems for the 
Achilles tendon using the Outcome measures in Rheumatoid Arthritis Clinical Trials 
(OMERACT) definition [112]. This has been used in a small study of patients 
receiving anti-TNF therapy [113]. Although there was an improvement in the grey 
scale and total scores, the power Doppler scores failed to show any correlation with 
clinical improvement.  
 
1.5.2.3.2 Contrast enhanced Colour Doppler Ultrasound in visualization of 
vascularity at SI joints 
 
As ultrasound waves do not penetrate bone, only the posterior surface of the sacroiliac 
joints can be visualized. Hence, it has not been considered a useful modality in 
imaging this structure. However, recent reports have shown the use of micro-bubble 
contrast-enhanced colour Doppler ultrasound (CDUS) to demonstrate sacroiliitis. A 
study comparing this technique to MRI scans found that contrast enhanced colour 
Doppler ultrasound was sensitive and showed a high negative predictive value for 
detection of active sacroiliitis against MRI scanning [114]. This study also found that 
while unenhanced colour Doppler ultrasound only detected sacroiliitis in 16 % of 
affected joints, contrast-enhanced CDUS was able to detect this in 94% of joints.  
 
A subsequent study using second generation micro bubble contrast media, showed 
that contrast enhanced ultrasound was able to differentiate between active sacroiliitis 
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and inactive SI joints [115]. While the dorsal SI joint cleft showed an enhancement 
depth of 18.5mm (range 16-22.1), the depth in those with inactive joints was 3.6mm 
(range 0-12) and 3.1mm (range 0-7.8) in healthy controls. The sensitivity and 
specificity of this technique in their hands was 100%. 
 
1.5.2.3.3 Colour Doppler ultrasound in visualization of the spinal blood flow- 
the application of Resistive Index 
 
Inflammation is usually associated with neo-vascularisation. These blood vessels are 
easy to visualise in rheumatoid arthritis where joints are easily accessible to 
ultrasound. By comparison, the spine and sacroiliac joints are deep seated and hence 
not easy to visualise. Conventionally, power Doppler is used for imaging neo-
vascularisation as this detects slow blood flow (which is common in neo-
vascularisation) and is independent of direction of flow. Colour Doppler on the other 
hand, is dependent of direction of blood flow and measures the amount of blood 
flowing through the vessel. One method of studying blood flow is by calculating the 
resistive index.  
 
The resistive index (RI) is calculated as (peak systolic velocity- end diastolic velocity) 
/ peak systolic velocity. End diastolic velocity in arteries supplying the muscular 
structures in the back is usually zero and hence RI is 1. In most vascular organ beds, 
RI is between 0.7-0.8. In the presence of inflammation, the peak systolic velocity is 
low and end diastolic velocity may be higher and hence RI falls. Therefore, resolution 
of inflammation is associated with a rise in RI. 
 
To date, there are only 2 studies that have attempted to assess changes in RI in arteries 
supplying the spine and sacroiliac joints. The first paper was published by Arslan et al 
[116] in 1999. This study visualized blood vessels in and around the sacroiliac joints 
in 21 patients with active sacroiliitis of varied aetiology. They compared the RI at 
baseline to a control group of 6 patients with osteoarthritis and 8 healthy volunteers. 
They found that the RI in patients with active sacroiliitis was significantly lower than 
in the control group. They went on to repeat the scans after treatment and showed that 
RI increased significantly. 
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A subsequent study by Unlu et al [117] studied RI in blood vessels in SI joints, 
lumbar spine and thoracic spine in a more homogenous group of 39 AS patients 
compared  with 14 healthy controls. They then treated the AS patients, 11 of whom 
received anti-TNF therapy and repeated the scans at 12 weeks. They found that RI 
values for the SI joints, thoracic and lumbar spine were lower in AS patients when 
compared to controls. Patients were stratified according to disease activity. Those 
with active disease had a lower RI of the thoracic and lumbar spine, than those with 
inactive disease. Treatment with anti-TNF therapy in this group resulted in a 
significant increase in RI in the SI joints and lumbar spine but not in the thoracic 
spine. The authors proposed that this could be used as a biomarker of response to 
therapy. However, no comparison was made with MRI findings. 
 
Recently, a Spanish study [118]assessed the validity of spectral Doppler in sacroiliitis 
as defined by presence of Doppler signal within the sacroiliac joint with a resistive 
index below 0.75. They studied 106 patients of which 53 had spondyloarthritis (SpA) 
with symptoms suggestive of sacroiliitis, 26 SpA patients without symptoms and a 
third group of 27 which consisted of healthy volunteers and patients with mechanical 
back pain. US scans picked up Doppler signal in 37 patients of which 33 were 
symptomatic SpA patients. This technique had a positive predictive value of 70.5% 
and a negative predictive value of 84.5%. It showed a sensitivity of 68.6% and a 
specificity of 85.7%). They did not however, study changes in resistive index with 
treatment. 
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1.5.3 Laboratory biomarkers of response to therapy in AS 
 
In contrast to rheumatoid arthritis, where ESR and CRP correlate well with disease 
activity, laboratory biomarkers that correlate with disease activity in AS has proved to 
be elusive. Prospective laboratory biomarkers in AS can be classified into acute phase 
reactants, immunological cellular subsets that circulate and infiltrate into inflamed 
tissue, genetic markers, inflammatory mediators such as cytokines and chemokines 
and finally cartilage and bone biomarkers which may reflect the active process within 
the bone. While genetic markers such as HLA B27 are reliable markers of disease 
susceptibility and may aid in diagnosis, they do not change with treatment. However, 
genetic polymorphisms may predict response to a particular form of drug therapy. In 
order to obtain any meaningful data from genetic studies, large numbers are required. 
This makes it difficult to use genetic markers in predicting response to therapy. 
 
1.5.3.1 Acute Phase Reactants 
 
Initial studies assessing the role of ESR and CRP in AS, suggested that they 
correlated poorly with disease activity [49].  Serum amyloid A (SAA) is an Apo- 
lipoprotein synthesized by activated monocytes and macrophages in the liver. A 
recent study showed that SAA levels were high in AS patients and that SAA levels 
correlated with BASDAI (r = 0.43, p=0.007) as well as with ESR (r = 0.52, p =0.001 ) 
and CRP (r =0.65, p <0.001) [119].  
 
A subsequent Dutch study [120]comparing ESR, CRP and SAA in 155 AS patients 
before and after anti-TNF therapy, found significant decrease in all 3 acute phase 
reactants with treatment and showed a correlation to disease activity measured by 
BASDAI. Elevated baseline CRP and SAA values were most predictive of a response 
to anti-TNF therapy.  Similarly, in a study of 851 AS patients recruited to trials 
evaluating Coxibs and NSAIDs, a correlation was found between CRP and BASDAI 
as well as BASFI. They showed a difference in CRP in patients receiving NSAIDs/ 
Coxibs versus placebo and the treatment effect was greater when patients had high 
CRP values at baseline [121]. 
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Only 40-60% of patients with AS demonstrate CRP values above the lowest 
reportable value for the CRP assay (usually 5-10mg/L). With the introduction of 
highly sensitive CRP (hsCRP) assays, this level has now been lowered to 0.1mg/L, 
allowing detection of CRP levels in a larger cohort of patients. A study comparing 
conventional CRP to hsCRP in a group of 153 AS patients, found a good correlation 
between the 2 assays but a better correlation between hsCRP and clinical parameters 
compared to the conventional CRP assay. In the subgroup of patients with 
undetectable CRP using conventional assay, there was a clear trend for fatigue, 
stiffness and functional disability and higher values of hsCRP [122]. Highly sensitive 
CRP values have now been recommended for calculation of ASDAS scores.  
 
Hence ESR, CRP and SAA have been shown to change with therapy and this change 
is more noticeable when baseline levels are high. There is still no clear surrogate 
marker of improvement in disease activity when baseline levels of these biomarkers 
are within normal range which is the case in a significant number of AS patients.  
 
1.5.3.2 Immunological cell subsets in AS 
 
There have been a number of studies investigating the cellular subsets thought to be 
involved in the pathogenesis of AS. However, very little data is currently available on 
the relationship of these cell populations to disease activity or response to therapy. 
 
Evidence of immunological cells being involved in the pathogenesis of AS is 
primarily derived from biopsies obtained from sacroiliac joints, the spine as well as 
hip joints. While the latter is easy to obtain from patients undergoing hip replacement, 
the former two are difficult to obtain unless patients require spinal surgery. As 
patients only undergo surgery later in the disease process, it is difficult to obtain tissue 
material in early disease. 
 
In a small study of 5 patients with active AS, needle biopsies from sacroiliac joints 
showed dense infiltrates containing T cells and macrophages. CD3+, CD4+, CD8+ 
and CD 14+ cells were found diffusely within the tissues [123]. Another small study 
of histological samples of facet joints from eight AS patients undergoing spinal 
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surgery, found infiltrates of aggregates of CD4+, CD8+ and CD20+ lymphocytes 
[124]. These were present even in cases of AS with long-standing disease and 
significant ankylosis, suggesting that active inflammatory foci may be present even in 
late stages of AS. 
 
Higher levels of circulating CD8+ CD28- T cells were found in patients with AS than 
in the healthy population. Also levels of CD8+ CD 28- T cells have been reported to 
correlate with metrology scores [125]. HLA-B27 is known to present specific peptides 
to CD8+ T lymphocytes (cytotoxic T lymphocytes). Recent studies have shown that 
B27 may also be recognised by CD4+ T cells [126].  These cells lack the CD28 co-
stimulatory molecule but carry the natural killer (NK) receptor present on NK cells 
that allows them to recognize MHC I molecules such as HLA B27. Levels of 
circulating CD4+ CD28- T cells have also been shown to correlate with disease status 
(metrology scores) in AS patients [127].  
 
On comparing T cell subsets in patients with SpA, RA and polymyalgia rheumatica 
versus healthy volunteers [128], the levels of CD3+CD4+CD28-  memory/effector T 
cells were found to be higher in synovial fluid and to a lesser extent peripheral blood 
of SpA patients compared to other groups. Also naïve T cells 
(CD28+CD45RA+CD4+ /CD8+) were reduced and memory T cells 
(CD28+CD45RO+CD4+/CD8+) , activated T cells (CD8+CD25+) and T-Regs 
(CD4+CD25
hi
) were also increased in synovial fluid compared to peripheral blood.  
 
 
Another group of CD4+ T cells thought to be important in pathogenesis of AS is the 
Th17 subset. Jandus et al [129] showed increased numbers of circulating Th17 cells in 
patients with spondyloarthropathy as compared to RA or vitiligo by multi-parameter 
flow cytometry and immuno-histochemistry. Th17 cells from these AS patients 
showed advanced differentiation  and were polyfunctional in terms of T cell receptor-
driven cytokine production (IL-17, IL-2 and TNF α).  
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1.5.3.3 Cytokines, chemokines and growth factors 
 
Cytokines in AS have been measured either directly in serum, by intracellular staining 
of peripheral blood mononuclear cells (PBMCs) or by measuring cytokine gene 
expression through mRNA microarrays. Serum levels of both pro-inflammatory 
cytokines like TNF α and IL-6 as well as anti-inflammatory cytokines like IL-10 and 
TGF β have been found to be elevated in AS [130]. Significant reductions in IL-6 
have been reported after treatment with infliximab [131].  High levels of baseline IL-6 
and CRP were found to be associated with a response to anti-TNF therapy. Early 
reductions in IL-6 were associated with improvements in disease activity and spinal 
inflammation on MRI. A similar study [132] assessing 22 different cytokines found an 
association between serum IL-1α and response to infliximab therapy.  
 
Drouart et al [133] studied the potential use of VEGF as a biomarker of disease by 
measuring levels in 105 SpA patients versus 50 RA and 64 healthy volunteers. They 
found serum VEGF levels were significantly higher in AS and RA patients. VEGF 
levels correlated with BASDAI, ESR and CRP but were not associated with 
syndesmophytes or grade of sacroiliitis. Significant reduction in VEGF has been 
reported after treatment with infliximab [131] 
 
Levels of cytokines vary at different locations throughout the body and fluctuate as 
cytokines have short half lives [130]. Hence, serum levels may not accurately reflect 
cytokine levels in synovial inflammation or enthesitis. A number of studies have used 
flow cytometry to obtain specific information regarding intracellular cytokine 
expression in peripheral blood mononuclear cells. Baeten et al [134] evaluated IL-2, 
IL-4, IL-10 and IFN γ expression in CD3+ T cells and CD3+/CD56+ NK T cells in 21 
patients with spondyloarthropathy and compared this to 20 patients with RA and 15 
healthy controls. The cytokine profile was also repeated in the SpA patients after 
treatment with Infliximab. They found a low percentage of IFN γ and IL-2 positive 
cells and a higher percentage of IL-10 positive cells in the SpA group as compared to 
patients with RA or healthy controls, suggestive of an impaired Th1 cytokine profile. 
Treatment with infliximab induced an increase in percentage of cells positive for IFN 
γ and IL-2 suggesting a restoration of Th1 cytokine profile.  
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However, a subsequent German study [135] examined intracellular IFN γ, TNFα, IL-4 
and IL-10 expression in  CD4 and CD8 T cells from AS patients. They reported a 
decrease in TNFα and IFN γ secreted by T cells after 12 weeks of infliximab therapy. 
They also reported an increase in IFN γ and TNF α  positive CD4+ and CD8+ T cells 
in AS patients treated with etanercept [136].  The authors argue that interaction of 
infliximab with TNF α down regulates Th1 cytokines while the binding of TNF 
molecules to etanercept up regulates Th1 response secondary to low circulating TNF 
levels [137].  
 
Apart from Th1 and Th2 type cytokines, there is a growing interest in the Th17-
related cytokines in AS. Shen et al [138] studied cytokine expression in AS patients 
and compared it to RA patients as well as normal controls. Using eight-colour flow 
cytometry, they analyzed surface phenotype, chemokine receptor and intracellular 
cytokine expression of IL-17, IL-22, IFN γ and IL-10 in PBMCs. They found 
significantly higher percentages of IL-17 and IL-22 positive CD4+ T cells in patients 
of AS and RA as compared to healthy controls. They also reported a correlation 
between IL-17 positive CD4+ T cells in PBMCs and the amount of IL-17 in PBMC 
culture supernatants. These IL-17 producing cells also produced IL-22 and IFN γ but 
not IL-10. 
 
IL-23 is the main inducer of Th-17 polarization of naïve T cells. Although Th-17 
related cytokines are present in synovial fluid from both SpA and RA patients, levels 
of IL-23 correlate with disease activity in RA but not SpA [139].  IL-23 is composed 
of a p40 subunit shared with IL-12 and a p19 subunit specific to IL-23. A study that 
assessed serum and synovial levels of p40 subunit of IL-12/23, found no significant 
change in levels after anti-TNF therapy [140]. 
 
Chemokines are molecules responsible for attracting T cells into inflamed tissues. Th1 
cells show surface expression of chemokine receptors CCR5 and CXCR3. These 
receptors bind ligands like CCL5 (RANTES), CCL3 (MIP-1α), CXCL9 (MIG) and 
CXCL10 (IP-10).  On the other hand, Th2 cells express CCR3, CCR4 and CCR8 and 
bind to chemokines like CCL-17 (TARC). Th17 cells express CCR6 and CCR4. CCL-
20, the ligand for CCR6, has been found to be increased in inflamed joints. 
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A study that examined lymphocytic expression of chemokine receptors and 
intracellular cytokine production [141] in AS patients versus controls, found a type 1 
immune reaction on CD 28- T cells from AS patients. The chemokine CXCL-9 (MIG) 
was increased in sera of active AS patients and treatment with anti-TNF agents 
resulted in a reduction in CCL-5 (RANTES), CXCL-10 (IP-10) (type I chemokines) 
but also CCL-17 (type II chemokine).  
 
1.5.3.4 Bone and cartilage biomarkers 
 
Cartilage and bone markers may potentially serve as important biomarkers in 
Ankylosing Spondylitis as they reflect the end result of inflammation or bone 
metabolism. Cytokines such as TNFα increase osteoclast precursor cells in the 
circulation.  In addition to TNFα, other pro-inflammatory cytokines such as IL-1, IL-6 
and IL-17 induce the expression of RANKL which encourages osteoclast 
differentiation leading to bone loss.  
 
Gengenbacher et al [142] studied the effects of infliximab on bone resorption by 
osteoclast precursor cells (OCPs) in AS and RA patients. This study found that 
blocking of TNF α resulted in a strong reduction of bone resorption by OCPs which 
was much faster in RA as compared to AS. This inhibition was associated with 
reduced disease activity and osteocalcin levels. 
 
In contrast to RA, where RANKL is over-expressed and OPG is under-expressed in 
active synovitis leading to bone loss and erosions [143], the level of OPG is not 
reduced in AS [144] . A study by Kim et al [145] found that both sRANKL and 
sRANKL /OPG ratios were up-regulated in AS patients and correlated with reduced 
bone mineral density (BMD) and radiological changes. Hence, an imbalance between 
RANKL and OPG may play a role in bone resorption.  
 
A new marker for bone metabolism is isoform 5b of tartrate resistant acid phosphatase 
(TRAP5b) which is a specific osteoclast enzyme. It has been found to be elevated in 
bone diseases such as osteoporosis or skeletal metastasis. A study by Toussirot et al 
[146] found TRAP5b to be a more sensitive marker than CTX-I for evaluating the 
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level of bone resorption in AS. This was postulated to be due to the fact that TRAP5 
evaluates bone resorption by enzymatic activity where as CTX-I assesses collagen 
breakdown.  
 
MMP3 has been shown to be an independent predictor of radiographic progression in 
patients with AS [147]. A more recent study found that MMP3 is raised in AS and a 
significant drop in MMP-3 levels was seen with anti-TNF therapy [148]. 
 
Articular cartilage is composed of type II collagen and a proteoglycan called 
aggrecan. When type II collagen breaks down, it generates neoepitopes- C2C and C1-
2C and causes chondrocytes to up regulate biosynthesis of C-propeptide of type II 
collagen (CPII). Breakdown of aggrecan leads to increase of the 846 epitope. A recent 
study found that elevated CPII, 846 epitope and CPII: C2C ratio  in AS patients 
compared to controls. Only the CPII:CPC ratio correlated with CRP suggesting it may 
be useful as a marker of disease activity [149].  
 
A study of markers of bone resorption (CTX I) and cartilage degradation (CTX II), 
found that both were increased in patients with AS [150]. The levels of these analytes 
correlated with each suggesting on-going simultaneous processes. However, only 
CTX-II was associated with radiological damage and progression in AS, suggesting 
that bone proliferation and degradation may be uncoupled processes in AS. An earlier 
Korean study had reported a correlation between CTX-I and disease activity [151]. 
 
Apart from bone loss, AS is also characterized by new bone formation which occurs 
through activation of osteoblasts which are derived from mesenchymal stem cells. 
The differentiation of osteoblasts is controlled by the bone morphogenic protein 
(BMP) family (which includes TGF-β) as well as the Wnt protein family. Cytokines 
such as TNF α induce both Dickkopf- 1 (DKK-1) as well as Sclerostin, both of which 
are strong inhibitors of the Wnt pathway hence inhibiting bone formation. The Wnt 
pathway in turn controls the expression of OPG which inhibits RANKL/RANK 
interaction. At a molecular level, TNF α stimulates expression of Dickkopf (DKK)-1.  
Ossification depends on bone morphogenetic proteins (BMPs). Treatment with anti-
TNF α agents results in resolution of inflammation, allowing signalling through Wnt 
and growth factors such as BMP-2 to induce new bone formation [15].  
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Another bone biomarker that is thought to be important in AS is Sclerostin, an 
inhibitor of bone formation that is expressed by osteocytes. A recent study that 
observed Sclerostin expression by osteocytes in joints derived from patients with RA, 
OA, AS and healthy controls, reported that sclerostin was expressed in a majority of 
osteocytes in RA and healthy controls but it was lower in OA and nearly absent in AS 
patients. The same study also looked at serum levels of sclerostin, which were found 
to be lower in AS patients than in healthy controls. Moreover, low sclerostin levels 
correlated with formation of new syndesmophytes [152]. 
 
Appel et al [153] looked at the correlation between inflammation and new bone 
formation in patients of AS over 2 years. They found that rising levels of bone 
alkaline phosphatase (BAP) were negatively correlated with MMP3 in patients with 
spondyloarthropathies treated with adalimumab. They hence postulated that new bone 
formation in AS occurs if inflammation is successfully treated and hence may be part 
of a healing process. Serum levels of BAP and osteocalcin in AS do not differ from 
normal but have been shown to significantly increase after 12 weeks of treatment with 
etanercept [154]. 
 
Visvanathan et al [131]evaluated the relationship between bone mineral density 
(BMD), biomarkers of bone turnover (Bone alkaline phosphatase [BAP], osteocalcin 
and CTX I) and inflammation (IL-6, vascular endothelial growth factor [VEGF] and 
transforming growth factor [TGF] β) in patients with AS treated with infliximab. This 
study reported a significant correlation between baseline levels of IL-6, VEGF, 
osteocalcin, BAP and CTX and increases in spinal BMD at weeks 24 and 102 after 
infliximab therapy. Multiple regression analysis showed that high baseline osteocalcin 
levels and an early increase in BAP at week 2 were significantly associated with 
increases in BMD scores of the spine and hip after infliximab therapy.  
 
Although a number of bone and cartilage markers have been studied so far, none has 
come into routine clinical use as a marker of disease status evaluation or of response 
to therapy. One of the problems with evaluating bone biomarkers is that they need to 
be correlated to radiographic change which we know takes a few years to develop. 
There have been no studies correlating bone biomarkers with acute inflammatory 
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changes on MRI scans. More work is needed in this area before any definite 
biomarkers of response are established. 
 
1.6 Aims 
 To study how clinical, imaging and laboratory biomarkers change with 
therapy in patients with AS treated with gold standard anti-TNF agents 
as well as a novel PDE 4 inhibitor, apremilast, in a clinical trial setting.  
 To explore volumetric analysis of lesions on MRI and study its 
correlation to existing semi-quantitative methods.  
 To correlate changes in clinical, imaging and laboratory biomarkers in 
order to identify an objective biomarker of response to therapy.  
1.7 Study Layout 
I set out to achieve these by studying the following biomarkers: 
 Clinical outcome measures including the Bath Indices and ASDAS 
 MRI changes through semi-quantitative scoring using the Berlin score 
 Laboratory biomarkers including inflammatory markers, bone biomarkers as 
well as cytokines, chemokines and growth factors. 
 Exploratory volumetric analysis of lesions on MRI  
As there were differences in patient groups and methodology in each of these, they are 
reported separately in different chapters that follow. 
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Chapter 2: Clinical Outcome Measures as biomarkers of 
response to therapy 
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2.1 Introduction: 
 
Response to therapy in AS can be measured in many different ways- clinical response 
through patient questionnaires, improvement of bone oedema on MRI scans, 
improvement in inflammatory markers such as ESR or CRP and in the long term, the 
development of syndesmophytes on plain X-rays. Of all these measures, patient 
reported subjective questionnaires remain the favoured approach in routine clinical 
practice. This is largely because they are easy to administer, show changes with short 
term intervention and have been validated as effective tools to measure response to 
therapy. Other measures such as MRI do not correlate well to clinical outcome 
measures and hence this limits their utility as biomarkers of response to therapy. 
Changes on X-rays are very slow and can take up to many years to develop. 
Inflammatory markers are useful when raised at baseline but this is only in a small 
minority of patients.  
In this chapter, we study the various clinical outcome measures in both a clinical trial 
setting as well as routine clinical practice. 
 
2.2 Methods: 
 
2.2.1 Patient populations 
 
Biomarkers were studied in 2 patient cohorts. The first was a clinical trial setting 
where AS patients were randomised to receive apremilast, an oral phosphodiesterase 
inhibitor, or placebo (1:1). This is henceforth referred to as the START cohort 
(Spondylitis Trial of Apremilast for better Rheumatic Therapy). The second cohort 
consisted of AS patients treated with anti-TNF therapy having failed to respond to 
conventional medication. This is referred to as the anti-TNF cohort and served as a 
gold standard comparator to the START cohort. 
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2.2.1.1 START cohort  
2.2.1.1.1 Study design 
This was a single-centre, randomized, double-blind, placebo-controlled, Phase II, 
investigator-led pilot study carried out at the Kennedy Clinical Trials Unit 
(Clinicaltrials.gov number NCT00944658). It was conducted in accordance with good 
clinical practice and received ethics approval from the Hammersmith Research ethics 
committee. Each patient provided written informed consent. 
The study involved a 12-week, double-blind, placebo-controlled period followed by a 
4-week follow-up for safety and clinical assessments. Patients were randomized 1:1 to 
receive apremilast 30 mg BID or placebo in a double-blind fashion. An un-blinded 
pharmacist allocated patients to receive either placebo or active drug according to a 
randomization code generated by Celgene, the company that manufactures apremilast. 
All other study personnel remained blinded to treatment until the end of the double-
blind period. Patients were started on apremilast 10 mg BID or placebo and the dose 
was titrated by 20 mg every 2 days until the maximum dose of 30 mg BID was 
achieved on day 5. Apremilast or placebo was then given daily until day 85 (week 
12). Patients were allowed to continue stable doses of NSAIDs but were not allowed 
DMARDs within 8 weeks of randomization or corticosteroids in oral/ parenteral form 
within 4 weeks of randomization. 
 
1..1.1 2.2.1.1.2 Patients 
Key inclusion criteria included patients satisfying the modified New York criteria for 
AS with disease duration of at least 2 years. Patients were required to have symptoms 
of back pain and stiffness confirmed with a score of ≥1 on questions 2 and 5 of the 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI); which pertain to 
spinal pain and stiffness. They also required the presence of active bone oedema 
either in the spine or sacroiliac joints confirmed by magnetic resonance imaging 
(MRI). Patients with prior treatment with TNF inhibitors were permitted to enrol 
allowing for a washout period. 
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Patients were excluded if there were abnormalities on routine blood tests other than a 
raised erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), any 
contraindications to MRI scanning, or positive tuberculosis testing (Mantoux and TB 
Elispot). 
 
2.2.1.1.3 Clinical Outcome measures 
Bath Indices (BASDAI, BASFI, BASMI and BAS-G) were recorded at all time points 
(Day 0, 8, 15, 27, 56, 85 and 113). In addition, patient also had tender and swollen 
joint counts recorded as well as FACIT-F scores. ASDAS scores were then calculated 
in this patient population.  
 
2.2.1.1.4 Statistics 
Analysis of Co-variance (ANCOVA) was used to compare improvements in Bath 
Indices and FACIT-F scores at each time point using baseline values as covariate. 
This analysis was carried out by BrighTech International, statisticians appointed by 
Celgene Corporation that funded the clinical trial, using the SAS package. A p-value 
of 0.05 was considered to be statistically significant. A post-hoc analysis of 
improvement in ASDAS between the two arms of the study was done by applying 
Mann-Whitney U-test using GraphPad Prism software. 
 
2.2.1.2 Anti-TNF cohort 
This was a prospective study which recruited patients with a confirmed diagnosis of 
AS  primarily from Imperial College Healthcare NHS Trust outpatient clinics but also 
from other referring NHS hospital trusts that were about to start anti-TNF therapy 
having failed at least two previous NSAIDs.  
2.2.1.2.1 Patients 
Some of the patients were already part of an ongoing study entitled, ‘The impact of 
TNF blockade on effector T cell populations in patients with Rheumatoid arthritis, 
Psoriatic Arthritis and Ankylosing Spondylitis treated with anti-TNF therapy’ 
[EudraCT No: 2009-012424-87]. Others were recruited on the study entitled 
“Molecular mechanisms and pathways in chronic inflammatory and degenerative 
disease”. Both studies received ethical approval from Hammersmith Research Ethics 
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Committee. All patients satisfied the modified New York Criteria for AS had a BASDAI 
of ≥ 4 with a spinal VAS of ≥ 4 at two time points at least one month apart. They were 
all screened for tuberculosis by a chest X-ray, Mantoux test and a TB Elispot prior to 
commencing anti-TNF therapy as per local guidelines. 
2.2.1.2.2 Study Design 
All patients were treated with either etanercept 50mg subcutaneous weekly or 
adalimumab 40mg subcutaneous fortnightly. Patients were seen at baseline prior to their 
first injection and then at the end of 3 months of therapy. Patients were allowed to 
continue with NSAIDs and DMARDs provided the doses were stable for 4 weeks prior 
to starting anti-TNF therapy. Patients were not allowed parenteral or oral steroids for 4 
weeks prior to staring anti-TNF therapy. 
2.2.1.2.3 Clinical outcome measures 
Patients had BASDAI, BASFI and BASMI recorded at baseline and 12 weeks after 
commencing therapy. They also had HAQ, SF-36 and FACIT-F scores recorded.. 
ASDAS could not be calculated in this patient cohort as BAS-G which is one of the 
parameters required to do so was not recorded in this patient cohort. 
2.2.1.2.4 Statistics 
Paired t-test and Wilcoxon matched pairs test were used to measure response in Bath 
indices between baseline and 12 weeks using GraphPad Prism software. Again, a p-
value of 0.05 was considered to be statistically significant. 
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2.3 Results 
2.3.1 START cohort 
 
56 patients were screened of which 38 patients were recruited to the START study.   
The reasons for screen failure were as follows:  
Positive TB screen: 2 
Presence of metal in situ (contraindication to MRI scanning): 2 
Absence of bone oedema on MRI: 6 
Withdrawal of consent after screening: 2 
Did not score high enough on BASDAI to qualify: 2  
Duration since diagnosis less than 2 years: 1 
No clinical evidence of AS: 2 
Abnormal liver function tests: 1 
2 patients dropped out of the study due to adverse events within a week of starting 
treatment, both of whom were on apremilast. Of the remaining 36, 19 patients received 
placebo and 17 received apremilast.  
 
2.3.1.1 Baseline characteristics and Patient Demographics: 
Of the 36 patients that completed the study, 32 were male and 4 were females. Ethnic 
distribution was as follows: 32 Caucasian, 3 Asian and 1 patient of African origin. 
The baseline characteristics in the two groups are listed in table 2.1. These show that 
patients receiving apremilast were older with longer disease duration but these 
differences were not statistically significant. Although BASDAI and BASFI were 
similar in the two groups, given the longer disease duration in the group receiving 
apremilast, the BASMI was higher in this cohort of patients.  
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Table 2.1: Patient characteristics seen in the two groups at baseline. Patients in the 
apremilast arm were older with longer disease duration and had higher BASMI scores 
than patients in the placebo group. 
 Placebo 
Mean (SD) 
Apremilast 
Mean (SD) 
p-value 
Age (Yrs) 39.21 (13.3) 44.88 (11.1) 0.17 
Disease duration (Yrs) 18.39 (10.17) 20.88 (12.32) 0.51 
BASDAI 4.36    ( 1.757) 4.79    (2.161) 0.52 
BASFI 3.49     (2.208) 4.55    (2.429) 0.178 
BASMI 3.16     (1.598) 4.48    (1.963) 0.032 * 
BASG 4.13      (2.329) 4.33    (2.850) 0.816 
Night pain 4.03      (2.524) 4.25    (2.940) 0.814 
FACIT-F 
110.04 
(26.147) 
107.75  (25.716) 0.793 
 
 
2.3.1.2 BASDAI as a biomarker of response: 
 
Table 2.2 and Figure 2.1 show changes in BASDAI with treatment over time. Although 
both groups show an improvement in BASDAI, the drop in BASDAI in the active arm 
is higher in the group treated with apremilast. This however, does not achieve a drop by 
2 BASDAI units and the differences between the two groups are not statistically 
significant. Of note, there is a trend to continuous improvement in BASDAI even at day 
85 when treatment is stopped suggesting that if treatment were continued for longer, 
this may have resulted in further benefit which may have been statistically significant. 
Cessation of therapy in both groups swiftly resulted in return of BASDAI back to 
baseline 4 weeks later. 
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Table 2.2: Change in BASDAI at various time points with treatment. Although there 
was a greater improvement in BASDAI in the apremilast arm, BASDAI did not drop 
by 2 units or 50% of baseline in this group. 
Visit Placebo( n=19) 
Mean change from 
baseline (SD) 
Apremilast (n=17) 
Mean change from 
baseline (SD) 
p-value 
(ANCOVA) 
Day 8 -0.22 (1.134) -0.54 ( 0.861) 0.382 
Day 15 -0.62 ( 1.778) -0.78( 1.144) 0.874 
Day 29 -0.34 ( 1.503) -1.05 ( 1.336) 0.154 
Day 57 -0.47 ( 1.606) -1.37 ( 1.314) 0.090 
Day 85 -0.77 ( 1.474) -1.59 ( 1.485) 0.139 
Day 113 -0.41 ( 1.699) -0.70 ( 1.975) 0.837 
 
 
 
Fig 2.1: Change in BASDAI from baseline in the two treatment groups [CC-1004 
represents patients receiving apremilast]. There is a steady improvement in 
BASDAI more so in the active arm until the medication is withdrawn. There 
after there is a rise in BASDAI scores in both arms of the study. 
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2.3.1.3 BASFI as a biomarker of response to therapy 
 
Change in BASFI with treatment is shown in table 2.3 and Figure 2.2. Like the 
BASDAI, there was an improvement seen in the BASFI which was more marked in 
the apremilast group. On applying ANCOVA, this was statistically significant. 
However, as there was one outlier, use of a non-parametric measure resulted in loss of 
the statistical significance (p=0.11). Interestingly, patients clinically only reported an 
improvement on apremilast at the end of the 2
nd
 month of therapy which corresponds 
to an improvement on BASFI.  
 
Fig 2.2: Change in BASFI with treatment [CC-1004 represents patients receiving 
apremilast]. The fall in BASFI scores is more pronounced in the active arm with 
very little if any change in the placebo arm. This is reversed on stopping the 
medication in the active arm. 
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Table 2.3: Change in BASFI at various time points with treatment. Change in BASFI 
was almost statistically significant in the apremilast arm at Day 85.  
Visit Placebo( n=19) 
Mean change from 
baseline (SD) 
Apremilast (n=17) 
Mean change from 
baseline (SD) 
p-value 
(ANCOVA) 
Day 8 -0.28 ( 0.267) -0.57 ( 0.283) 0.462 
Day 15 -0.25 ( 0.424) -1.05 ( 0.444) 0.215 
Day 29 -0.18 ( 0.298) -1.10 ( 0.316) 0.044  
Day 57 -0.36 ( 0.390) -1.15 ( 0.413) 0.181 
Day 85 -0.43 ( 0.379) -1.57 ( 0.401) 0.050 ** 
Day 113 -0.32 ( 0.467) -0.98 ( 0.513) 0.359 
 
** p value 0.108 when non-parametric tests applied 
2.3.1.4 BASMI as a biomarker of response to therapy 
 
BASMI is the only clinical outcome measure in patients with AS that can be 
measured objectively. However, it takes a while to see changes in BASMI especially 
when disease duration is long standing and the patients have already developed spinal 
ankylosis. Hence, it was not surprising to see very little change in BASMI in the two 
patient groups with no statistically significant differences. The change in BASMI with 
treatment is shown in Table 2.4 and figure 2.3. 
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Table 2.4: Change in BASMI at various time points with treatment. Little change was 
observed with BASMI in either treatment group. 
Visit Placebo( n=19) 
Mean change from 
baseline (SD) 
Apremilast (n=17) 
Mean change from 
baseline (SD) 
p-value 
(ANCOVA) 
Day 8 -0.02 ( 0.132) -0.28 ( 0.140) 0.213 
Day 15  0.12 ( 0.200) -0.23 ( 0.210) 0.275 
Day 29 -0.11 ( 0.165) -0.28 ( 0.175) 0.495 
Day 57 -0.26 ( 0.160) -0.26 ( 0.170) 0.996 
Day 85 -0.27 ( 0.187) -0.44 ( 0.199) 0.555 
Day 113 -0.16 ( 0.192) -0.13 ( 0.212) 0.908 
 
 
 
 
 Fig 2.3: Change in BASMI with treatment [CC-1004 represents patients receiving 
apremilast]. BASMI shows little change with treatment in either treatment 
groups, although a small improvement is seen after 2 months of apremilast. 
 
 62 
 
2.3.1.5 BAS-G as a biomarker of response to therapy 
 
The BAS-G is the patient’s global assessment of the disease and its impact on 
lifestyle. The BAS-G (table 2.5, fig 2.4) showed a greater drop in the cohort treated 
with apremilast than placebo. However, the difference between the active and placebo 
arm was not statistically significant. 
 
Table 2.5: Change in BAS-G at various time points with treatment. BAS-G showed a 
gradual improvement with time in the apremilast arm. 
Visit Placebo( n=19) 
Mean change from 
baseline (SD) 
Apremilast (n=17) 
Mean change from 
baseline (SD) 
p-value 
(ANCOVA) 
Day 8  0.01 ( 0.368) -0.17 ( 0.389) 0.737 
Day 15 -0.03 ( 0.650) -0.07 ( 0.679) 0.965 
Day 29  0.27 ( 0.517) -0.14 ( 0.547) 0.589 
Day 57 -0.38 ( 0.510) -0.12 ( 0.556) 0.738 
Day 85 -0.22 ( 0.528) -1.30 ( 0.558) 0.166 
Day 113  0.08 ( 0.579) -0.37 ( 0.634) 0.600 
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Fig 2.4: Change in BAS-G with treatment [CC-1004 represents patients receiving 
apremilast]. Patient report an improvement in BAS-G on active medication at 
the end of 3 months but this is lost on stopping medication. 
 
 
 
 
2.3.1.6 FACIT-F as a biomarker of response 
 
The FACIT-F is another subjective measure of response. An improvement in the 
patient’s condition is associated with a rise in FACIT-F. Like all other clinical indices, 
the FACIT-F (table 2.6, fig 2.5) also showed an improvement in both groups with a 
greater improvement in the active arm but this difference was not statistically 
significant. 
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Table 2.6: Change in FACIT-F at various time points with treatment. No statistically 
significant differences were seen with treatment 
Visit Placebo( n=19) 
Mean change from 
baseline (SD) 
Apremilast (n=17) 
Mean change from 
baseline (SD) 
p-value 
(ANCOVA) 
Day 8  3.31 ( 2.586)  6.83 ( 2.734) 0.357 
Day 15  1.53 ( 3.523)  6.80 ( 3.680) 0.313 
Day 29  0.39 ( 3.424)  6.71 ( 3.620) 0.214 
Day 57  6.13 ( 2.972)  9.70 ( 3.142) 0.416 
Day 85  5.20 ( 2.971)  9.24 ( 3.141) 0.358 
Day 113  1.00 ( 3.818)  4.35 ( 4.182) 0.559 
 
 
 
 
Fig 2.5: Change in FACIT-F with treatment [CC-1004 represents patients 
receiving apremilast]. FACIT-F improved in both treatment groups although this 
was slightly better in the active arm than placebo. 
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2.3.1.7 ASAS response and ASDAS as biomarkers of response 
 The ASAS and ASDAS are composite indices obtained by feeding data from various 
indices into formulae as described in the previous chapter. They have now been 
validated as tools to measure response to therapy.  
Six patients (35.3%) in the apremilast group versus three (15.8%) in the placebo group 
achieved an ASAS20 response (p=0.25) after three months on therapy. Similarly, four 
patients (23.5%) in the apremilast group versus one patient (5.3%) in the placebo group 
achieved an ASAS40 response (p=0.17). ASAS 5/6 responses were achieved by three 
patients in the apremilast group versus one in the placebo group.  
A post hoc analysis of mean (SD) change in ASDAS after 3 months of therapy showed 
a reduction of 0.46(0.66) in the apremilast group versus 0.15(0.71) in the placebo group 
(p=0.35 by Mann-Whitney). ASDAS improvements greater than or equal to 1.1 were 
observed in 4/17 apremilast patients and 1/19 placebo patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.6: Change in ASDAS from baseline to Day 85 of treatment. Although there 
were improvements in both groups, the difference was not statistically significant 
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2.3.2 Anti-TNF cohort 
 
16 patients that were about to start anti-TNF therapy were recruited on ‘The impact of 
TNF blockade on effector T cell populations in patients with Rheumatoid arthritis, 
Psoriatic Arthritis and Ankylosing Spondylitis treated with anti-TNF therapy’ study. 
One patient did not go on to start anti-TNF therapy and hence dropped out of the 
study. A further 6 patients were recruited on the “Molecular mechanisms and pathways 
in chronic inflammatory and degenerative disease” study. Hence a total of 21 patients 
that received anti-TNF therapy were studied over a 3 month period. 
 
2.3.2.1 Baseline characteristics and Patient Demographics: 
 
The cohort consisted of 17 males and 4 female patients. The mean (SD) age of the 
patients was 38.2 (9.4) years with a disease duration of 10.9 (9.8) years. Most of the 
21 patients were Caucasians but there were 4 Asian and 1 Afro-Caribbean patient. 5 
patients had previously participated in the START study before starting anti-TNF 
agents. Only 4 out of the 21 patients were treated with etanercept, the soluble TNFα 
receptor, with the rest receiving adalimumab, the fully humanized Antibody to TNFα. 
2 patients were also receiving concomitant methotrexate and 3 were receiving 
sulfasalazine. 
 
The baseline BASDAI in this cohort of patients was 5.6 (2.06) units. The mean 
BASFI at baseline was 4.53 (2.07) [n=18] and baseline BASMI was 3.41 (1.62) units. 
BAS-G was not recorded in this group of patients; hence ASAS and ASDAS response 
could not be calculated in this cohort. 
 
2.3.2.2 Response to anti-TNF therapy using clinical indices 
 
Data was available only at baseline and at the end of 3 months of therapy, hence 
paired t-test or Wilcoxon Matched pairs test was applied. All three Bath indices 
showed a statistically significant improvement with treatment with anti-TNF therapy. 
The detailed results are as shown in table 2.7. 
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Table 2.7: Change in BASDAI, BASFI and BASMI with anti-TNF therapy 
  
Outcome measure Baseline  
Mean (SD) 
Week 12 
Mean (SD) 
p-value 
BASDAI 5.8 (2.2) 2.6 (2.4) 0.0003 
BASFI 4.8 (2.3) 2.7 (2.2) 0.006 
BASMI 3.5 (1.7) 2.7 (1.1) 0.001 
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2.4 Discussion 
The results from the anti-TNF cohort show that the Bath indices effectively show 
change with therapy and are still reliable measures of disease activity in routine 
clinical practice. However, this was not the case with apremilast, where the changes 
were smaller and failed to achieve statistical significance. It is important to note that 
most of the clinical indices show a placebo effect. Of all the indices, the BASFI 
showed the smallest improvement with placebo, yet showed an almost statistically 
significant improvement in the apremilast group. BASFI may hence be a more 
specific marker of response to therapy. The ASAS 20, 40 and 5/6 responses take the 
BASFI into account and may hence may also be effective tools to measure response to 
therapy. The ASDAS lays more stress on the patient global score which is similar to 
the BAS-G. It also takes into account raised CRP levels as well as peripheral disease 
which is seen in a small proportion of patients with AS. 
 
The results of the START study show that apremilast may have a role in the 
management of AS patients. As this was a pilot study, a 3 month period of 
observation was used to assess response assuming that if there was a response, it 
would be similar to anti-TNF therapy. However, the data clearly shows that the 
response to apremilast is slower and patients do not actually notice an improvement 
till 2 months after commencing therapy. If the treatment duration were longer, it may 
have been possible to see a further drop in Bath Indices and hence see a statistically 
significant response. This short study does however make the case for apremilast to be 
studied in further clinical trials as disease modifying therapy in patients with AS. A 
recently published phase II study of apremilast in psoriatic arthritis shows that the 
drug is also effective in controlling peripheral disease with 43.5% of  165 patients 
receiving apremilast 20mg BD and 38.5% of patients receiving apemilast 40mg OD 
versus 11.8% of those receiving placebo showed a ACR 20 response [155]. 
 
In order to assess the efficacy of this drug in AS further, long term studies are 
required which would allow for assessing effect not just on clinical and biochemical 
parameters but also on imaging. A further phase III study is now underway using 
apremilast in Ankylosing Spondylitis. 
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Chapter 3: Semi-quantitative scoring of lesions on MRI as 
a biomarker of response to therapy in AS 
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3.1 Introduction 
 
Over the last decade, MRI has played an important part in understanding of disease 
pathogenesis. It has also helped with early diagnosis of the condition by showing 
areas of bone oedema which would appear normal on plain X-rays. This has led to 
MRI taking centre stage in this condition with changes to classification criteria and 
the development of a new disease entity called early or non-radiographic 
spondyloarthritis [156].  
 
There is a disparity between clinical scores (BASDAI) and MRI findings. This 
remains unexplained. More recent reports have shown a correlation between CRP and 
ASDAS scores and MRI findings [157]. There is also the issue of scoring changes on 
MRI scans with at least 6 different scoring systems being used in different parts of the 
world which have been detailed in chapter 1. All of these scoring systems remain 
semi-quantitative. They all take into account the area of lesion, giving it a numerical 
score depending on the extent of the lesion. More recent modifications have used 
change in intensity and involvement of lateral elements as well, giving these systems 
more credibility. Although most of these scoring systems have been validated in a 
number of studies as reflecting change with therapy, they only estimate changes seen 
by semi-quantitative scores. This chapter discusses the utility of Berlin Score as a 
biomarker of response to therapy and the problems with semi-quantitative scoring. 
  
Most clinical MRI scans for the spine tend to be restricted to the area of suspected 
pathology which in most cases is the sacroiliac joints. However, recent reports have 
shown that bone oedema lesions can be seen in other spinal regions as well especially 
in the thoracic spine, which is difficult to visualize using X-rays due to overlapping 
structures. Hence, imaging of the whole spine along with sacroiliac joints is required 
to obtain the clearest picture at a given time point. Most clinical scans use 1.5 Tesla 
MRI scanners and subject patients to T1 weighted sequences which helps detect 
chronic changes and fatty lesions at areas of previous inflammation as well as STIR 
sequences that detects active bone oedema representing inflammation.  
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3.2 Methods 
This section describes the development of a scanning protocol for the whole spine and 
sacroiliac joints that was used to scan all patients in this study.  
3.2.1 Sequence development at 3T 
 
The initial sequence optimization was carried out as part of on an ongoing study of 
MRI sequence development by the team at the Robert Steiner Unit, Hammersmith 
Hospital. This already had previous ethics approval (08/H0711/82) from the local 
ethics committee. This work was done by radiographers Ms Amy McGuinness and 
Ms Emer Hughes with guidance from Dr Anshul Rastogi and Dr Adrian Lim.  Prof Jo 
Hajnal provided the technical advice on this project. I took over from Dr Rastogi, 
recruiting patients for image optimization and coordinating between the radiographers 
and radiologists. A 3T scanner was used because the same scanner had previously 
been used for optimization for imaging the wrist in Rheumatoid arthritis in work 
undertaken by Dr Rastogi in the department. Images obtained previously on the 1.5T 
scanner were not of optimum quality and hence this scanner was not used. 
 
The MRI protocol for whole spine and sacroiliac joints was devised by scanning 9 
healthy volunteers and 5 patients on a 3 Tesla (3T) MRI Philips Achieva system using 
an 8 channel spine coil at the Robert Steiner Unit. Standard Phillips moving table 
protocols were implemented consisting of T1 weighted STIR, Spectral fat suppression 
sequence (SPIR) and PROSET (fat or water selective excitation) sequences. 
Optimization for the 3T system was performed exploring a range of different 
repetition times (TR) for the T1 weighted sequence (200-500ms) and a range of 
differing inversion times (TI) for the STIR sequence (60-300ms).  
 
The standard Philips PROSET sequence was applied with comparative optimisation 
being performed from the previous WRIST RA parameters. This included using 
different TRs and flip angles (FA). SPIR was found to be relatively unreliable using 
the 3T system for large field of view spine protocols and therefore omitted from the 
final protocol.  
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Further optimization of all sequences was performed in order to minimize the effect 
from image artefacts and subject motions (voluntary-swallowing and involuntary –
vascular flow, respiration and peristaltic bowel movements). This included exploring 
different shim settings (pencil beam/ volume shim) and the application of saturation 
bands over the areas of motion. 
 
Different resolution and signal to noise ratio (SNR) qualitative assessments were done 
to look at improving resolution of the spine images with various voxel sizes (0.9 mm 
to 1.5mm) and different Sensitivity Encoding (SENSE) settings.  
 
The efficiency of whole spine scanning was also explored. The protocol required 3 
sequences at 4 contiguous vertebral locations to be obtained. Table movement 
between spinal segments takes time, therefore to improve patient comfort and 
decrease table movements the scanning order was modified from acquiring all T1W 
sequences, then all STIR sequences followed by all PROSET sequences, to scanning 
all 3 weightings at each of the 4 spinal levels. This decreased the number of table 
movements from 9 to 3, decreasing the overall scan time. Individual region scanning 
was followed by fusion using the Philips post processing tool mobiview. 
 
The protocol was further modified by Ms Amy McGuinness in conjunction with Dr 
Adrian Lim, Consultant Musculoskeletal Radiologist, to increase the signal to noise 
ratio and optimize the window width and level of the final images to ensure a 
successful transfer of images to the PACS system. 
 
 The voxel size was increased to 1.25mm from 1.1mm. The field of view was also 
increased from 264x264mm to 320x300mm. SENSE was turned off and saturation 
bands turned on, improving the quality of images. A further 5 AS patients were 
scanned on the modified protocol before and after anti-TNF therapy. The scans were 
then scored by 2 musculoskeletal radiologists who felt there was a significant change 
in signal using this protocol as against the previous protocol. 
 
The protocol was then applied to scan study patients to obtain images of the whole 
spine and sacroiliac joints at screening and on completion of 12 weeks of therapy. T1 
weighted and STIR sequences were obtained of the whole spine and sacroiliac joints. 
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Additional Proset sequences were obtained for the sacroiliac joints. Scans were 
reported by Dr Adrian Lim to confirm that patient had evidence of active bone 
oedema at screening. 
 
 
3.2.2 Scanning protocol 
 
The following standard operating procedure was followed by the radiographers while 
scanning patients using the Philips scanner. 
 
1. Find protocol (spine START study) 
2. Centre mid cervical spine ~ C5 i.e. midway between sternal notch (T2) and 
angle of mandible (C3). 
3. Run moving table sagittal survey – fuse 3 regions into whole sagittal spine 
image in advanced viewing. 
4. Position coronal off fused saggital whole spine image. 
5. Fuse 3 coronal regions into whole spine coronal image in advanced viewing. 
6. Open ‘3 region planning’ sequence. (30mm overlapping). NB. DO NOT RUN. 
This sequence is for setting up only. 
7. Position on fused saggital and coronal whole spine images along the midline 
of the spine to include whole spine from Left (L) to Right (R), Foot Head 
(FH). 
8. In Offsets/ angulations (off/ang) note offsets for all 3 stacks (A, B and C) in 
FH, antero-posterior (AP) and right to left (RL) directions. 
9. Reference Scans - Copy offset FH positions for stack A, B and C  
10. Set up C-spine – enter offsets/ang for stack C 
11. Set up T-spine – enter offsets/ang for stack B 
12. Set up L-spine – enter offsets/ang for stack A 
This will automatically change the offsets for all sequences with the same 
geometry. The software tool, Scan Align, was used to position the cervical, 
thoracic and lumbar sagittal stacks contiguously. 
13. Set up axial survey through sacrum. 
14. Position coronal SIJ field of view (FOV) and run sequences. 
Confirm coverage of 
vertebral bodies from L-R 
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15. SIJ - Proset shim test – a quick low resolution scan to accurately position our 
pencil beam (pb) volume shim voxel. This determines correct excitation of the 
water signal in an inhomogeneous B0. 
-position pb volume shim voxel to cover the whole of the spine. i.e. from the 
front of the vertebral bodies to the spinous process, R to L and the FOV 
superiorly to inferiorly. 
- run shim test and view image noting quality of saturation of fat. Note that 
this needs to be homogenous along the whole FOV. If not then 
reposition/change FOV of pb volume shim voxel and rerun test and fat 
excitation review. 
16. If no signal from fat is present – run coronal proset sequence. Check coverage. 
17. Fusing 3 regions into whole spine: 
- Advanced viewing 
- Select C, T and L spine of the same sequence. i.e. T1, STIR. 
- Right mouse click – mobiview 
- Scroll through images, changing window width (WW) and window level 
(WL) as appropriate 
- Click smooth fusing icon 
- Store fused images 
18. If there are neural anomalies or disc prolapses identified run T2W fast field 
echo (FFE) axial scans through region of interest. (Parallel to the intervertebral 
disc space, including the exit foramina superiorly for disc or whole lesion in HF 
direction). 
19. Send all images to mridb, DVD queue # 4 and burn a DVD labelled with 
patient number and time point. Fused mobiview images and SIJ Proset sequence 
should be sent to PACS for reporting. 
 
3.2.3 Patient cohorts 
All patients that consented to the START study, who did not have any contra-
indications to MRI scanning, were subjected to a scan at screening and all 36 who 
completed the study had a further scan at 12 weeks after treatment with either 
Apremilast or placebo. With the anti-TNF cohort, all patients consented to the study 
entitled ‘The impact of TNF blockade on effector T cell populations in patients with 
 75 
Rheumatoid arthritis, Psoriatic Arthritis and Ankylosing Spondylitis treated with anti-
TNF therapy’, were offered MRI scans before and after treatment but this was not 
essential to their participation in the study.  Patients recruited on the study entitled 
“Molecular mechanisms and pathways in chronic inflammatory and degenerative 
disease” were also subjected to MRI scanning at baseline and 3 months after anti-TNF 
therapy. 
 
3.2.4 Anonymization of scans 
All scans were anonymized for patient identity. Pre and post treatment scans were 
randomly annotated as scan A or B. The radiologists that scored the scans were 
unaware of what treatment the patient had received. This allowed for blinding of the 
individuals scoring the scans. 
  
3.2.5 Scoring using Berlin method 
 
All scans were scored using the Berlin Score by Dr Adrian Lim and Dr Keshthra 
Satchithananda, Consultant musculoskeletal radiologists, with both radiologists 
conferring with each other before scoring the scans together. The Berlin score was 
chosen by the radiologists as they felt this was easy to use and a quicker method of 
scoring than other scoring systems. This has been detailed previously in chapter 1. 
Briefly, each spinal segment was scored between 0-3 and the total spinal score out of 
69 was calculated. Similarly, each side of the sacroiliac joint was scored between 0-3 
and a total score was calculated out of 12. All scores were added to calculate total 
spinal and SIJ scores. These in turn were added to give the total MRI score. Pre and 
post treatment scores were compared using paired t-test or Wilcoxon matched pairs 
test in the anti-TNF cohort and by ANCOVA for the START study. 
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3.3 Results 
3.3.1. START study cohort- change in MRI scores with treatment 
 
Scans were available for 48 patients screened with MRI at baseline. Of these, 6 
patients did not show evidence of bone oedema at baseline and another 2 patients 
withdrew consent after screening. Of the remaining 38 patients, 2 patients withdrew 
from the study leaving 36 patients for whom paired scans were available at baseline 
and 3 months after apremilast therapy. 
 At baseline, patients in the apremilast group had a statistically significant higher total 
spine score as contrasted with those receiving placebo. Patients in the placebo arm 
however, had a slightly higher total SIJ score, although this was not statistically 
significant. When the total scores were compared, patients on apremilast had a higher 
score although the difference did not reach statistical significance. The Berlin scores 
were compared using ANCOVA giving the following results listed in table 3.1, 3.2 
and 3.3. There was no statistically significant improvement in any of the scores using 
Berlin scoring for this cohort of patients. Of note even patients receiving placebo 
showed an improvement in MRI scores.  
 
Table 3.1: Change in Total Spine scores from baseline 
 
Visit 
Placebo 
(n=19) 
Mean (SD) 
Apremilast 
(n=17) 
Mean (SD) 
p-value 
Baseline   3.21 ( 4.638)   7.47 ( 7.054) 0.038 * 
Day 85   2.58 ( 3.746)   6.12 ( 7.245)  
Diff Mean 
(SD) 
 -0.63 ( 1.422)  -1.35 ( 4.197) 0.988 
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Table 3.2: Change in Total SIJ scores from baseline 
 
Visit 
Placebo 
(n=19) 
Mean (SD) 
Apremilast 
(n=17) 
Mean (SD) 
p-value 
Baseline   3.16 ( 2.834)   2.71 ( 3.077) 0.649 
Day 85   3.05 ( 2.953)   2.12 ( 2.690)  
Diff Mean 
(SD) 
 -0.11 ( 1.696)  -0.59 ( 0.939) 0.228 
 
Table 3.3: Change in Total MRI scores from baseline 
 
Visit 
Placebo 
(n=19) 
Mean (SD) 
Apremilast 
(n=17) 
Mean (SD) 
p-value 
Baseline 6.37 ( 4.958) 10.18 ( 8.301) 0.100 
Day 85 5.63 ( 4.245) 8.24 ( 8.592)  
Diff Mean 
(SD) 
-0.74 ( 2.156) -1.94 ( 3.976) 0.494 
 
 
3.3.2 Anti-TNF cohort- change in MRI scores with treatment 
 
16 AS patients were screened for the study entitled, ‘The impact of TNF blockade on 
effector T cell populations in patients with Rheumatoid arthritis, Psoriatic Arthritis 
and Ankylosing Spondylitis treated with anti-TNF therapy’. Of these, one patient 
withdrew from the study and 4 patients did not get scans either at baseline or follow 
up either due to contra-indications or patient choice. A further 3 patients did not 
undergo scanning 3 months after anti-TNF therapy due to claustrophobia. Follow up 
scan images on one patient were unavailable due to technical reasons. An additional 8 
patients were recruited on the study entitled, “Molecular mechanisms and pathways in 
chronic inflammatory and degenerative disease” had both baseline and follow up scans.  
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Paired data was hence available from 12 out of 15 patients treated with anti-TNF 
therapy. The improvement in Berlin score with anti-TNF therapy is shown in table 
3.4. In two patients, no lesions were detected at baseline on MRI in patients starting 
anti-TNF therapy. There was a statistically significant improvement in scores for total 
spine (p=0.05). The improvement in SIJ scores also approached statistical significance 
(p=0.055), while the improvement in total MRI score (Spine and SIJ together) was 
also statistically significant (p=0.03). 
 
Table 3.4: Change in Berlin scores with anti-TNF therapy  
MRI Berlin 
score 
Pre-treatment 
Mean (SD) 
Post-treatment 
Mean (SD) 
p-value 
(Wilcoxon’s matched pairs test) 
Spine score 5.67 (6.95) 2.73 (5.13) 0.05 
 SIJ score 4.27 (4.22) 2.53 (2.72) 0.055 
Total score 9.93 (9.79) 5.26 (7.12) 0.03 
 
When the patients were divided into those that showed a response clinically with a 
50% improvement in BASDAI or a drop of ≥2 units, there were 10 responders and 5 
non-responders. While the improvement in Berlin score was statistically significant in 
the responders (p=0.02) (Fig 3.1), this was not the case in the non-responders 
(p=0.85). 
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Fig 3.1: Change in Berlin Total (Spine and SIJ) score in responders on anti-TNF 
therapy 
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MRI total spine and SIJ in non-responders
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Fig 3.2: Change in Berlin total score in non-responders to anti-TNF therapy. 
 
 
 
 
3.3.3 Correlation between MRI total Berlin score and total BASDAI scores 
 
3.3.3.1 Anti-TNF cohort 
 
When total MRI scores were correlated to BASDAI scores using Spearman Rank 
correlation, there was no correlation seen either at baseline or follow up (Fig 3.3 and 
3.4). There was also no correlation between percentage change from baseline in 
BASDAI versus the percentage change from baseline in the total spine MRI score 
[r=0.32, p=0.24] (fig 3.5). 
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Fig 3.3: Correlation between baseline BASDAI and total MRI Berlin score in anti-
TNF cohort 
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Fig 3.4: Correlation between follow up BASDAI and total MRI Berlin Score in anti-
TNF cohort 
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Fig 3.5: Percentage change in total MRI score versus percentage change in total 
BASDAI score 
3.3.3.2 START study cohort 
 
Similarly, there was no correlation seen between baseline or follow up BASDAI and 
MRI Berlin total scores in the START study cohort (Fig 3.6 and 3.7). There was an 
even poorer correlation between percentage change from baseline in BASDAI versus 
the MRI total Berlin score in this cohort [r=0.03, p=0.84] (Fig3.8). 
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Fig 3.6: Correlation between baseline BASDAI and Berlin total MRI scores at 
baseline in the START study cohort 
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Fig 3.7: Correlation between BASDAI and Total MRI Berlin scores at follow up in 
START study cohort 
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Fig 3.8: Correlation between percentage change in BASDAI versus percentage 
change in MRI total Berlin score in the START cohort 
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3.4 Discussion 
 
The Berlin MRI scoring system was selected for this study as it is relatively easy to 
use. The patients were being followed up over a period of 3 months where chronic 
changes were unlikely to develop and hence the original ASspiMRI scoring system 
described by Braun et al which provided a score between 1-6 for both activity and 
chronicity would not be applicable. As we developed our own scanning protocol, we 
did not follow the recommended protocol for SPARCC scoring and hence were 
unable to apply this method for scoring scans. This system has the advantage of 
scoring only 6 areas which are taken as representative of the entire scan. Also the 
protocol did not allow for complete visualization of the transverse processes and 
hence other systems such as SPARCC or the Aarhus-Madsen system could not be 
applied. 
 
 
One of the important aspects that this study highlights is the absence of active bone 
oedema lesions on MRI at baseline in patients starting anti-TNF therapy. These are 
patients with BASDAI scores of above 4 which clearly show the disparity between 
clinical and imaging biomarkers. Similarly, 6 patients screened for the START study 
also showed no active bone oedema lesions in spite of qualifying for the study on 
clinical scores. This may be due to the fact that the protocol did not allow for 
visualization of the posterior and transverse elements hence missing lesions in these 
areas. However, it is also possible that MRI is just not as sensitive a biomarker as we 
would like and does not always show evidence of active disease in AS patients. This 
has already been shown in other histopathological studies where there was evidence 
of active inflammation even though the MRI did not show bone oedema. Perhaps, the 
sequences used for scanning need further development to better identify areas of 
inflammation on MRI scans. 
 
This also leads on to the lack of correlation between improvement in clinical and MRI 
scores in both patient cohorts. It is not clear whether there is a lag in improvement in 
the MRI lesions or just a disparity between what the patient scores on clinical 
questionnaires and what is seen on the MRI. A long term study of repeated MRI scans 
in patients on effective therapy may be able to answer this question. An important 
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factor to consider is the fact that Berlin scoring only takes into account the relative 
improvement in area of the lesion with scores only changing when there is >25% 
relative improvement in the area of the lesion. It does not take into account the more 
subtle improvement both in area or intensity of the lesion which may correlate to an 
improvement in clinical scores. There is hence a case for developing a more robust 
quantitative volumetric analysis which would allow us to study exact improvements in 
area or volume as well as intensity of lesions. These can then be correlated to the 
clinical scores which remain gold standards for assessing response to therapy. The 
difficulty with such a volumetric analysis remains the fact that most MRI scanning 
protocols usually scan patients taking images in the form of slices with gaps between 
the two slices. This is because scanning without gaps takes much longer especially if 
large sections of the body are to be scanned. Scanning with gaps would hence not 
allow for a true volumetric analysis to be carried out unless there was a way to take 
these gaps into account and calculate volumes. Chapter 5 and 6 detail my attempts at 
carrying out volumetric analysis on our 2 patient cohorts using the current protocol. 
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Chapter 4: Laboratory biomarkers of response to therapy 
in Ankylosing Spondylitis 
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4.1 Introduction 
 
Unlike clinical and imaging biomarkers which have been found to be useful in 
monitoring response to treatment in routine clinical management of AS, laboratory 
biomarkers largely remain research tools and are not routinely measured in day to day 
practice. The classical acute phase response markers such as ESR and CRP may be 
elevated in a minority of AS patients but this is not so for the majority and therefore at 
the cohort level, as well as in the case of most individuals, they represent poor 
markers of response. IgA has been shown to be elevated in this group of patients but 
is again not routinely measured as a marker of response to therapy. 
In this chapter, I discuss the different classes of laboratory biomarkers in addition to 
traditional markers such as ESR, CRP and IgA. The first class of biomarkers relates to 
bone biology which is important as bone formation is central to this condition. The 
second class relates to cytokines and growth factors. These are detailed further in 
relevant sections below. 
 
4.2 Methods 
 
4.2.1 Patient cohorts 
Similar to the clinical and imaging data, laboratory biomarkers were studied in 2 
separate cohorts. These include the START study cohort and the anti-TNF cohort 
detailed in chapter 2. 
 
4.2.1.1 START study cohort 
As detailed previously, this included 36 patients that were randomised to receive 
either apremilast (n=17) or placebo (n=19). The laboratory biomarkers were studied 
only at baseline and at 12 weeks on study medication i.e. just before withdrawal of the 
study drug. Although samples were collected at all other time points during the study, 
they were not analyzed due to cost and time constraints.  
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4.2.1.2 Anti-TNF cohort 
This included 15 AS patients recruited to the study, ‘The impact of TNF blockade on 
effector T cell populations in patients with Rheumatoid arthritis, Psoriatic Arthritis 
and Ankylosing Spondylitis treated with anti-TNF therapy’ [EudraCT No: 2009-
012424-87]. In addition, 4 others were recruited on the study entitled “Molecular 
mechanisms and pathways in chronic inflammatory and degenerative disease”. The 
patient characteristics of this cohort are described in section 2.3.2. Samples were 
analyzed at baseline and 12 weeks after anti-TNF therapy. 
 
4.2.2 ESR, CRP and IgA levels 
 
Routine biochemistry including CRP and haematology including ESR were performed 
at all patient visits by the laboratory at Charing Cross Hospital, Imperial College 
Healthcare NHS Trust. Additionally, serum IgA levels were also processed at baseline 
and 12 weeks after starting therapy. The normal range for CRP was considered up to 
5mg/L at the start of the study. However, the biochemistry laboratory changed its 
assay within a few months of start of the study to the highly sensitive CRP assay 
allowing detection of levels as low as 0.5mg/L.  
 
4.2.3 Bone biomarkers  
 
These were measured by me using enzyme-linked immunosorbent assays (ELISAs) at 
the Kennedy Institute in the laboratory of Mr Peter Charles assisted by his 
technicians, Ms Erin Paterson and Ms Muslima Chowdhury. Blood samples were 
centrifuged at 1300g for 15 minutes within 2 hours of sampling with serum and 
plasma samples stored at -80
o
C. The following commercially available ELISA assays 
were used: Osteocalcin, Tartarate resistant acid phosphatase (TRAP5b), 
Osteoprotegrin (OPG) and Bone alkaline phosphatase (BAP) [MicroVue Bone Health, 
Quidel Corporation, CA, USA], Matrix metalloproteinase 3 (MMP-3) [Quantikine , 
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R&D systems, Abingdon, UK] and Human serum Receptor Activator of NF-κB 
Ligand (sRANKL)[ Peprotech Inc, NJ, USA] . Commercially available DuoSet 
ELISA development system [R&D systems] was used to measure DKK-1 levels in 
serum. A sandwich ELISA protocol was developed using R& D Systems 
Recombinant Human Sclerostin, Biotinylated Anti-human Sclerostin antibody (1:500 
dilution) and monoclonal anti-human Sclerostin antibody (2μg/ml) to measure 
sclerostin levels in plasma and serum. Further details of individual assays are shown 
in table 4.1. 
 
 
5 of the 8 analytes were tested using a sandwich ELISA. While the assays for OPG 
and MMP3 used pre-coated plates, assays for RANKL, Dkk-1 and sclerostin involved 
coating plates with a capture antibody overnight at 4
o
C. Any unbound antibody was 
then washed away and a blocking reagent was added. This was then washed off and 
the samples, standards and controls, if provided, were added for a short incubation 
period to capture the analyte. The unbound analyte was then washed away and a 
conjugated detection antibody, which is directed to a different epitope on the analyte, 
was added. .Following incubation, unbound antibody was washed away and an 
amplification agent (e.g. Streptavidin Horseradish peroxidase) was added which 
bound to the conjugated antibody. Following a further wash, addition of the assay 
recommended substrate, (e.g. hydrogen peroxide and tetramethylbenzidine) causes a 
change in colour. In order to stop the reaction, the assay recommended stop solution 
(e.g. 2N sulphuric acid) was added which caused a further change in colour. The 
absorbance was measured using Spectrophotometry at appropriate wavelength 
(450nm for TMB) using microtiter plate reader software Mikrowin 2000. 
 
 
TRAP5b and BAP were measured by direct immunocapture assays. Here the antibody 
binding to the analyte was coated on to the micro plate well.  When the sample was 
added to the well, the analyte present in serum bound the antibody directly. The 
enzyme activity of the analyte in the sample was then detected using the substrate, in 
this case p-Nitrophenyl phosphate, which resulted in a colour change. 0.5N NaOH 
was used as stop solution. Optical density was measured at 405nm. 
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The osteocalcin assay was a competitive assay. Here the microplate wells were coated 
already with osteocalcin which competed with the osteocalcin present in the sample to 
bind to the anti-osteocalcin antibody. Goat anti-mouse IgG antibody conjugated to 
alkaline phosphatase was then added which bound to the already bound anti-
osteocalcin antibody. P-Nitrophenyl phosphate was used as the substrate for this assay 
with 0.5N NaOH as the stop solution. Optical density was measured as before at 
405nm. 
 
Samples were run at 3 different time points through the study period in batches prior 
to unblinding in the case of the START study cohort. Pre and post-treatment samples 
for each patient were run together on the same ELISA plate to reduce variance. Each 
sample was run in duplicate. Concentration values of analytes were calculated by non-
linear regression (curve fit) with variable slope using GraphPad Prism software. The 
average concentration was then calculated for each sample and this value was used for 
further analysis.  
 
Levels of sclerostin were initially measured in the plasma in the START cohort. This 
was because when levels of sclerostin were measured in normal volunteers comparing 
plasma and serum samples, levels were found to be higher in plasma and within 
quantifiable range in most samples. However, as there were no plasma samples 
available in most of the anti-TNF cohort, levels of sclerostin were measured in serum 
as well in the START cohort in order to make direct comparisons between the 2 
cohorts. 
 
 
The normal ranges, sensitivity and coefficient of variation for the commercially 
available assays are shown in table 4.2.  
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Table 4.1: Summary of various commercial ELISA assays used to measure bone biomarkers 
Analyte 
 
Kit used 
 
Type of ELISA 
 
Sample 
 
Standard Capture antibody 
 
Detection 
antibody 
 
Conjugate Substrate 
 
Optical 
Density 
RANKL Peprotech 
Human s-
RANK-Ligand 
ELISA kit 900-
K142 
Sandwich Serum Human s-
RANK-
Lignad 
(100μg/ml) 
Mouse anti-
hsRANK- 
Ligand(100μg/ml) 
Biotinylated 
antigen-
affinity 
purified 
Rabbit anti-
hsRANK-
Ligand  
Avidin HRP 
conjugate 
ABTS liquid substrate 405nm with 
correction 
set at 
650nm 
DKK-1 DuoSet ELISA 
Development 
system human 
Dkk-1 Cat # 
DY 1906 
Sandwich Serum Human 
DKK-1 
4000pg/ml 
Mouse anti-human 
Dkk-1 Ab  (4 
μg/ml) 
Biotinylated 
goat anti-
human Dkk-
1   
Streptavidin –
HRP 
Reagent A- H2O2 
Reagent B-
Tetramethylbenzidine 
(TMB) 
450nm with 
wavelength 
correction 
at 540nm 
Sclerostin R&D systems  Sandwich Plasma 
and/or 
Serum 
Recombinant 
human 
sclerostin 200 
μg/ml diluted 
to 10ng/ml 
Anti-human SOST 
Ab at 2 μg/ml 
Biotinylated 
Ab  
Streptavadin-
HRP 
Reagent A - H2O2 
Reagent B TMB 
450nm with 
reference at 
570nm 
OPG Microveue 
OPG ELISA 
sandwich Serum 
dil 1:3 
Human OPG Murine anti-human 
OPG Ab coated  
Anti-Human 
OPG Ab 
Streptavadin 
HRP  
Reagent A- H2O2 
Reagent B TMB 
450nm 
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MMP3 Quantikine  
(R&Dsystems) 
Human total 
MMP-3 
Immunoassay 
sandwich Serum 
diluted 
10 fold 
in 
diluent 
RD5-
10 
Recombinant 
human pro-
MMP3 in 
buffered 
protein base 
Polyclonal 
antibody against 
MMP-3 coated 
onto wells 
Polyclonal 
Ab against 
MMP-3 
conjugated 
to HRP 
 Reagent A- H2O2 
Reagent B TMB 
450nm with 
correction 
at 570nm 
Osteocalcin MicroVue 
Osteocalcin 
EIA kit (Quidel 
) 
Competitive 
immunoassay 
serum Lyophilised 
Osteocalcin  
Anti-osteocalcin 
antibody 
Anti-mouse 
IgG- 
alkaline 
phosphatase 
conjugate 
 p-Nitrophenyl 
phosphate 
405nm 
TRAP5b MicroVue 
TRAP5b EIA 
kit 
Direct 
Immunocapture 
assay 
serum Lyophilised 
Human 
TRAP5b 
Murine 
monoclonal anti-
TRAP5b 
antibodies coated 
onto plates 
  2-chloro-4-
nitrophenyl-phosphate  
405nm 
BAP MicroVue BAP 
EIA kit 
Capture 
immunoassay 
serum BAP purified 
from 
osteosarcoma 
SAOS-e cells 
Murine 
monoclonal anti-
BAP IgG antibody 
adsorbed onto strip 
wells 
  p-Nitrophenyl 
phosphate  
405nm 
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Table 4.2: Sensitivity, Normal Ranges and Coefficient of variation for the various 
bone biomarker assays 
Analyte Sensitivity Normal Range Coefficient of 
variation (%) 
RANKL* >1.5 pmol/L 0.48-9.28 pmol/L 6.7-7.1 (Intra) 
OPG‡ >0.4 pmol/L 5.28- 6.12pmol/L 2.1-3.5 (Intra) 
4.2-6.1 (Inter) 
Osteocalcin‡ >0.45ng/ml 3.7-10 ng/ml 4.8-10 (Intra) 
4.8-9.8 (Inter) 
TRAP5b‡ >0.2 U/L Men: 4.0±1.4 U/L 
Women:2.9±1.4 U/L 
(Premenopausal) 
Women: 4.3±1.5 U/L 
(Postmenopausal) 
1.9-2.2 (Intra) 
2.0-3.0 (Inter) 
BAP‡ >0.7 U/L Men: 15.0-41.3U/L 
Women:11.6-29.6 U/L 
(Premenopausal) 
Women: 14.2-42.7 U/L 
(Postmenopausal) 
3.9-5.8 (Intra) 
5.0 -7.6 (Inter) 
MMP3‡ 0.002-0.045ng/mL 2.1- 64.4 ng/ml 5.7-6.4 (Intra) 
7.0-8.6 (Inter) 
Dkk-1* > 62.5 pg/ml 2.18-3.55 ng/ml 5.2-7.6 (Intra) 
7.2-10.6 (Inter) 
Serum sclerostin* 
Plasma sclerostin* 
> 156 pg/mL 
>78 pg/ml 
366.3-1781pg/ml 
706.7-1696pg/ml 
1.5-4.1  (Intra) 
2.2-2.5 (Intra) 
5.8-8.7 (Inter) 
 ‡ Normal ranges and CVs quoted as reported by manufacturer 
    * Normal ranges quoted as determined by results of assays run on volunteers. Intra-
assay CVs based on 20 samples run in duplicate on a microplate. Inter-assay CVs 
based on results from 2 controls run on 3 plates. 
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4.2.4 Cytokines, Chemokines and Growth factors 
As there were a large number of analytes to be studied, the BD (Beckton Dickenson) 
cytometric bead array (CBA) system was used. This system combines the sensitivity 
of amplified fluorescence detected by flow cytometry to measure soluble analytes 
with a particle based immunoassay. This system allows testing for up to 30 analytes 
simultaneously using a very small serum sample.  
 
4.2.4.1 Principle of CBA 
 
The CBA system utilizes bead particles with fluorescence intensities in two different 
fluorescent parameters to simultaneously detect and quantify multiple analytes in the 
same sample. Each BD CBA Human Soluble Protein Flex set capture bead represents 
a single bead population which has a distinct fluorescence. Beads are coated with a 
capture antibody specific to a single soluble protein. Each bead is designated an 
alphanumeric position which indicates where the population is resolved in relation to 
other bead populations. Hence, beads with different positions are combined in the 
same assay to produce a multiplex assay. 
In a CBA Flex Set assay, standards and samples are incubated with a mixture of 
capture beads. After a short incubation period, a mixture of phycoerythrin (PE) - 
conjugated detection agent is added for a second incubation (Fig 4.1). The sandwich 
complexes formed are then acquired using BD FACSArray or other compatible 
analyzer. The files are then exported and filtered using FCS filter program before 
being imported into and analyzed using FCAPArray software program. 
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Fig 4.1: Principle of CBA: Capture beads are incubated with samples and PE-
conjugated detection reagent forming sandwich complexes. These are then detected 
using FACSArray software. 
 
4.2.4.2 Procedure of CBA- Preparing samples, standards and reagents 
 
1. Prior to starting the assay, the daily Start-up routine for the FACSArray was 
completed. 
2. A Rainbow Bead (8 peak) calibrator and a 30 Plex control Bead Mixture sample 
was run through to check QC/Calibration. 
3.  One vial containing the lyophilised standard bead for each Flex set to be used was 
emptied into a 15ml Falcon tube and this was labelled as ‘Top Standard’.  
4. Standards were reconstituted using 4ml of Assay Diluent provided in the kit to the 
beads. This was allowed to stand for 15 minutes. 
5. 8 tubes were labeled for 2-fold dilutions 1:2 -> 1:256.  500µl of Assay diluent was 
added to each tube. 
6. A 2-fold serial dilution was performed using the top standard tube as the starting 
"stock" solution and the top point on the standard curve.  An additional tube was 
prepared containing Assay Diluent only to serve as a zero standard. 
Beads 
Sample 
Detection antibodies 
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7. Another 15ml Falcon tube was labelled Mixed Capture Beads. The number of 
standards or samples to be tested was calculated, and then an additional 2-4 
"samples" were added to that number to allow for a dead volume. 
8. After vortexing the individual vials of Capture Beads for 15 seconds, 1ul of 
Capture Beads per standard/sample (as calculated in step 7) was added for each 
Flex set to be used. 500µl of Wash Buffer was added.  This was then centrifuged 
at 2000g for 5 minutes. The resulting supernatant was then discarded without 
dislodging the bead pellet.  
9. The Capture Beads were then re-suspended in Capture Bead Diluent provided in 
the kit for serum/plasma allowing 50µl per standard/sample to be tested. This was 
then stored away from direct light. 
10. A third 15ml Falcon tube was labeled Mixed PE Detection Reagent. The number 
of standards/samples to be tested was calculated and several additional tests were 
added to ensure there was enough reagent prepared. For each Flex Set, 1µl of PE 
Detection reagent per standard/sample to be tested was added to the Mixed PE 
Detection Reagent tube.  
11. Allowing a final volume of 50µl per standard/sample to be tested, the PE 
Detection Reagent was diluted using Detection Reagent Diluent.  
12. This was stored at 4ºC away from sunlight. 
13. Finally tubes were labeled with individual sample ID’s and then serum samples 
were diluted1:4 with Assay diluent (15µl of sample to 45µl of Assay diluent). 
 
4.2.4.3 Assay procedure 
 
1. 100µl of Wash Buffer was dispensed into each well of the filter plate to be 
assayed taking care not to perforate the filter membrane at the base of the well. 
 
2. The Wash Buffer was then removed using vacuum manifold with pressure not 
exceeding 10” Hg.  Wells were aspirated until drained (2-10 seconds).  To 
ensure the filter was no longer porous following the aspiration, the plate was 
tapped to remove excess moisture from the bottom of the filter plate on to 
absorbent tissue. 
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3. The “Mixed Capture Beads” tube was then vortexed and 50µl of Mixed 
Capture Beads was dispensed into each well. 
 
4. 50µl of standard or sample was added to the designated wells on the filter 
plate. The “zero” standard was dispensed into one additional well at the end of 
the plate to allow for a cluster test prior to the full analysis of the plate. 
 
5. The plate was covered and placed on an orbital plate shaker at 500rpm for 5 
minutes.  It was then removed from the shaker and incubated for 1 hour away 
from direct light. 
 
6. 50µl of “Mixed PE Detection Reagent” was added to each well. 
 
7. The plate was again covered and placed on the orbital plate shaker at 500rpm 
for 5 minutes.  The plate was then removed from shaker and incubated for 2 
hours away from direct light. 
 
8. Reagents were then aspirated using vacuum manifold as in step 2. 
 
9. The beads were re-suspended in Wash Buffer.  A minimum of 150µl was 
allowed to ensure there was enough Wash Buffer for two acquisition cycles 
through the FACSArray plus 50µl excess as dead volume.  The plate was 
covered and placed on the orbital plate shaker at 500rpm for 5 minutes. 
 
10. All samples were acquired using the FACSArray on the day of the experiment.   
 
4.2.4.4 Routine Acquisition & Analysis of Experiments 
 
Sample data was acquired using the FACSArray and the FACSArray software.  An 
initial single acquisition from the additional "zero" well was analyzed to ensure the 
correct number and positioning of the bead clusters before proceeding to acquire the 
data for the remainder of the standards/samples on the plate.   Data files were then run 
through the FCS Filter program to and gated to select for the population of interest 
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removing any debris from the file to be analyzed.  The filtered files were then 
imported into the FCAP software where bead clusters were linked to the analyte they 
represented and standard curves obtained for each analyte. 
 
4.2.4.5 Analytes measured and their bead positions 
 
The table below shows the bead positions of the various analytes measured using 
the CBA array. A total of 19 analytes were measured.  As some of these occupied 
the same bead position, two separate multiplexes were run. All the START study 
samples were run together on the same plate while all the anti-TNF samples were 
run together on a second plate. The tables below and their corresponding figures 
(Table 4.3, figure 4.2) on the right side show the various analytes measured in the 
first multiplex with their bead positions. 
 
    Table 4.3: Bead positions of the various analytes measured using CBA 
 
Bead 
Pos. 4 5 6 7 8 9 
A IL-2   IL-5 IL-6     
  ICAM-1           
B   IP-10   IL-10 IFN-α MIP-1α 
    IL-17A     VEGF   
C TNF         GM-CSF 
  TNF R1           
D         MCP-1 E-Selectin 
              
E   IL-12p70 IL-13 IFN-γ MIG   
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Fig 4.2: The position of the analytes measured using the 2 plex sets- the tables list the 
alphanumeric position while the figures show actual bead positions. 
 
 
4.2.4.7 IL-12 and IL-23 assays 
 
Given the important role that IL-12 and IL-23 have been shown to play in the 
pathogenesis of spondyloarthropathy [158], these were also measured using Sandwich 
ELISA as this was not available on the CBA panel. Commercially available 
Quantikine Human IL-23 and IL-12/23 p-40 immunoassays (R&D systems) were 
used to measure these analytes. The assays used microplates coated with a polyclonal 
antibody specific for IL-23 p-19 subunit or IL-12 p40 subunit respectively. Standards 
and samples diluted with assay diluent provided were added to the wells to allow any 
IL-23 or IL-12 in samples to bind the antibody. After washing the wells, an enzyme-
linked polyclonal antibody specific for IL-23 p40 subunit or IL-12 respectively was 
Plex 1 Bead Pos. 
IL-2 A4 
IL-5 A6 
IP-10 B5 
IL-10 B7 
IFN-α B8 
TNF C4 
GM-CSF C9 
MCP-1 D8 
IL-12p70 E5 
IFN-γ E7 
Plex 2 Bead Pos. 
sCD54 (ICAM-1) A4 
IL-6 A7 
IL-17A B5 
VEGF B8 
MIP-1α B9 
TNF R1 C4 
CD62E (E-
Selectin) D9 
IL-13 E6 
MIG E8 
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added. Any unbound antibody-enzyme reagent was washed away and the substrate 
(mixture of hydrogen peroxide and TMB) was added to produce a colour change. The 
reaction was stopped by adding 0.5N sulphuric acid and the optical density measured 
at 450nm with correction at 540nm. Concentration values of analytes were calculated 
by non-linear regression (curve fit) with variable slope using GraphPad Prism 
software. The average concentration was then calculated for each sample and this 
value was used for further analysis. 
4.2.5 Statistics 
Levels of analytes pre and post treatment were compared using paired t-test or 
Wilcoxon matched pairs test in both the anti-TNF and START cohorts. Where levels 
of analytes were below the sensitivity range for the assay, the lowest accurately 
detectable value for that assay was recorded and used for further analysis. Although 
not all data was normally distributed, Mean (SE) was quoted in all results in order to 
uniformly report results. The percentage change from baseline in the different 
analytes was compared between apremilast and placebo arms using Mann-Whitney U-
test or unpaired t-test as appropriate (p<0.05 considered as significant) in GraphPad 
Prism.  In order to establish whether laboratory biomarkers reflect change in disease 
activity, exploratory analysis was carried out using Spearman Rank Correlation. 
Correlations between the various laboratory biomarkers and BASDAI as well as with 
MRI Berlin scores were studied. Because of small patient numbers in each group, it 
was not possible to do a cluster analysis. As the study was not powered to detect 
statistical significance, only trends towards correlation were looked for. However, 
where p-values were <0.05, this was reported as being statistically significant. 
 
4.3 Results 
 
Laboratory biomarkers were studied in 17 patients receiving apremilast and 19 
receiving placebo in the START cohort. Both plasma and serum were available for 
this cohort of patients. In the anti-TNF cohort, laboratory biomarkers were studied in 
18 patients as insufficient serum was available to test for bone biomarkers in one 
patient. However, cytokines and growth factors studied using CBA were available in 
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all 19 patients as this only required a very small amount of serum. No plasma was 
available in 15 out of the 19 patients receiving anti-TNF therapy.  
4.3.1 ESR, CRP and serum IgA levels 
ESR, CRP and IgA levels were recorded in all 36 patients at both time points. In the 
anti-TNF cohort, CRP was recorded in all 18 patients at both time points but ESR 
values were missing at baseline in one patient and at follow up in another. IgA values 
were measured in 14 out of the 18 patients. 
4.3.1.1 Anti-TNF cohort 
CRP levels were less than 5mg/L in half the patients tested and above 10mg/L in only 
3 patients. However, there was a statistically significant drop in levels of CRP post 
anti-TNF therapy (fig 4.3A). CRP levels rose in 2 patients, which were accompanied 
by a rise in BASDAI scores.   
Similarly, ESR levels were above 20mm in only 7 out of 16 patients. Here again, a 
statistically significant drop in levels was seen (Fig 4.3B). The same patient that had 
shown a rise in CRP levels also had a rise in ESR but this was less marked.  
There was no statistically significant change in IgA levels (Fig 4.3C) in this cohort 
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Fig 4.3 Change in CRP (A), ESR (B) and IgA levels (C) with anti-TNF therapy. The 
figure shows significant changes in ESR and CRP levels but not in IgA levels. 
4.3.1.2 START study cohort 
 
Baseline CRP levels were above 5 mg/L (normal cut off for laboratory) in 8 of the 17 
patients receiving apremilast and 8 of the 19 patients receiving placebo. There was no 
statistically significant change in levels of CRP seen either with Apremilast or 
Placebo (Fig 4.4). 
 
Similarly, ESR levels were above 20mm/hr in only 4 patients each receiving 
apremilast and Placebo respectively. No statistically significant change in levels of 
ESR was seen with treatment. Levels of IgA in this cohort did not show any 
statistically significant change in either treatment group. 
 
When percentage change from baseline in levels of CRP, ESR and IgA levels was 
compared between the two treatment arms of the study, there was again no 
statistically significant change noted between the two groups (Table 4.4). 
 
Table 4.4: Percentage change from baseline in levels of CRP, ESR and IgA levels in 
the two treatment arms of the START study- no significant differences seen  
Biomarker Apremilast* (n=17) Placebo* (n=19) p value 
Serum CRP, mg/L 32.6±22.3 28.99±22.7 0.72 
ESR, mm/hr -2.32±8.75 7.34±10.12 0.25 
Serum IgA, mg/dl 0.69±3.0 1.1±2.6 0.91 
*Data are mean±SE (%). 
 
 
 
 
 
 
 
 
 102 
 
 
 
 
 
Change in CRP in Apremilast group
B
as
el
in
e
Fo
llo
w
 u
p
0
20
40
60
p=0.93
Timepoints
C
R
P
 m
g
/L
Change in CRP in Placebo group
B
as
el
in
e
Fo
llo
w
 u
p
0
10
20
30
40 p=0.74
Timepoints
C
R
P
 m
g
/L
 
 
Change in ESR in Apremilast group
B
as
el
in
e
Fo
llo
w
 u
p
0
20
40
60
p=0.14
Timepoints
E
S
R
 (
m
m
/h
r)
Change in ESR in Placebo group
B
as
el
in
e
Fo
llo
w
 u
p
0
20
40
60
80
p=0.42
 
 
Change in IgA in Apremilast group
B
as
el
in
e
Fo
llo
w
 u
p
0
2
4
6
8 p=0.8
Timepoints
Ig
A
 l
e
v
e
ls
 m
g
/d
l
Change in IgA in Placebo group
B
as
el
in
e
Fl
oo
w
 u
p
0
2
4
6
8
p=0.82
Timepoints
Ig
A
 l
e
v
e
ls
 m
g
/d
l
 
 
Fig 4.4: Change in levels of CRP, ESR and IgA levels in the apremilast and placebo 
groups in the START cohort. No statistically significant changes were seen in levels 
in either group with treatment. 
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4.3.1.3 Correlation of CRP, ESR and IgA levels to BASDAI scores  
There were no correlations seen between percentage change from baseline in 
BASDAI and percentage change in CRP, ESR or IgA levels. However, there was a 
very strong correlation seen between percentage change from baseline in ESR versus 
CRP in the anti-TNF cohort (r =0.76, p=0.0006) and Placebo group (r=0.53, p=0.02) 
but not in the Apremilast group. 
 
4.3.2 Bone biomarkers 
4.3.2.1 Anti-TNF cohort 
 
Levels of bone biomarkers at baseline and follow up in the anti-TNF cohort are shown 
in table 4.5. A statistically significant decline in the levels of OPG (Fig 4.5) was seen 
with anti-TNF therapy but no change in levels of RANKL. There was no statistically 
significant change in RANKL: OPG ratio although there was a trend towards increase 
in ratios. The levels of RANKL and sclerostin were higher than those seen in the 
START study. There was a trend towards decline in levels of Dkk-1 and Sclerostin 
although these changes were not statistically significant. There was also a trend 
towards rise in BAP and Osteocalcin with a drop in levels of MMP3. There was little 
change observed in TRAP5b levels with anti-TNF therapy. 
 
Table 4.5: Change in bone biomarkers with anti-TNF therapy (n=18) 
Biomarker Baseline* Follow-up* p-value 
Serum RANKL, pmol/L 43.9±13.9 43.1±15.0 0.85 
Serum OPG, pmol/L 4.1±0.5 3.6±0.5 0.03 
RANKL:OPG 14.3±4.8 14.9±5.7 0.32 
Serum Dkk-1, ng/ml 3.6±0.4 3.4±0.4 0.22 
Serum sclerostin, pg/ml 1043±309 949.3±313.9 0.30 
Serum BAP, U/L 35.4±2.4 36.5±3.0 0.49 
Serum osteocalcin, 
ng/ml 
7.8±0.6 8.7±0.4 0.17 
Serum MMP3, ng/ml 2.1±0.3 1.7±0.2 0.12 
Serum TRAP5b, U/L 2.5±0.1 2.4±0.2 0.54 
*Data are mean±SE. 
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Fig 4.5 Change in OPG levels with anti-TNF therapy- shows a significant drop in 
levels of OPG with anti-TNF therapy. 
 
 
4.3.2.2 START study cohort 
There were no significant differences in levels of bone biomarkers between the two 
groups at the baseline. Levels of the biomarkers at baseline and follow up (with p-
values comparing the difference) for placebo and apremilast groups are shown in 
tables 4.6 and 4.7. Percentage changes from baseline in bone biomarkers in the two 
treatment groups are shown in Table 4.8. There was a statistically significant drop in 
mean levels of RANKL (p=0.04) as well as RANKL: OPG ratios (p=0.008) in the 
apremilast treatment group, but not in OPG levels which remained relatively 
unchanged. RANKL levels were below the detectable range for the assay at both time 
points in 5 of the 17 patients treated with apremilast. There was also a statistically 
significant decrease in plasma sclerostin levels (p=0.02) and a trend towards reduction 
in levels of Dkk-1 (p=0.18). When treated patients were classified as responders or 
non-responders with response being defined as a decrease in BASDAI by at least 1 
unit, a statistically significant fall in sclerostin was only observed in the apremilast 
treated responder population (Figure 4.6). 
There was a rise in levels of osteocalcin in the apremilast group which approached 
statistical significance (p=0.058). Similarly, there was a trend towards rise in TRAP5b 
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levels in patients on apremilast compared to placebo (p=0.26). Patients on placebo 
showed a trend towards decrease in levels of BAP (p=0.12). MMP3 levels did not 
show much change in either group. 
 
Table 4.6: Change in bone biomarkers with apremilast (n=17) 
Biomarker Baseline* Follow-up* p-value 
Serum RANKL, pmol/L 7.2±3.6 5.9±2.9 0.08 
Serum OPG, pmol/L 4.1±1.8 3.9±1.5 0.27 
RANKL:OPG 1.5±0.5 1.4±0.5 0.15 
Serum Dkk-1, ng/ml 4.06±0.5 3.7±0.7 0.51 
Plasma sclerostin, pg/ml 793.7±149.2 724.2±166.2 0.18 
Serum BAP, U/L 32.4±3.5 33.0±3.5 0.42 
Serum osteocalcin, 
ng/ml 
12.3±1.1 14.0±1.5 0.04 
Serum MMP3, ng/ml 21.3±7.0 20.7±6.3 0.3 
Serum TRAP5b, U/L 2.7±0.34 2.9±0.37 0.34 
*Data are mean±SE. 
 
Table 4.7: Change in bone biomarkers with placebo (n=19) 
Biomarker Baseline* Follow-up* p-value 
Serum RANKL, pmol/L 6.0±1.7 6.2±2.0 1.0 
Serum OPG, pmol/L 3.9±1.5 3.4±1.0 0.05 
RANKL:OPG 2.2±0.8 2.3±0.9 0.6 
Serum Dkk-1, pg/ml 4.1±0.4 4.2±0.4 0.86 
Plasma sclerostin, pg/ml 796.2±146.7 841.8±161.4 0.26 
Serum BAP, U/L 29.2±1.9 26.8±2.0 0.13 
Serum osteocalcin, 
ng/ml 
11.3±0.8 11.2±0.9 0.83 
Serum MMP3, ng/ml 13.3±2.5 14.3±3.1 0.98 
Serum TRAP5b, U/L 2.8±0.3 2.6±0.3 0.24 
*Data are mean±SE. 
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Table 4.8 Mean percentage change from baseline in bone biomarkers 
Biomarker Apremilast* (n=17) Placebo* (n=19) p value 
Serum RANKL -14.7±6.0 3.6±5.47 0.04
†
 
Serum OPG -2.01±4.4 -7.2±4.3 0.4 
RANKL:OPG -12.6±6.4 15.4±7.4 0.008
†
 
Serum Dkk-1 -11.7±11.1 8.1±9.7 0.18 
Plasma sclerostin -14.3±5.5 18.7±11.3 0.02 
Serum BAP 2.6±2.4 -6.5±5.1 0.12 
Serum osteocalcin 13.5±5.5 0.48±3.9 0.058 
Serum MMP3 -0.08±5.9 7.5±8.4 0.92 
Serum TRAP5b 7.6±6.5 -2.7±6.3 0.26 
*Data are mean±SE (%). 
†
Excludes one outlier that had RANKL levels below recordable range at baseline. 
BAP, bone alkaline phosphatase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
MMP3, matrix metalloproteinase 3; OPG, osteoprotegrin; RANKL, human serum receptor activator of 
NF-κB ligand 
 
 
Fig 4.6: Change in plasma sclerostin levels with treatment in the START cohort 
showing a drop in levels of plasma sclerostin only in responders to apremilast. 
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4.3.2.3 Trends in bone biomarkers in various subgroups of patients 
 
The table 4.9 below summarizes the trends in the various bone biomarkers in patient 
sub-groups as per response to therapy. Except for plasma sclerostin levels in patients 
on apremilast, there were no statistically significant differences between responders 
and non-responders in any of the groups.  
 
While response to treatment with apremilast is associated with a fall in RANKL and 
RANKL: OPG ratio, response to anti-TNF therapy is associated with a rise in 
RANKL: OPG ratio. This is largely because response to anti-TNF is associated with a 
drop in OPG levels. Also, levels of RANKL and hence RANKL:OPG ratios were 
much higher in the anti-TNF cohort as against the START cohort. It is not clear 
whether this was related to increased disease activity in the anti-TNF group or a 
difference in the standard curve when levels were measured for this group. This in 
turn would make it difficult to interpret the difference in trends seen in the two patient 
cohorts. 
 
Although response in both groups is associated with a decline in sclerostin levels, in 
the Apremilast group, there is an associated decline in Dkk-1 while with anti-TNF 
therapy this is seen to rise. This is also the case with patients on placebo who are on 
concurrent NSAID therapy. There was a drop in TRAP5b levels after anti-TNF 
therapy which was not seen with apremilast. 
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Table 4.9: Summary of trends in percentage change from baseline in bone biomarkers 
in each treatment group taking into account response to treatment 
 
Biomarker 
 
Apremilast patients 
  
Anti-TNF patients 
  
Placebo patients 
  
  
Responders 
n=9 
Non-
responders 
n=8 
Responders 
n=10 
Non-
Responders 
n=8 
Responders 
n=6 
Non-
responders 
n=13 
RANKL ↓ ↓ ↓ ↑ ↕ ↨ 
OPG ↨ ↓ ↓ ↓ ↕ ↕ 
RANKL:OPG ↓ ↓ ↑ ↑ ↑ ↑ 
Pl. Sclerostin ↓ ↑ N/A N/A ↑ ↑ 
Sr Sclerostin ↓ ↕ ↓ ↑ ↓ ↑ 
DKK-1 ↓ ↑ ↑ ↓ ↑ ↓ 
BAP ↕ ↑ ↑ ↕ ↓ ↓ 
TRAP5b ↑ ↕ ↓ ↓ ↕ ↓ 
MMP3 ↓ ↑ ↕ ↓ ↑ ↕ 
Osteocalcin ↑ ↑ ↑ ↑ ↨ ↨ 
 
↓ Reduction in levels with treatment 
↨ No trend for change in levels with treatment 
↑ Increase in levels with treatment 
 
 
4.3.3 Cytokines, chemokines and growth factors 
 
Results of analytes measured using CBA as well as ELISA (IL-12 p40 and IL-23) are 
tabulated below. Levels of ICAM-1 could not be measured using a multiplex assay as 
the dilution of the sample produced results that were out of range for the assay. There 
were no results available from the IL-23 ELISA as all samples were below the limit 
of quantitation for the assay and thus no change could be detected. These could not be 
repeated using other assays due to time and funding constraints.  
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Samples from 10 healthy volunteers were run on the same assay to produce normal 
ranges although these were not age and sex matched for the study population. As a 
whole, the group was younger with only 2 volunteers above the age of 50. The male is 
to female ratio was 4:1. Normal ranges obtained along with sensitivity for each 
analyte are listed in table 4.10 below. 
 
Table 4.10: Sensitivity and normal ranges of the analytes studied 
Analyte Sensitivity Normal range 
TNF α (pg/ml) >20 8.1 - 64.6 
TNF α RI (pg/ml) >40 622.0 - 2715.3 
IFN γ (pg/ml) >10 7.3 - 85.7 
IL-2 (pg/ml) >20 15.7 - 70.5 
IL-5 (pg/ml) >5 < 14.6 
IL-6 (pg/ml) >5 8.9 - 17.5 
IL-10 (pg/ml) >10 5.1 - 27.3 
IL-12p70 (pg/ml) >10 5.0 - 52.4 
IL-12 p40 (pg/ml) >31.2 34 - 246 
IL-13 (pg/ml) >5 0.0 - 10.1 
IL-17 (pg/ml) >20 0.0 - 42.5 
IP-10 (pg/ml) >10 64.2 - 1368.1 
MCP-1 (pg/ml) >20 72.6 - 545.4 
MIG (pg/ml) >20 298.0 - 992.2 
MIP 1 α (pg/ml) >20 10.7 - 48.3 
VEGF (pg/ml) >40 54.8 - 265.9 
E-Selectin(pg/ml) >40 10294.6 - 44823.8 
GMCSF (pg/ml) >5 4.5 - 17.1 
IFN α (pg/ml) >10 0.0 - 38.0 
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4.3.3.1 Anti-TNF cohort 
 
Mean (SE) of levels of each analyte measured are shown in table 4.11 below. The p-
values compare change in levels on applying paired t-test or Wilcoxon matched pairs 
test. Results for IL-10 and IL-13 should be interpreted with caution as almost half the 
patients had values below lowest detectable value for the assays. Similarly, the results 
of the IL-17A assay also only showed values within quantifiable range for only a third 
of the patients. 
 
Table 4.11: Change in analytes measured in anti-TNF cohort 
Analyte Baseline* Follow up* p-values 
TNF α (pg/ml) 25.08 (2.86) 48.52 (12.7) 0.15 
TNF α RI (pg/ml) 1786 (157.7) 1593 (129.2) 0.05 
IFN γ (pg/ml) 28.5 (5.5) 22.6 (1.8) 0.97 
IL-2 (pg/ml) 34.9 (4.8) 29.9 (2.1) 0.66 
IL-5 (pg/ml) 6.53 (0.64) 5.84 (0.27) 0.95 
IL-6 (pg/ml) 14.2 (2.25) 14.2 (3.4) 0.41 
IL-10 (pg/ml) 12.4 (1.5) 10.3 (0.37) 0.84 
IL-12p70 (pg/ml) 19.4 (3.6) 14.3 (0.9) 0.59 
Il-12 p40 (pg/ml) 92.01 (13.3) 94.2 (14.7) 0.8 
IL-13 (pg/ml) 5.9 (0.6) 6.9 (1.2) 0.7 
IL-17 A (pg/ml) 29.4 (6.0) 35.7 (10.5) 1 
IP-10 (pg/ml) 215.6 (62.8) 170.2 (43.0) 0.09 
MCP-1 (pg/ml) 182 (21.4) 180.9 (22.1) 0.94 
MIG (pg/ml) 1518 (733.5) 498.1(90.9) 0.12 
MIP 1 α (pg/ml) 34.3 (8.9) 37.6 (9.3) 0.85 
VEGF (pg/ml) 192 (38.7) 200.6 (43.9) 0.89 
E-Selectin(pg/ml) 27413 (2242) 23614 (2476) 0.02 
GMCSF (pg/ml) 7.5 (0.9) 6.5 (0.29) 0.7 
IFN α (pg/ml) 15.9 (2.5) 13.5 (1.7) 0.9 
*Data are mean±SE (%). 
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Levels of TNFα were below detectable range in two thirds of the patients at baseline 
but rose to within detectable range in 7 out of 12 patients at follow up. A small drop in 
levels of TNFα was seen in 3 patients only. A statistically significant drop in levels of 
TNF receptor I and E-Selectin levels (Fig 4.7) was also recorded after anti-TNF 
therapy. There was also a trend towards drop in levels of IP-10 and MIG after 
treatment although this was not statistically significant.  
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Fig 4.7: Change in levels of TNF Receptor I and E-Selectin in the anti-TNF cohort 
 
4.3.3.2 START study cohort 
 
Levels of analytes measured for the placebo group (n=19) and apremilast group 
(n=17) are shown in table 4.12 and 4.13 below. The p-values compare the change in 
levels from baseline to follow up. Percentage change in level of the analytes between 
the treatments groups are shown in table 4.14.  
 
Similar to the anti-TNF cohort, levels for TNFα, MIP1α, IL-10 and IL-17 were below 
the detectable range in a large number of patients in both the placebo and apremilast 
groups. There was a statistically significant drop in levels of TNF RI in patients 
treated with apremilast, although this did not achieve significance when percentage 
change from baseline was compared between the two treatment arms. There was also 
a drop in IL-12p40 levels in the apremilast arm which was almost statistically 
significant (p=0.06), but again not enough to produce statistically significant 
differences between percentage change from baseline between the two treatment 
arms. There was a trend towards fall in levels of MIG and IP-10 in patients treated 
with apremilast. There were no statistically significant differences in the level of any 
of the analytes analysed before and after treatment in the placebo arm of the study. 
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Table 4.12: Change in analytes measured in placebo group 
Analyte Baseline* Follow up* p-values 
TNF α 30.2 (4.5) 27.9 (4.1) 0.8 
TNF α RI 1122 (67.1) 1095 (70.8) 0.45 
IFN γ 34.06 (6.8) 31.5 (6.5) 0.7 
IL-2 47.3 (7.05) 45.2 (6.9) 0.57 
IL-5 7.57 (0.84) 7.17 (0.79) 0.48 
IL-6 11.9 (1.4) 12.5 (0.8) 0.64 
IL-10 14.7 (1.9) 13.9 (2.1) 0.57 
IL-12p70 23.3 (4.6) 22.7 (4.7) 0.63 
Il-12 p40 92.3 (10.4) 91.2 (11.4) 0.86 
IL-13 5.8 (0.4) 6.3 (0.34) 0.16 
IL-17 20.1 (0.6) 20.5 (0.8) 0.75 
IP-10 120.4 (14.1) 136.2 (18.1) 0.43 
MCP-1 242.2 (23.1) 239.3 (25.8) 0.86 
MIG 254.6 (20.7) 345.2(70.9) 0.5 
MIP 1 α 22.6 (1.4) 21.6 (0.94) 0.5 
VEGF 139.7(20.5) 141.1 (18.5) 0.76 
E-Selectin 13977 (1416) 12931 (1118) 0.23 
GMCSF 8.6 (1.3) 8.5 (1.3) 0.61 
IFN α 18.2 (3.05) 17.5 (3.01) 0.66 
*Data are mean±SE (%). 
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Table 4.13: Change in analytes measured in apremilast group 
Analyte Baseline* Follow up* p-values 
TNF α 27.13 (3.9) 30.9 (4.8) 0.24 
TNF α RI 1149 (77.05) 1053 (72.6) 0.004 
IFN γ 28.8 (5.8) 34.7 (7.1) 0.42 
IL-2 45.3 (5.8) 48.02 (7.2) 0.86 
IL-5 7.1 (0.79) 8.01 (1.04) 0.55 
IL-6 14.76 (2.51) 14.08 (1.74) 0.74 
IL-10 13.7 (2.0) 15.4 (2.5) 0.27 
IL-12p70 20.3 (4.1) 24.1 (5.0) 0.37 
Il-12 p40 105.2  (13.5) 97.2 (11.3) 0.06 
IL-13 6.6 (0.7) 6.2 (0.6) 0.8 
IL-17 23.2 (2.9) 22.6 (3.3) 0.64 
IP-10 148.3 (23.9) 144.08 (33.1) 0.45 
MCP-1 222.7 (24.4) 214.6 (19.6) 0.67 
MIG 348 (48.4) 324.8 (66.9) 0.3 
MIP 1 α 34.3 (8.9) 37.6 (9.3) 0.85 
VEGF 133.2 (18.1) 140 (21.2) 0.52 
E-Selectin 13812 (1663) 13585 (1479) 0.84 
GMCSF 7.8 (1.1) 8.9 (1.5) 0.55 
IFN α 17 (3.03) 19.2 (3.5) 0.49 
*Data are mean±SE (%). 
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Table 4.14: Percentage change from baseline in analytes: apremilast vs. placebo 
 
Analyte Apremilast* Placebo* p-values 
TNF α 23.7 (15.4) 24.4 (24.3) 0.5 
TNF α RI -7.6 (2.3) -1.8 (2.9) 0.13 
IFN γ 44 (32.1) 99.7 (70.7) 0.23 
IL-2 20.3 (21.07) 48.5 (39.7) 0.6 
IL-5 20 (14.9) 21.2 (22.9) 0.37 
IL-6 28.8 (26) 31 (19.7) 0.86 
IL-10 18.8 (12.8) 25.6 (26.5) 0.35 
IL-12p70 43.8 (27.7) 79.5 (55.2) 0.46 
IL-12 p40 -3.9 (5.2) -2.4 (5.8) 0.41 
IL-13 5.2 (10.7) 15.4 (7.5) 0.43 
IL-17 8.1 (17.4) 2.4 (3.8) 0.26 
IP-10 -0.03 (12.5) 21.4 (12.9) 0.25 
MCP-1 4.9 (8.8) 4.6 (9.6) 0.92 
MIG -3.1(11.6) 29.8 (16.6) 0.16 
MIP 1 α 4.9 (13.03) 10.2(6.1) 0.97 
VEGF 6.4 (6.4) 11.7 (9.7) 0.75 
E-Selectin 1.98 (7.3) -2.2 (5.8) 1 
GMCSF 21.5 (18.34) 48.5 (38.7) 0.39 
IFN α 28.1 (19.7) 67.1 (47.9) 0.58 
*Data are mean±SE (%). 
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4.4 Correlation between clinical, imaging and laboratory biomarkers 
 
In an attempt to find a laboratory biomarker that reflects change in clinical and 
imaging biomarkers, the various bone biomarkers were correlated to BASDAI and to 
MRI Berlin scores. Correlations were first studied at baseline. Percentage change in 
biomarkers was then compared to percentage change in BASDAI and MRI Berlin 
scores after treatment. The various correlations between individual biomarkers is 
shown in appendix 7 (at baseline) and appendix 8 (following treatment). 
4.4.1 Correlation between BASDAI and bone biomarkers in the three groups 
Table 4.15 shows correlations of bone biomarkers with BASDAI at baseline. At 
baseline, a positive correlation between BASDAI and MMP3 was seen in both patient 
groups. Similarly, a negative correlation was seen between plasma sclerostin and 
baseline BASDAI in the START study at baseline, but this was not measured in the 
anti-TNF cohort. Positive correlations were seen between BASDAI and Dkk-1 as well 
as TRAP5b in the anti-TNF cohort but not in the others. These associations were not 
statistically significant. 
 
Table 4.15: Correlations between BASDAI and bone biomarkers at baseline (p<0.05) 
Baseline concentrations 
of analytes 
BASDAI at baseline 
Anti-TNF START cohort 
RANKL -0.09 
0.01 
OPG 0.09 
-0.16 
RANKL:OPG -0.11 
0.04 
BAP 0.17 
-0.28 
TRAP5b 0.35 
0.08 
MMP3 0.43 
0.37 
Osteocalcin 0.08 
-0.30 
Sr Sclerostin 0.05 
-0.10 
Dkk-1 0.40 
0.12 
Plasma Sclerostin - 
-0.32 
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When comparing percentage change from baseline, correlation was noted between 
percentage change in BASDAI vs. percentage change in RANKL and RANKL: OPG 
ratio (Table 4.16). In the apremilast cohort, this correlation was negative while a weak 
positive correlation was seen in the anti-TNF cohort. In the apremilast arm, while in 
most cases a drop in BASDAI was associated with a drop in RANKL, in 2 cases 
RANKL increased on treatment. Also where values at both time points were below 
the limits of quantitation, no change in RANKL was recorded with a drop in 
BASDAI. Hence, it is difficult to ascertain whether this was a true negative 
correlation. A weak positive correlation was seen with OPG in 3 cohorts. Also, in the 
anti-TNF and placebo cohorts, the correlation of MMP3 with BASDAI was a negative 
one while the correlation was positive in the apremilast cohort. A weak positive 
correlation was seen between BASDAI and serum sclerostin in both the anti-TNF and 
apremilast cohorts. No such correlation was seen with serum sclerostin in the placebo 
arm although a weak positive correlation was seen with plasma sclerostin. 
 
Table 4.16: Percentage change from baseline: BASDAI versus bone biomarkers 
(p<0.05) 
% change in 
concentration of 
analytes 
%change from baseline-BASDAI 
anti-TNF Apremilast Placebo 
RANKL 0.39 -0.68 0.16 
OPG 0.29 0.22 0.21 
RANKL:OPG 0.12 -0.56 -0.19 
BAP -0.04 -0.13 0.16 
TRAP5b -0.02 -0.06 0.15 
MMP3 -0.41 0.28 -0.28 
Osteocalcin 0.07 0.07 -0.16 
Serum Sclerostin 0.18 0.25 0.00 
Dkk-1 -0.01 0.04 -0.22 
Plasma Sclerostin - 0.27 0.18 
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4.4.2 Correlation between MRI and bone biomarkers in the three groups 
 
At baseline, there were no correlations seen between MRI Berlin scores and baseline 
levels of bone biomarkers (Table 4.17).  
 
Table 4.17: Correlation between MRI scores and bone biomarkers at baseline 
(p<0.05) 
Baseline 
concentrations 
Baseline MRI scores 
anti-TNF START cohort 
RANKL 0.08 0.04 
OPG 0.11 -0.16 
RANKL:OPG 0.12 0.09 
BAP 0.10 0.11 
TRAP5b -0.08 0.14 
MMP3 0.07 0.03 
Osteocalcin -0.08 -0.13 
Serum Sclerostin 0.01 -0.07 
Dkk-1 -0.13 0.00 
Plasma Sclerostin - 0.03 
 
 
 
When comparing percentage change from baseline between MRI scores and bone 
biomarkers, there was a strong negative correlation between Dkk-1 and MRI scores in 
the anti-TNF group as well as a trend towards negative correlations with MMP-3, 
BAP and osteocalcin in this group (Table 4.18). There were non-significant 
correlations seen with BAP, RANKL and OPG but not with RANKL: OPG ratio in 
the apremilast group. The only correlation seen in the placebo group was a positive 
correlation with plasma sclerostin. 
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Table 4.18: Correlation between percentage change in concentration of bone 
biomarkers versus percentage change in MRI Berlin score (p<0.05) 
 
%change in 
concentration 
%Change from baseline MRI score 
anti-TNF Apremilast Placebo 
RANKL 0.44 -0.22 -0.14 
OPG 0.39 -0.31 0.12 
RANKL:OPG 0.38 -0.04 -0.07 
BAP -0.61 -0.27 -0.06 
TRAP5b 0.49 0.10 -0.05 
MMP3 -0.44 0.01 -0.02 
Osteocalcin -0.51 0.04 0.09 
Serum Sclerostin 0.11 -0.10 0.17 
Dkk-1 -0.70 -0.04 -0.04 
Plasma Sclerostin - 0.06 0.31 
 
 
 
 
4.4.3 Correlation between BASDAI and cytokines, chemokines and growth 
factors in the two groups at baseline 
 
At baseline, both groups differed from each other in correlations with BASDAI (Table 
4.19). In the anti-TNF group, negative correlations were seen between BASDAI 
scores and concentrations of TNFα, IL-12p70, IP-10 and MCP-1 but also with IFN γ, 
IFN α and IL-10. In the START cohort, satistically non-significant positive 
correlations were seen with GM-CSF, IP-10, IL-10 and IL-6 while a negative 
correlation was seen with MIG. 
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Table 4.19: Correlation between BASDAI scores versus Cytokines, chemokines and 
growth factors at baseline (p<0.05) 
Baseline Baseline BASDAI 
Concentrations anti-TNF START cohort 
GMCSF -0.01 0.24 
IFN alpha -0.41 0.19 
IFN gamma -0.22 0.10 
IL-2 -0.09 0.13 
IL-5 -0.05 0.09 
IL-10 -0.38 0.22 
IL-12 p70 -0.66 0.12 
TNF alpha -0.48 0.18 
IP-10 -0.54 0.22 
IL-6 -0.05 0.25 
MCP-1 -0.60 0.01 
MIP 1 alpha 0.20 0.07 
MIG -0.08 -0.20 
IL12p40 -0.37 -0.16 
IL-13 0.10 -0.03 
IL-17 A 0.23 -0.16 
TNF RI 0.00 -0.06 
VEGF 0.20 -0.06 
E-Selectin 0.24 0.09 
 
When comparing percentage change from baseline, differences were seen in all 3 
groups (Table 4.20). While a positive correlation was found between percentage 
changes in BASDAI vs. percentage change in E-Selectin levels in the anti-TNF 
cohort, a weaker negative correlation was seen in the apremilast cohort. In contrast, a 
weaker negative correlation was seen with VEGF in the anti-TNF group while a 
positive correlation was seen in the apremilast group. Weak positive correlations were 
seen with most cytokines except MIG in this patient group. A much stronger negative 
correlation was seen with MIG in the placebo cohort.  
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Table 4.20: Correlation between percentage change in BASDAI versus percentage 
change in cytokines, chemokines and growth factors (p<0.05) 
%Change in 
Concentrations 
%change in BASDAI 
anti-TNF Apremilast Placebo 
GMCSF -0.01 0.26 -0.18 
IFN alpha -0.24 0.28 -0.11 
IFN gamma 0.18 0.20 -0.11 
IL-2 0.04 0.19 -0.12 
IL-5 0.11 0.23 -0.11 
IL-10 -0.18 0.17 -0.07 
IL-12 p70 -0.11 0.20 -0.07 
TNF alpha -0.09 0.34 0.02 
IP-10 0.07 0.26 -0.28 
IL-6 -0.06 0.38 -0.12 
MCP-1 0.41 0.30 0.13 
MIP 1 alpha -0.41 0.20 0.02 
MIG 0.38 -0.11 -0.53 
IL12p40 0.33 0.15 0.01 
IL-13 -0.28 0.16 -0.08 
lL17 A -0.46 0.06 -0.27 
TNF RI -0.22 -0.01 -0.20 
VEGF -0.14 0.21 -0.16 
E-Selectin 0.48 -0.30 0.09 
4.4.6 Correlation between MRI scores and cytokines, chemokines and growth 
factors in the two groups at baseline 
On comparing MRI scores at baseline to baseline concentrations of cytokines, 
chemokines and growth factors, there were no consistent correlations seen in the two 
groups (Table 4.21). A negative correlation was seen between MRI scores and IFNα 
in the anti-TNF cohort. There was a statistically non-significant negative correlation 
seen with TNF α, IL-12 p70 and VEGF in this group. No correlations were seen in the 
START cohort. 
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Table 4.21: Correlation between MRI Berlin Scores vs. cytokines, chemokines and 
growth factors at baseline (p<0.05) 
Baseline 
Concentration 
Baseline MRI scores 
anti-TNF START cohort 
GMCSF 0.40 0.12 
IFN alpha -0.78 0.13 
IFN gamma 0.38 0.13 
IL-2 0.16 0.05 
IL-5 0.46 0.01 
IL-10 -0.30 0.17 
IL-12 p70 -0.47 0.11 
TNF alpha -0.53 -0.02 
IP-10 -0.21 0.22 
IL-6 0.12 0.02 
MCP-1 -0.26 -0.03 
MIP 1 alpha -0.04 -0.14 
MIG 0.20 0.28 
IL12p40 0.00 -0.005 
IL-13 -0.29 -0.06 
IL-17 A -0.02 0.06 
TNF RI 0.27 0.18 
VEGF -0.54 -0.05 
E-Selectin 0.08 0.09 
 
 
After treatment, percentage change in levels of IL-6, TNF RI, IL-13 and IL-17A  
showed a negative correlation with percentage change in Berlin scores in both 
apremilast and anti-TNF cohorts (Table 4.22). Change in TNF α levels showed a 
negative correlation with MRI scores in apremilast group but were positively 
correlated to MRI change in the anti-TNF cohort. While a positive correlation was 
seen between percentage change in MRI scores and VEGF in all three groups, this 
was particularly strong in the placebo group. 
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Table 4.22: Correlation between percentage change from baseline in MRI Berlin 
scores versus percentage change in cytokines, chemokines and growth factors 
(p<0.05) 
%change in 
concentration 
%change from baseline -MRI scores 
anti-TNF Apremilast Placebo 
GMCSF 0.13 -0.30 -0.05 
IFN alpha 0.26 -0.20 -0.09 
IFN gamma 0.19 -0.16 -0.13 
IL-2 0.21 -0.20 -0.09 
IL-5 0.33 -0.02 -0.11 
IL-10 0.13 -0.21 -0.08 
IL-12 p70 0.16 -0.19 -0.14 
TNF alpha 0.68 -0.18 -0.25 
IP-10 0.08 -0.35 0.17 
IL-6 -0.60 -0.38 0.00 
MCP-1 -0.18 -0.11 0.32 
MIP 1 alpha -0.77 -0.05 0.00 
MIG -0.39 -0.16 0.16 
IL12p40 0.02 0.32 0.06 
IL-13 -0.84 -0.32 -0.15 
IL-17 A -0.67 -0.42 0.14 
TNF RI -0.62 -0.21 -0.17 
VEGF 0.14 0.20 0.52 
E-Selectin 0.05 -0.17 0.20 
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4.5 Discussion 
 
In this chapter, I have described the changes to different laboratory biomarkers in the 
three patient cohorts. Inflammatory markers such as ESR or CRP did show an 
improvement with treatment in the anti-TNF cohort but there was no correlation seen 
between percentage change in BASDAI and change in ESR or CRP. Also, the 
inflammatory markers did not show much change in the apremilast or placebo 
cohorts. The change in IgA was insignificant in all 3 cohorts suggesting that this may 
not be a reliable biomarker when monitoring change over short periods of treatment.  
 
One would expect that correlations between laboratory biomarkers and clinical 
indices as well as imaging markers would be the same in both patient groups at 
baseline, but differences were seen both in the bone biomarkers as well as cytokines at 
baseline between the two groups. It is difficult to know whether this was related to 
differences in disease activity between the anti-TNF and START cohorts. 
Furthermore, one would expect to see similar changes in the laboratory biomarkers 
after treatment with either anti-TNF or apremilast, given that both show improvement 
in clinical and imaging scores. This again proved not to be the case. 
 
The bone biomarkers were probably the most informative subset of biomarkers 
studied showing change with treatment that differed between the different therapeutic 
agents. The most apparent difference between the anti-TNF and apremilast groups 
was in the RANKL: OPG ratio. There was a negative correlation between change in 
this ratio and change in BASDAI seen in patients treated with apremilast, whilst a 
positive correlation was seen in patients treated with anti-TNF therapy. It is not clear 
whether this was due to the statistically significant drop in OPG levels or a rise in 
RANKL or possibly both in the anti-TNF group. This may suggest a different 
mechanism of action between the two drugs. A correlation was seen with percentage 
change in BASDAI versus percentage change in the RANKL:OPG ratio in the 
apremilast group suggesting that at least in the apremilast cohort, there may be a link 
between disease activity and the RANKL:OPG ratio. Previous studies have proposed 
that CREB, which is activated by phosphodiesterase inhibition, may inhibit activation 
of NF-κB by competing for CREB co-activators [159]. However, there are no other 
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published reports on the effect of apremilast on RANKL in other patient cohorts to 
compare our results with. 
 
A rise in osteocalcin was common to both apremilast and anti-TNF therapy. A 
marginal rise in BAP with a fall in MMP3 was also seen in both the anti-TNF and 
apremilast with opposite effects seen in the placebo group. Osteocalcin and BAP are 
markers of bone formation. The fact that the level of BAP increased in both anti-TNF 
and apremilast cohorts suggests that this may represent a reparative process after 
inflammation has settled or an improvement in bone density in these AS patients. 
There were no bone density scans performed to prove the latter but percentage change 
from baseline in MRI scores in the anti-TNF cohort showed a trend towards negative 
correlation with percentage change in levels of BAP consistent with the hypothesis 
that resolution of osteitis is accompanied by rising bone anabolism. However, given 
the variable volumes of osteitis involvement in the spines of the anti-TNF treated 
cohort, it is perhaps not surprising that statistically significant relationships between 
MRI changes and BAP were not observed. MMP3 is required for both the breakdown 
and production of extra-cellular matrix. A reduction in levels was seen in both cohorts 
but a trend towards a negative correlation between percentage change in MMP3 and 
both percentage change in BASDAI as well as MRI scores was only seen in the anti-
TNF cohort. 
 
TRAP5b is a marker of osteoclastic activity. Levels of TRAP5b did rise in the 
apremilast group but dropped marginally in the anti-TNF cohort as well as in the 
placebo arm. There was a trend towards a positive correlation between percentage 
change in TRAP5b and percentage change in MRI score in the anti-TNF cohort. 
Given the greater reduction in MRI scores in this group, the corresponding trend in 
TRAP5b may reflect a decreasing osteoclastogenesis that accompanies resolution of 
bone oedema lesions. The opposite effect in the apremilast cohort is difficult to 
explain but may represent concurrent processes of osteoclastogenesis and 
osteoblastogenesis with bone remodelling. In fact, when percentage change in 
TRAP5b was correlated to percentage change in RANKL: OPG, there was a strong 
negative correlation seen between these two biomarkers in the apremilast cohort 
(Appendix 8). 
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Sclerostin and Dkk-1 are inhibitors of the Wnt pathway and hence inhibit bone 
formation. A drop in levels of these biomarkers would therefore indicate a release of 
this inhibition leading to new bone formation. At baseline, there was a strong positive 
correlation between RANKL and sclerostin in all three patient cohorts suggesting that 
sclerostin levels play an important role in the pathophysiology of AS (Appendix 7). 
There was a correlation seen between Dkk-1 and sclerostin at baseline but only in the 
anti-TNF cohort. It is not clear whether this was due to the fact that patients in the 
anti-TNF cohort had higher disease activity with higher MRI Berlin scores or this was 
just a statistical coincidence. 
 
A significant drop in plasma sclerostin levels was seen in the apremilast group but 
levels of sclerostin in plasma could not be measured in the anti-TNF cohort as plasma 
samples were unavailable for testing. There was a similar trend with a drop in serum 
sclerostin in this group although this association was weak. A fall in levels of 
sclerostin was mirrored by a fall in Dkk-1 levels in the apremilast group. This was 
less clear, however, in the anti-TNF group possibly suggesting a change in the 
relationship between these biomarkers after treatment. Dkk-1 levels also strongly 
correlated to changes in Berlin scores in the anti-TNF cohort but not to change in 
BASDAI. There was also a positive correlation between percentage change in levels 
of Dkk-1 and percentage change in osteocalcin, which is a marker of bone formation, 
in the anti-TNF cohort.  
 
It is also interesting to note that there were different biomarkers showed correlation to 
clinical and imaging biomarkers. Changes in BASDAI correlated better with change 
in RANKL: OPG and sclerostin levels. However, changes in osteocalcin, BAP, 
TRAP5b and Dkk-1 (in the anti-TNF cohort) correlated better with MRI changes. 
MMP3 was the only bone biomarker which correlated with both clinical as well as 
imaging scores. This would suggest that different biomarkers are indicative of 
different processes within disease pathogenesis. 
 
Cytokines, chemokines and growth factors showed little change with therapy in the 
apremilast and placebo groups. Like the bone biomarkers, there were different 
correlations seen between BASDAI as well as baseline MRI scores and this group of 
biomarkers in the different patient groups which are difficult to explain. In particular, 
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a positive correlation between baseline MRI score and TNF receptor I levels was seen 
in the anti-TNF and apremilast cohort but a negative correlation was seen in the 
placebo cohort. Similarly, a trend towards a positive correlation was seen between 
baseline MRI scores and VEGF in the apremilast and placebo groups but there was a 
trend towards a negative correlation in the anti-TNF cohort.  
 
 In the anti-TNF cohort, there was a drop in the level of TNF RI and a rise in the 
circulating TNF levels. The rise in circulating levels of TNFα after anti-TNF is a well 
recognised phenomenon and has been previously described in the early studies with 
anti-TNF agents in rheumatoid arthritis [160]. This does not however represent a true 
rise in the circulating levels of bioactive analyte. Similar results have been shown by 
others in patients with AS receiving etanercept therapy [136]. When percentage 
change from baseline in TNF α and TNF RI was compared with percentage change in 
BASDAI, no correlation was seen. However, on comparing these with percentage 
change in MRI scores in this cohort, a direct correlation was seen between these 
parameters and MRI scores. The drop in TNF RI, but not the rise in TNF, were also 
seen in the apremilast group but did not correlate to either BASDAI or MRI scores in 
this group. 
 
 Percentage change in E-selectin levels correlated with change in BASDAI in the anti-
TNF cohort. No other significant correlations were seen with BASDAI in the 
apremilast group, but a negative correlation was seen with change in MIG levels in 
the placebo group.  
 
On comparing percentage change in cytokines, chemokines and growth factors with 
percentage change in Berlin MRI scores, correlations were seen in IL-13, IL-17A, 
MIP1α and TNF α in the anti-TNF cohort. These correlations may not be true as there 
were a lot of patients that had levels below the limits of quantitation for these assays.  
A trend towards a negative correlation was also seen between percentage change in 
MRI scores and percentage change in concentrations of IL-6 as well as TNF RI levels 
in the anti-TNF cohort. No significant changes were seen in IL-6 with apremilast. 
This would be in keeping with findings in pre-clinical studies on human synovium 
where there was a reduction in IL-6 but this reduction was quite modest [35]. This 
may also explain why CRP levels did not fall in this group of patients. In the placebo 
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cohort a positive correlation was observed between percentage change in VEGF and 
percentage change in MRI Berlin scores suggesting increased vascularity in areas of 
bone oedema in this patient cohort.  
 
When reviewing distinctions in biomarker responses observed between anti-TNF 
treated patients and those participating in the apremilast trial, it is important to note 
that the clinical effect size is of greater magnitude with anti-TNF than was observed 
with apremilast. Furthermore, and importantly, apremilast modulates a number of pro-
inflammatory cytokines but also augments some anti-inflammatory cytokine activity. 
This might in part explain differential responses of biomarkers, such as RANKL: 
OPG. However, the clinical significance and implications of these observations, if 
any, with respect to progression of syndesmophyte formation and  long term ankylosis 
will require further research. 
 
To summarize, a universal laboratory biomarker that reflects changes in the patient’s 
clinical picture remains elusive in AS. Laboratory biomarkers are probably more 
helpful in understanding the mechanism of disease processes and the mode of action 
of drugs than in assessing response to therapy. While the RANKL: OPG ratio seems 
to play an important role in disease pathogenesis, it is affected differently by different 
drugs, and this diversity of action may be something which would benefit from further 
investigation. Similarly the interaction between sclerostin and Dkk-1 appears to differ 
with different treatment agents. Markers of bone formation such as BAP and 
osteocalcin may be helpful but the changes seen are small over the short time period 
of this study and may require studies with long time frames to examine their true 
usefulness. Markers of bone loss such as MMP3 and TRAP5b did not show adequate 
change to reflect the clinical picture. Changes in cytokines, chemokines and growth 
factors tend to be more uniform between different treatment groups with TNF RI and 
E-selectin being potential biomarkers of response but these seem to be less sensitive 
to change and require large improvements in clinical scores before significant 
differences in their circulating levels can be observed.  
 
 128 
 
4.6 Limitations and Future Work: 
 
A large number of correlations were calculated between various biomarkers without 
applying Bonferroni’s correction and hence this is likely to lead to some associations 
that would occur by coincidence. The numbers in each patient cohort were not 
calculated with a view to assess change in laboratory biomarkers but to assess clinical 
response. Hence, the analysis was purely exploratory rather than to answer a direct 
question. Due to small numbers, patients treated with etanercept and adalimumab in 
the anti-TNF were not studied separately. There were also a lot of results that were 
below the detectable range of assays where minimum detectable values for individual 
assays were used for calculations that may have resulted in correlations that do not 
truly exist.  
 
Further work needs to be done to understand the complex relationships between bone 
biomarkers, cytokines, chemokines and growth factors. It is also important to 
understand what happens to these biomarkers in the early stage of AS and to study 
them progressively over a patient’s lifetime to understand changes that occur with 
disease flares and with new bone formation.  
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Chapter 5: Volumetric analysis of lesions on MRI using 
Dynamika software as a biomarker of response to therapy 
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5.0 Abstract: 
Introduction: There are a number of different scoring systems available to score 
active bone oedema lesions on STIR sequences of MRI scans in AS patients. All of 
these methods provide a semi-quantitative scoring and correlate poorly to clinical 
scores.  
Aim: To quantify the extent of inflammatory disease in the spine and changes therein 
with treatment which reflect changes in clinical state to a greater extent than existing 
measures by developing a volumetric MRI-based technique. 
Methods: AS patients about to start anti-TNF therapy were consented to have an MRI 
scan prior to and 12 weeks after commencing anti-TNF therapy. All patients were 
scanned using the same scanner and the same protocol at both time points. Scans were 
anonymized for patient identity and time points. They were previously scored using 
Berlin score by 2 musculoskeletal radiologists concurrently. They were subjected to 
volumetric analysis using Dynamika software by 2 scorers independently. Area in 
mm
2
 and intensity of lesions on individual slices were compared using Bland-Altman 
plots. Volumes of entire lesions were calculated in mm
3
. Volumes and intensity of 
lesions were also compared using Bland-Altman plots. Volumes of all lesions on each 
scan were added together to calculate total volume as well as mean intensity of all 
lesions. The volume of lesions was then compared to total Berlin scores as well as 
BASDAI scores using Spearman Rank correlation. Percentage changes in volume, 
intensity and the product of volume and intensity were also compared to percentage 
change in BASDAI scores. Correlations were also made with bone biomarkers. The 
software was further modified to allow for automated volume generation and the 
process of scoring repeated by one of the scorers to allow for intra-observer 
variability. 
Results: 11 pairs of scans were available for scoring at the 2 time points. Bland-
Altman plots for area in mm
2
, volume in mm
3
, mean and maximum intensity showed 
good inter-observer variability. A good correlation was seen between total volume 
scores using volumetric analysis and total Berlin scores, more so at baseline (r=0.7) 
than at follow-up (r=0.4). No correlation was seen with BASDAI scores. However, 
when percentage change from baseline in BASDAI was compared to percentage 
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change from baseline in Berlin score, volume of lesions, intensity as well as the 
product of volume and intensity, a good correlation was seen between BASDAI and 
volume in mm
3
 (0.8 for scorer 1 and 0.6 for scorer 2) as well as the product of volume 
and intensity (0.7 for both scorers). A poor correlation was seen between Berlin scores 
and BASDAI (r=0.2). Intra-observer variability could only be tested for scans at 
baseline as the number of lesions amenable to automated volumetric analysis was 
insufficient to allow comparison of scans at follow up. 
When manual scores were compared before and after treatment, there was a 
statistically significant improvement in BASDAI, MRI Berlin scores for all patients 
but also a statistically significant improvement in the product of volume and intensity 
for those that responded to treatment (n=8). A positive correlation was seen with 
RANKL: OPG ratio and a negative correlation was seen with MMP3. 
 
Conclusion: Volumetric analysis of active bone oedema lesions on STIR MRI 
sequences compares well to semi-quantitative scoring using the Berlin method. Unlike 
semi-quantitative scoring, volumetric analysis also shows a good correlation to 
change in BASDAI scores hence linking clinical and imaging biomarkers. 
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5.1 Introduction 
 
In the last 3 chapters, I have discussed the utility of various clinical, laboratory and 
imaging biomarkers. Although semi-quantitative scoring showed significant change 
with treatment where there was a large change from baseline, a poor correlation was 
seen between clinical scores and semi-quantitative scores. This chapter describes a 
novel methodology to carry out volumetric analysis of lesions. The hypothesis was 
that if one could quantify the volume of bone oedema on MRI scans this would be a 
more sensitive measure of change with treatment than existing semi-quantitative 
scoring. At the same time, combining the volume with intensity may improve the 
correlation with clinical scores as in some cases only intensity of lesions changes with 
treatment. 
 
 Although, the concept of quantification is not new to MRI and software such as 
ImageJ allows this to be carried out, it does so on individual slices of MRI scans. We 
initially devised a scanning protocol which allowed for slices of 1mm x 1mm x 1mm, 
without any gaps between slices hence allowing for true volume to be calculated. 
However, this technique did not yield good quality pictures and the protocol had to be 
modified to allow for gaps between slices in order to improve image quality. Hence, it 
became necessary to develop software that would take these gaps into account 
between slices. Image Analysis, a commercial organization based in Leeds, modified 
an existing software program, Dynamika, for this purpose.  
 
5.2 Methods 
 
5.2.1 Patients and scans 
 
The anti-TNF cohort was used for this proof of concept study. Scans from this cohort 
were anonymized and numbered 1 to 15 by one of the radiographers. Scans carried 
out at the two time points on the same patient were randomly annotated as A and B.  
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5.2.2 Volumetric analysis using Dynamika 
 
Quantitative analysis using Image Analysis software, Dynamika, was carried out on 
the anonymized scans for anti-TNF patients by 2 scorers (me- scorer 1 and Dr Adrian 
Lim- scorer 2) independently.  
 
The region of interest (ROI) showing bone oedema on each slice of the STIR 
sequence was drawn using a free hand tool. The area of the ROI was calculated in 
pixels and millimetres (mm
2
). The volume of the ROI was then calculated in voxels 
and mm
3
 by adding the area in pixels in each slice ROI. Maximum intensity along 
with mean and standard deviation was recorded. Inter-observer variability was then 
tested using Bland Altman plots for area in mm
2
, volume in voxels and mm
3
 as well 
as maximum and mean intensity of lesions. 
 
Volume of individual lesions on each scan was added to produce a total volume score. 
The average of mean intensity for all lesions on each scan was also calculated to 
produce a mean intensity score for each scan. These were then compared to Berlin 
MRI scores.  
 
The whole process was repeated by me after the software was modified to allow 
automatically generated regions of interest (ROIs) by using intensity of the lesion. 
This allowed for comparison of two different methods. As the same data set was 
analyzed by the same observer on 2 separate occasions, it hence allowed intra-
observer variability to be calculated. 
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5.2.3 Protocol for scoring lesions using Dynamika 
 
The following standard operating procedure was followed: 
1. Dynamika software was launched and a file loaded on to workspace eg. 1A 
2. DICOM series was selected. If available, mobiview STIR sequence was 
selected in order to visualize the whole spine. This allowed one to pick out 
lesions and go to respective scans. Where this was not available, individual 
segments were screened i.e. cervical, thoracic etc to locate lesions. 
3. The scan was loaded and then dragged from analysis context into Dynamika 
window to open the scan. 
4. An image magnification of 300%- 400% was selected from the drop down 
menu instead of zoom to fit option in order to find smaller lesions which may 
not be otherwise seen. 
5. After identifying lesions, individual spinal segment scans were reviewed. 
6. Once the lesion was found on the individual segment scan, the ROI button in the 
Dynamika window was clicked on. This automatically opened the ROI 
manager window in the Analysis context screen. Using the cursor, the lesion 
was then outlined. 
7. After the software was modified, in order to draw an auto ROI, the Auto 
Polygon function was selected from the drop down menu. 
8. The cursor was then placed over the lesion and the area with maximum intensity 
was clicked on. The program automatically produced a ROI. If this fit well 
with the area to be outlined, right click to select. This changed the yellow 
outline to a pink outline and brought up the parameters in the analysis context 
box below. If ROI needed to be modified (Fig 5.1), double clicking within the 
ROI brought out even more points in the pink outline which were dragged to 
fit the shape wanted. Alternatively, re-clicking on a different part of the lesion 
would produce a different shape of the ROI. 
9. When lesions were not amenable to auto ROI, changing to ‘Freehand’ in the 
drop down menu from ROI manager allowed for the cursor to draw the outline 
around the lesion manually. 
10. When satisfied with the ROI drawn, the ROI was given a name. For eg: 1A 
STIR cervical C5 upper anterior lesion or something shorter which conveyed 
the same meaning. 
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11. The same process was repeated in the next slice where the lesion was seen, 
until all slices with the lesion were covered. 
12. Once all slices for an individual lesion were covered, they were grouped 
together as a volume ROI. The volume ROI was renamed eg. 2A STIR lumbar 
L3 upper posterior lesion. If any changes to the volume were needed, 
ungrouping the volume ROI allowed for slices to be included or excluded. 
13. The process was repeated for all lesions in the same scan i.e. Lumbar STIR 
sequence.  
14. Once all lesions for that particular scan were covered, an HTML report was 
generated by clicking on reports and then on HTML report. This brought up a 
summary of all lesions scored with volumes as well as intensities. This was 
then cut and paste into an excel sheet for further analysis. 
 
5.2.4 Statistical methods 
 
The area, volume and intensity of lesions were compared between scorers using Bland 
Altman plots. This was selected rather than Cohen’s kappa coefficient as the variables 
compared were continuous data and not categorical. Also, the numbers were relatively 
small. Berlin scores were correlated to volume scores using Spearman Rank 
correlation. Similarly, volumetric scores were correlated to BASDAI scores and bone 
biomarkers using Spearman Rank correlation. Finally, the improvement in volumes 
after anti-TNF therapy was compared using paired t-test or Wilcoxon matched pairs 
test. 
Bland and Altman [161] first described a method of comparing results obtained by 
different measurement techniques to establish agreement between them. They showed 
that by plotting the difference between the observations obtained by the two 
techniques against the mean of observations obtained, the resulting scatter plot better 
reflected the agreement between the two techniques when the points lie between the 
95% confidence interval on either side of the mean difference. This method was 
shown to be more appropriate for this purpose than Correlation coefficient which 
shows the strength of a relation between two variables and not the agreement between 
them. It is also useful to analyse repeatability of a single measurement method or to 
compare measurements by 2 different observers. 
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     (A)        (B) 
 
                                       (C)        (D) 
Fig 5.1: The figures show how ROI drawn using Auto ROI functions can be modified using free hand tool on Dynamika. The Auto ROI drawn 
in Fig 5.1 (A) can be modified by right clicking to bring up more points in the pink outline. These can then be moved outwards (B) to produce 
the final ROI size (C). Once the required ROI is obtained, click outside to change the outline and hence save the ROI (D). 
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5.3 Results 
 
Of the 15 MRI paired data sets of anti-TNF patients, it was not possible to open the 
pre-treatment scan for one patient (9A) and post-treatment scan for another (5B) using 
Dynamika. Images for scan 15B could not be copied due to the scan being stored in a 
different format. Lastly, there were no lesions seen either at baseline or follow up in 
one patient. This left 11 pairs of scans for which volume of lesions were available 
both at baseline and follow up. Change from baseline in total MRI Berlin scores in 
these remaining 11 patients was recalculated and a p-value of 0.04 was obtained (table 
5.2). However, no correlation was seen between percentage change from baseline in 
Berlin scores and percentage change in BASDAI [r=0.2, p=0.56] (table 5.3). 
 
5.3.1 Inter-observer variability using anti-TNF cohort- comparing area in mm2, 
volume in mm3 and intensity 
 
There was a large difference between the scorers in the actual number of lesions 
scored by each of them. I scored more lesions than Dr Lim. In order to study inter-
observer variability, only data sets where data was available from both scorers were 
compared for area in mm
2
 for individual slices and total volume in mm
3
 for whole 
lesions.  
Comment: In this chapter, for inter and intra-observer variability studies, only slices 
and lesions common to both scorers were used in order to establish whether this new 
technology compares favourably between users that are attempting to carry out the 
same task. 
 
5.3.1.1 Area in mm2 
A total of 247 slices were common to both scorers at baseline while 130 slices were 
common to both scorers at follow up. The reduction in number represents the 
improvement in lesions with anti-TNF therapy. The Bland-Altman plots below (Fig 
5.2) show that most of the scores fell between the 95% levels of agreement. The 
difference between the scores was smaller when the size of the lesion was small.  
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Bland-Altman plot of Area in mm2 at baseline:Difference vs average
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(A) 
Bland-Altman plot of Area in mm2 at follow up:Difference vs average
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(B) 
Fig 5.2: Bland-Altman plots of area of lesions in mm
2
 as drawn on individual MRI 
slices compared between the 2 scorers. Plot (A) shows scores at baseline while (B) 
shows scores at follow-up. The X-axis shows the average of the two scores while the 
Y-axis shows the difference between the two scorers. The dotted line in the centre on 
the Y-axis represents 0 i.e. no difference in the area in mm
2
 between scorers. The two 
horizontal lines on either side represent the 95% limits of agreement. Lesions at 
follow up were smaller than at baseline as evidenced by smaller averages.  
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5.3.1.2 Volume in mm3 
 
When volumes of lesions were compared between the two scorers, similar results 
were seen (Fig 5.3). Volume was measured for 39 lesions scored at baseline and 25 at 
follow up. The levels of agreement were much closer to each other than for the area in 
mm
2
.   
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Bland-Altman plot of Vol in mm3 at follow up:Difference vs average
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(B) 
Fig 5.3 Bland Altman Plots of volume of lesions in mm
3
 of lesions compared between 
the 2 scorers. Plot (A) shows scores at baseline while (B) shows scores at follow-up. 
The X-axis shows the average of the two scores while the Y-axis shows the difference 
between the two scorers. Most of the scores fell within the 95% levels of agreement 
which were quite narrow as compared to area in mm
2
. 
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5.3.1.3 Mean intensity of lesions 
Apart from area in mm
2
 and volume in mm
3
, Dynamika records the maximum as well 
as mean intensity of lesions on each slice as well as that of the whole lesion (once 
volume of the lesion is calculated). Fig 5.4 (A&B) show the results of Bland-Altman 
plots for mean intensity for individual slices while Fig 5.4 (C&D) for the lesions as a 
whole. The results were similar for both slices as well as whole lesions. The 
agreement was stronger for mean intensity of lesions rather than individual slices with 
very few points falling outside the 95% levels of agreement. 
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Bland-Altman plot of Mean intensity at baseline for slices:Difference vs average
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Bland-Altman plot of Mean intensity at follow up for slices:Difference vs average
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(A)          (B) 
Bland-Altman plot of Mean intensity at baseline for lesions:Difference vs
average
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Bland-Altman plot of Mean intensity at follow up for lesions:Difference vs
average
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(C)          (D)    
Fig 5.4: Bland-Altman plots of mean intensity of lesions on individual slices (A&B) and whole lesions (C&D) for the two scorers. The plots 
show there was a good level of agreement between scorers with regards to mean intensity both at the level of individual slices as well as the 
whole lesion. 
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5.3.1.3 Maximum intensity of lesions 
While the mean intensity depends on the extent of the lesion, the maximum intensity 
represents the brightest area on each slice or of each lesion. This was strikingly 
similar and in fact identical in a number of cases. The plots (Fig 5.5) show a large 
number of points where the difference between the two scorers was zero irrespective 
of the average of maximum intensity. The results were comparable for maximum 
intensity of whole lesion as well as individual slices with very few points falling 
outside the 95% levels of agreement. 
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Bland-Altman plot of Max intensity at baseline for slices:Difference vs average
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Bland-Altman plot of Max intensity at follow up for slices:Difference vs average
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(A)          (B) 
Bland-Altman plot of Max intensity at baseline for lesions:Difference vs average
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Bland-Altman plot of Max intensity at follow up for lesions:Difference vs average
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(C)        (D)  
 
Fig 5.5: Bland-Altman plots of maximum intensity of lesions on each slice (A&B) and of whole lesions (C&D). The plots show a large number 
of points where the scores for maximum intensity was identical between the two scorers. 
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5.3.2 Comparison of semi-quantitative to volumetric scores 
Having established a good inter-observer variability between scorers using Dynamika, 
we then studied the correlation between scores obtained on Berlin scoring and those 
obtained through volumetric analysis.  
Comment: It was difficult to compare individual scores obtained for lesions using 
volumetric and Berlin scoring as lesions are scored separately on each vertebra for 
volumetric analysis and as a disco-vertebral unit for Berlin scoring. In order to make a 
comparison between the two methods, the total volume of all lesions on each scan 
(spinal added to sacroiliac joint scores) was compared to the total Berlin score for the 
corresponding scan using Spearman Rank Correlation. If the total volumes calculated 
for each scan by individual scorers were compared, they were significantly different 
from each other. Hence, correlations were sought against Berlin score and BASDAI 
separately for each scorer at the two separate time points studied. 
When the volumetric scores were compared to Berlin scores at baseline, a good 
correlation was obtained independently for the two observers (Fig 5.6). This is in spite 
of the fact that there were differences in number of lesions scored between the two 
scorers. 
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Fig 5.6 Spearman Rank Correlation between total volumes of lesions on each scan 
compared to the total MRI Berlin Score at baseline. The graphs show a good 
correlation between the two methods for the two scorers independently. 
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On comparing the scores at follow up (Fig 5.7), there was a weaker correlation for 
scorer 2 with correlation coefficient (r) of 0.47 (p=0.14). There was no correlation 
seen for scorer 1, however, this was due to 2 high scores for volume of lesions when 
Berlins scores were 0 and 1 respectively. On exclusion of these values, the results 
were comparable with the r value being 0.4. 
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Correlation of MRI scores and volume in mm3 -Scorer 2 (Follow up)
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(B) 
Fig 5.7: Spearman Rank Correlation of total MRI Berlin score compared to total 
volume of lesions in mm
3
 at follow up. Unlike the strong correlation seen at baseline, 
the correlation was weak for scorer 2 at follow up and there was no correlation seen 
for scorer 1. However, when two outliers were removed, the correlation coefficient (r) 
was comparable at 0.4 even for scorer 1. 
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5.3.3 Comparison of volume and intensity to BASDAI 
 
Given the lack of correlation between Berlin scores and BASDAI, we studied the 
correlation between volumetric scores as well as intensity of lesions using Dynamika 
to BASDAI scores. Table 5.1 shows the correlation coefficients for the comparisons. 
There were no significant correlations seen between the volume of lesions in mm
3
 and 
the mean intensity of lesions with BASDAI scores either at baseline or at follow up. 
 
Table 5.1: Spearman Rank correlation (r-values) of Volume in mm
3
 and mean 
intensity at baseline and follow up compared to BASDAI scores for the two scorers. 
None of the p-values for the correlation were statistically significant. 
Baseline Scorer 1 Scorer 2 
Volume in mm
3
 0.07 -0.4 
Mean intensity -0.38 -0.006 
Follow up   
Volume in mm
3
 -0.2 -0.01 
 Mean intensity 0.09 0.15 
 
 
5.3.4 Development of Auto ROI function and Intra-observer variability   
 
The Auto ROI (Region of Interest) function was developed using the Dynamika 
software to improve the accuracy in delineating the borders of the lesions. It utilizes 
the intensity of the lesion to automatically draw a region of interest when one clicks 
on an area of high intensity. In addition to accuracy, this also helps improve the speed 
at which the analysis is carried out. In order to study the effect of the auto ROI 
function on outcome, I repeated the scoring of the scans using the auto-ROI function 
prior to un-blinding to obtain a further set of results. This was then compared to my 
earlier score to obtain intra-observer variability, although it truly represents the 
difference in scores by the same observer when using manual and Auto ROI functions 
for scoring. 
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5.3.4.1 Comparison of scores for area in mm2, volume in mm3 and intensity 
using manual and Auto ROIs. 
 
In the first round of analysis, there was a disparity between the numbers of lesions 
scored by the two scorers. Hence, with this analysis, the two scorers came to an 
agreement as to which lesions should be subjected to analysis and which lesions 
scored previously should be removed from further analysis. 
 
In all cases, an attempt was first made to use the auto ROI function to quantify the 
lesion. However, this was only possible in about a third of the total lesions which 
were either of larger size or where there was a clear delineation of the lesion based on 
intensity. Most of these were lesions present at baseline and very few were those 
present at follow up after anti-TNF therapy (n=2). The following figures [Fig 5.8 (A 
to F) show the intra-observer agreement for area in mm
2
, volume in mm
3
 as well as 
mean and maximum intensity at baseline using manual and auto ROI. A general trend 
for an increase in disparity with increase in size of the lesion was seen. There was also 
an increase in disparity for intensity scores with higher averages for mean and 
maximum intensity.  
Comment: In general, the size of lesions using Auto ROI tended to be smaller and 
this in turn caused the mean intensity of lesions using Auto ROI to be higher than 
using manual ROI function. This could be interpreted as the auto ROI function being 
able to better delineate lesions and hence improve the utility of quantitative analysis 
as a biomarker. 
 
As the number of lesions amenable to auto ROI function at follow up was so small, no 
meaningful results could be obtained at follow up from this data set. Hence, no plots 
are shown. 
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Bland-Altman plot of Mean intensity at baseline for slices
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(A)              (C)      (E) 
Bland-Altman plot of Volume in mm3 at baseline
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Bland-Altman plot of Mean intensity at baseline for lesions
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(B)      (D)       (F) 
 
Fig 5.8: Bland-Altman Plot of area in mm
2
 (A), volume in mm
3
 (B), maximum (C&D) and mean intensity (E&F) of individual slices and whole 
lesions at baseline. Disparity between observations at the two time points increased with increased size of lesion.
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5.3.4.2 Correlation of Auto ROI to MRI Berlin scores as well as BASDAI  
 
In order to compare the utility of the Auto ROI function, the volume of lesions at 
baseline and follow up was correlated to MRI Berlin scores and BASDAI.  The 
correlation between volume of lesions at baseline to MRI Berlin scores was similar 
for both manual and Auto ROI (r=0.7). However, the correlation coefficient for 
volume of lesions at follow-up versus MRI Berlin scores improved from -0.04 to 0.4. 
The p value for the correlation was still not significant. This may indicate that the auto 
ROI function helped improve the correlation, although this may also be due to the fact 
that some lesions previously scored were excluded. However, given that only a third 
of lesions were actually subject to Auto ROI analysis, it is not surprising that this 
difference was not statistically significant. Also the Auto ROI function did not 
improve the correlation between BASDAI and volume of lesions or intensity either at 
baseline or follow up.  
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Correlation of MRI Berlin score at follow up and vol in mm3- Auto ROI
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(C)           (D) 
Fig 5.9: Correlation between volume of lesions and MRI Berlin scores at baseline (A&B) and at follow up (C&D). Auto ROI improved the 
correlation coefficient at follow up although this was not statistically significant. There was however still no correlation to BASDAI seen. 
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5.3.5 Volumetric analysis as a biomarker of response to therapy in the anti-TNF 
cohort 
 
In order to compare Berlin MRI scoring and volumetric analysis, total volume of bone 
oedema lesions in the spine and sacroiliac joints on each scan was added together. 
Similarly, the average of the mean intensity of all lesions on each scan was calculated. 
The total volume and mean intensity of the lesions was then compared pre and post-
treatment using paired t-test or Wilcoxon matched pairs test using the 11 sets of scans 
for the anti-TNF patients. The total volume was then multiplied by the mean intensity 
for each scan and the change in the product of volume and mean intensity was 
compared before and after treatment for the group as a whole and in those patients 
that were classified as responders on the basis of improvement in BASDAI by 2 units 
or 50% (n=8). Table 5.2 summarizes the various results showing that the product of 
total volume and mean intensity proved to be the best biomarker of response to 
therapy in the three different sets of scores. 
 
Table 5.2: p-values for change from baseline in BASDAI, Berlin MRI scores, 
Volume of lesion in mm
3
, average mean intensity and the product of volume and 
intensity for the two scorers as well as Auto ROI scores for scorer 1.  
 All patients (n=11) Responders (n=8) 
BASDAI 0.01  
MRI Berlin Score 0.04 0.04 
Vol ROI in mm3 (scorer 1) 0.19 0.02 
Vol ROI in mm3 (Auto ROI 
scorer 1) 
0.7 0.25 
Vol ROI in mm3 (Scorer 2) 0.32 0.11 
Intensity (scorer 1) 0.32 0.34 
Intensity (Auto ROI scorer 1) 0.13 0.11 
Intensity (scorer 2) 0.99 0.83 
Vol x Intensity (scorer 1) 0.07 0.01 
Vol x Intensity (Auto ROI 
scorer 1) 
0.15 0.02 
Vol xIntensity (scorer 2) 0.28 0.08 
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5.3.7 Correlation of percentage change from baseline in BASDAI to percentage 
change from baseline in volume in mm3, Mean intensity and the product of 
volume and intensity. 
 
Given the lack of correlation between BASDAI and Berlin MRI scores, I further 
studied the correlation between percentage change from baseline between BASDAI 
and volume of lesions in mm
3
, the mean intensity of lesions as well as the product of 
the volume and intensity. The results are tabulated in table 5.3. Although there was a 
lack of correlation between percentage change from baseline in MRI Berlin scores 
and BASDAI, there was a good correlation seen between BASDAI and the percentage 
change from baseline in the volume of lesions in mm
3
. There was also a lack of 
correlation between the percentage change from baseline in mean intensity and 
BASDAI. However, the percentage change from baseline in the product of volume in 
mm
3
 and mean intensity showed a good correlation with percentage change from 
baseline in BASDAI. 
 
Table 5.3 Correlation coefficients (r ) and p-values using Spearman Rank Correlation 
between percentage change from baseline in BASDAI versus percentage change from 
baseline in MRI Berlin Scores, total volume in mm
3
, mean intensity and the product 
of volume and intensity. 
 Correlation coefficient (r)  p-value 
MRI Berlin Score 0.2 0.56 
Vol ROI in mm
3
 (scorer 1) 0.82 0.002 
Vol ROI in mm
3
 (Auto ROI 
scorer 1) 
0.42 0.2 
Vol ROI in mm
3
 (Scorer 2) 0.63 0.04 
Intensity (scorer 1) 0.22 0.52 
Intensity (Auto ROI scorer 1) 0.33 0.33 
Intensity (scorer 2) 0.26 0.47 
Vol x Intensity (scorer 1) 0.68 0.02 
Vol x Intensity (Auto ROI 
scorer 1) 
0.53 0.09 
Vol xIntensity (scorer 2) 0.67 0.03 
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5.3.8 Correlation of percentage change from baseline in volume in mm3 and the 
product of volume and intensity versus change from baseline in bone 
biomarkers. 
 
In the last chapter, I found that percentage change in MRI Berlin score showed a trend 
towards correlation with percentage change in a number of bone biomarkers. I hence 
compared the scores obtained through volumetric analysis to bone biomarkers to see 
if these relationships were maintained. 
  
When percentage change from baseline in bone biomarkers was compared to 
percentage change from baseline in both the total volume of lesions in mm
3
 and the 
product of volume and mean intensity, a positive correlation was seen with RANKL: 
OPG ratio. On the other hand, there was a negative correlation seen with MMP3 
levels. No other correlations were seen. The Auto ROI function did not increase 
correlations to change in biomarkers except with RANKL: OPG ratio where the 
correlation was stronger than in all other groups.
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Table 5.4: Spearman Rank Correlation between percentage Change in volume as well as the product of volume and mean intensity versus 
percentage change from baseline in bone biomarker levels (p<0.05). The table shows a positive correlation between RANKL: OPG which 
attained statistical significance when compared to percentage change in volume calculated using Auto ROI function. It also shows a negative 
correlation with MMP3 which was statistically significant in all cases except in case of volume calculated using Auto ROI function. 
  RANKL OPG RANKL:OPG BAP TRAP5b MMP3 Osteocalcin Sr sclerostin Dkk-1 
Vol ROI in mm
3
 
 (Scorer 1) 0.28 -0.13 0.62 0.18 -0.02 -0.86 -0.17 0.18 0.23 
Vol ROI in mm
3
 
(Auto ROI Scorer 1) 0.30 -0.10 0.86 -0.01 -0.07 -0.60 -0.50 -0.23 -0.11 
Vol ROI in mm
3
 
 (Scorer 2) 0.35 -0.05 0.55 0.51 0.10 -0.74 -0.05 0.23 0.42 
Vol x Intensity  
(Scorer 1) 0.11 -0.33 0.43 0.35 -0.12 -0.96 0.12 0.30 0.44 
Vol x Intensity 
(Auto ROI Scorer 1) 0.30 -0.24 0.65 0.25 -0.14 -0.81 -0.14 0.20 0.25 
Vol xIntensity  
(Scorer 2) 0.35 -0.05 0.55 0.51 0.10 -0.74 -0.05 0.23 0.42 
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5.4 Discussion 
 
In this chapter I have described a new method of quantifying lesions using Dynamika 
software. This method allows us to measure the change in volume as well as intensity 
of lesions seen on STIR sequences of MRI scans from AS patients undergoing 
therapy. 
 
I have shown a good inter-observer variability between the two scorers for the area of 
lesions on individual slices in mm
2
 as well as for volume of lesions in mm
3
 for the 
whole lesion. The differences between scorers was lower for volume of lesions than 
for area on individual slices suggesting that although there may have been differences 
in the area of lesions on individual slices, these differences were reduced when 
volume of lesions were calculated. In addition, there was good inter-observer 
variability between scorers for the maximum and mean intensity of lesions seen on 
individual slices as well as of the whole lesion.  
 
There are a number of reasons for the differences seen between observers. Firstly, as 
the spine was scanned in 3 separate sections, some lesions were seen on more than 
one spinal segment. Hence, if one scorer scored the lesion on the cervical scan and the 
other on the thoracic scan, this led to significant differences in intensity of the lesion 
which varies markedly between individual scans even on the same patient at the same 
time point scanned using the same machine. It may have also led to differences in the 
number of lesions scored if the same lesion was scored twice. Secondly, there were 
differences between scorers estimating the extent of the lesion i.e. the number of 
slices through which the lesion extended. This largely depended on being able to 
distinguish the intensity of the lesion from surrounding tissue and was often difficult. 
As the intensity of the lesion was generally lower at the periphery of the lesion, this 
was difficult. Thirdly, there were differences in whether a lesion was scored or 
considered an artefact. This was especially the case in the thoracic spine where 
pulsations from the heart, aorta and respiratory movements often produce movement 
artefact making it difficult to assess the anterior border of thoracic vertebrae. Also 
when lesions are small and extend only on 2-3 slices, it is not always easy to 
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distinguish these from artefacts. Another important cause though was the fact that one 
reader was a trained musculoskeletal radiologist and the second, a rheumatologist 
without specialist training to do the scoring. Hence, while Dr Lim was confident is 
calling a lesion an artefact, I was not. This would explain why I scored more lesions 
than him. 
 
Other causes for discrepancies between scorers included differences in labelling of 
lesions with difficulty in counting the levels of vertebrae in the thoracic scans, where 
there was no reference point. There were also sometimes more than one lesion on 
individual slices which were scored as separate lesions by one scorer and together as 
one lesion by the second scorer. These differences did not matter when the total 
volume and mean intensity were compared for each scan at the two time points. 
 
In this chapter, I have also shown good correlation between the MRI Berlin scores 
and the volume of lesions in mm
3
 suggesting that the volumetric analysis compares 
well to an already accepted and validated scoring method. The correlation was poorer 
at follow up than at baseline as the lesions were likely to be smaller and fewer at 
follow up. Hence, although the volume of a lesion may change at follow up, it may 
not be significant enough to merit a change in its Berlin score. For example, if the 
lesion initially covered 50% of area or volume of a vertebra at baseline it would score 
a 2 on Berlin score. If this then improved to affect just 5% of the area or volume of a 
vertebra, the Berlin score would change to 1.  Hence, the change in score would be 
50%. However the change in area or volume would be 90%. The data would therefore 
suggest an improved sensitivity of this volumetric method to assess change when 
compared with the Berlin score.  
 
We were encouraged to develop the auto ROI function largely because of the marked 
similarity in the maximum intensity of the lesions scored by the two different scorers 
which in the majority of cases were identical. We felt that the automated ROI 
technique might reduce inter-observer variability and also allow lesions to be outlined 
quicker. Unfortunately, this could only be applied to larger lesions or to those where 
the intensity of the lesion was homogenous (Fig 5.10) and markedly different from 
surrounding tissue. An important cause for this was the fact that when lesions are 
heterogeneous in intensity, the resultant ROI drawn is very different when one clicks 
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on different areas of the lesion that may be of different intensity (Fig 5.11). For 
example, if one was to click on the most intense area within the lesion, a smaller 
lesion was generated where the intensity was uniformly increased. However, if one 
clicked onto an area just outside this where the intensity was not as high, although 
higher than surrounding tissue, a completely different shape to the lesion was 
obtained. It hence became essential to improvise with use of manual ROI in a large 
number of lesions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.10: Auto ROI function as applied to a large lesion which was homogeneously 
intense. The outline obtained on applying Auto ROI function fits the outline of the 
lesion. 
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(A)             (B) 
   
(C)         (D) 
Fig 5.11: Difficulties with Auto ROI function when the lesion is heterogeneous in intensity (A).  When one clicks on the most intense area of the 
lesion (B), a small ROI is generated involving only the most intense area. However, when one click outside this area over a less intense site (C), 
a completely different shaped ROI is generated. Hence, it became essential to use the manual ROI function in these cases (D). 
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When the various biomarkers- BASDAI, MRI Berlin Score and Volumetric scores 
were compared pre and post anti-TNF therapy, both BASDAI and MRI Berlin Score 
showed statistically significant improvements with therapy, while volume and 
intensity of lesions and their product did not. However, when results were compared 
for the 8 patients that satisfied criterion of response on BASDAI, there was a 
statistically significant improvement in the percentage change from baseline in the 
product of the volume and intensity of the lesion using both manual and Auto ROI 
function. Moreover, when this percentage change from baseline in volume in mm
3
, 
mean intensity and their product was correlated to percentage change from baseline in 
BASDAI, a good correlation was observed both for total volume in mm
3
 as well as for 
the product of volume and intensity but not for MRI Berlin scores. This would 
suggest this to reflect changes in clinical state to a greater extent than the Berlin score.  
 
The p-values were not significant for the Auto ROI scores. This may have been due to 
the fact that while individual scorers may have scored the same lesion at the two time 
points, with the Auto ROI, some of the lesions may have been dropped either at 
baseline or at follow up if they were considered to be artefacts by Dr Lim. 
 The concept of studying the intensity of lesions is not a new one. Both the SPAARC 
scoring system and the Aarhus Madsen system monitor a change in intensity. 
However, this is the first time that intensity of the lesion has been quantified and 
actual change from baseline has been recorded. The product of volume in mm
3
 and 
the intensity may hence represent a new biomarker of response to therapy and one that 
seems to show a good correlation to clinical biomarker such as BASDAI.  
 
Lastly, it was interesting to note the correlation between percentage change from 
baseline in both the volume as well as the product of volume and intensity versus 
change in MMP3. This was also seen with Berlin scoring but the correlation here was 
stronger (p<0.05). There was also a correlation seen with RANKL: OPG which was 
not seen with Berlin scores or with change in BASDAI. However, from chapter 4, this 
ratio seems to play an important part in disease pathogenesis. Further studies would 
be needed to validate this concept. 
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5.5 Limitations and further studies 
Although volumetric analysis using Dynamika seems promising, it is very time 
consuming to carry out the analysis and it cannot be applied to routine clinical cases 
or even in research studies in its current form. The software needs to be improved to 
allow for the auto ROI analysis to be applicable not just to all lesions but also to allow 
calculation of total volume automatically for the whole lesion rather than having to 
calculate individual ROIs on each MRI slice showing the lesion. Without this, its 
applicability remains limited. 
 
With the product of volume in mm
3
 and intensity being a new biomarker, it is 
essential that factors affecting intensity are regulated while scoring. Differences in 
baseline noise, window width and level between scans done at different time points on 
the same patient which can affect the intensity of lesions could not be controlled for 
using current version of Dynamika. Also, as the current MRI protocol for scanning 
allows for gaps between slices, the software estimates volume of the lesions by 
comparing the area of ROI between adjacent slices and factors in the slice gaps. This 
is hence not the true volume of the lesion but a good estimate.   
 
Lastly, we have shown that this method shows promising results when applied to a 
small cohort of patients on anti-TNF therapy. The changes seen in MRI following 
anti-TNF therapy are large and hence it is easy to pick up change with therapy. It 
would be important to apply this to larger cohorts such as the START study cohort 
where the difference before and after treatment are subtle to show that this is actually 
a more sensitive method to pick up change. 
 
5.6 Conclusion:  
 
Volumetric analysis of active bone oedema lesions on STIR MRI sequences compares 
well to semi-quantitative scoring using the Berlin method. Unlike semi-quantitative 
scoring, volumetric analysis also shows a good correlation to change in BASDAI 
scores hence linking clinical and imaging biomarkers. However, further work is 
needed to establish its utility as a biomarker of response to therapy in AS. 
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Chapter 6: Volumetric analysis of MRI bone oedema 
lesions in the clinical trial setting 
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6.1 Introduction:  
 
In the last chapter, I demonstrated the utility of a novel tool, Dynamika, in calculating 
the volume and intensities of bone oedema lesions in patients with AS. This was 
shown in patients undergoing anti-TNF therapy where patients tend to have active 
disease with likely high Berlin Scores on MRI at the start and large improvements in 
these scores after anti-TNF therapy. In this chapter, I discuss the role of volumetric 
analysis in the clinical trial setting in the START study cohort where changes in MRI 
scores post-treatment were modest. 
 
6.2: Methods 
 
6.2.1 Patients, scans and scoring 
 
Patients were recruited on to the START study (section 2.2.1.1) and went on to have 
MRI scans prior to randomization as well as 3 months after receiving either placebo 
or apremilast. All scans were randomized for patient identity, treatment received as 
well as time point so that each patient was assigned a number while each of the paired 
scans was randomly assigned as either A or B by one of the radiographers. Scans were 
read independently by two observers- myself (Scorer 1) and Dr Mikael Boesen 
(Scorer 2), Consultant Musculoskeletal Radiologist at the Parker Institute, 
Copenhagen, Denmark. Both observers followed the standard operating procedure for 
scoring lesions described in chapter 5 (section 5.2.3) but used only manual ROI 
function to draw ROIs. Due to the fact that the scorers were based in different 
countries, no training sessions could be held between the two observers prior to 
scoring of the scans, although attempts were made to further standardize scoring 
between the two using Skype and email.  
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6.2.2 Statistical methods 
Unlike the previous chapter, individual results for areas, volumes and intensities were 
not compared between the scorers as Mikael’s individual scores for lesions were not 
available to me. The volume of all lesions scored by each observer was added together 
to produce a total volume score for each scan. Total volumes calculated by the two 
observers were then compared using paired t-test or Wilcoxon matched pairs test as 
well as Bland Altman plots. The total volume of each lesion was multiplied by the 
mean intensity of that lesion to produce a volume x intensity score for that lesion. The 
scores for all lesions on each scan were again added up to produce a single score. 
Corresponding scores between observers were compared again using the above 
statistical tests. Total volume as well as the product of volume and intensity was then 
compared to Berlin scores using Spearman Rank Correlation. Improvement in total 
volumes as well as the product of volume and mean intensity was also calculated 
using paired t-test or Wilcoxon matched pairs test to assess response to therapy in 
each treatment arm of the START study. The percentage change in volume and 
product of volume and mean intensity between the Apremilast and Placebo group was 
compared using Mann-Whitney U test. Statistical significance was achieved if p value 
was <0.05. Cumulative distribution plots were produced for the two treatment arms by 
the team at Image Analysis to help show the spread of the data. Finally results were 
compared to BASDAI scores, bone biomarkers and cytokines to look for correlations 
between clinical, imaging and laboratory biomarkers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 164 
6.3 Results 
 
17 patients received apremilast and 19 patients received placebo. As noted previously 
in chapter3, patients in the apremilast cohort were older and had higher total spinal 
scores while patients in the placebo cohort had higher SIJ scores. The details of Berlin 
scoring results have previously been noted in table 3.1-3.3. For convenience, table 3.3 
is repeated below. 
 
Table 3.3: Change in Total MRI Berlin scores from baseline 
 
Visit 
Placebo (n=19) 
Mean (SD) 
Apremilast 
(n=17) 
Mean (SD) 
p-value 
Baseline 6.37 ( 4.958) 10.18 ( 8.301) 0.100 
Day 85 5.63 ( 4.245) 8.24 ( 8.592)  
Diff Mean (SD) -0.74 ( 2.156) -1.94 ( 3.976) 0.494 
 
6.3.1 Inter-observer variability –baseline total volume scores 
 
When comparing total volume scores at baseline between scorers, no statistically 
significant differences was seen between the two scorers (Fig 6.1). 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
Fig 6.1: Inter-observer variability for total volume at baseline. The figure (a) shows 
that on comparing the volumes using Wilcoxon matched pairs test, a p-value of 0.83 
was obtained suggesting that there were no statistically significant differences. On 
drawing the Bland-Altman plots (b), differences were seen between the scorers in 
larger lesions. 
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6.3.2 Follow up total volume scores 
At follow up, the difference between the two scorers was not statistically significant 
(p=0.08) [Fig 6.2 (a)]. The Bland-Altman plot shows more dots above zero suggesting 
that in most cases, scorer 1 measured larger volumes than scorer 2 [Fig 6.2(b)]. 
 
 
 
 
 
 
 
 
 
 
 
 
(a)   
 
 
 
 
 
 
 
 
 
 
(b) 
Fig 6.2: Inter-observer variability for volume in mm
3 
.Fig (a) shows comparison of 
scores using Wilcoxon matched pairs test with the difference being almost statistically 
significant. Fig (b) shows the Bland-Altman plot showing that scorer 1 generally had 
higher scores as compared to scorer 2 with more points lying above the zero line. The 
difference between scorers increased with increased size of the lesion. 
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6.3.3 Product of volume and intensity scores at baseline 
Similar to total volume scores, there were no statistically significant differences 
between the scorers for the product of volume and intensity of lesions at baseline. 
The Bland-Altman plot shows that except for one patient, both scorers agreed on 
scoring in most of the cases. 
 
 
 
 
 
 
 
 
 
 
     (a) 
 
 
 
 
 
 
 
 
 
 
 
(b) 
Fig 6.3: Inter-observer variability at baseline for the product of volume and intensity 
of the lesion. Fig (a) shows that there were no statistically significant differences 
between scorers. Fig (b) shows that with one exception, the product of volume and 
intensity was similar for most cases. 
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6.3.4 Product of volume and intensity at follow-up 
 
At follow up, there was still no statistically significant difference between the two 
scorers [Fig 6.4(a)]. The Bland-Altman plot shows again more points above the zero 
suggesting higher scores for scorer 1 than scorer 2. 
 
 
 
 
 
 
 
 
 
 
 
(a) 
Bland-Altman plot of Inter-observer variability for follow up volume x
Intensity:Difference vs average
0 20000 40000 60000 80000 100000
-100000
-50000
0
50000
100000
Average
D
if
f 
in
 V
o
l 
x
 i
n
te
n
s
it
y
 
(b) 
Fig 6.4: Inter-observer variability for the product of volume and intensity scores at 
follow- up. Fig (a) shows no statistically significant difference between scorers. Fig 
(b) shows that scorer 1 had higher scores than scorer 2. 
 
 
Inter-observer variability for follow up vol x intensity- Spine+SIJ
S
co
re
r 
1 
S
co
re
r 
2
0
50000
100000
150000
p=0.18
Observers
V
o
lx
In
te
n
s
it
y
 169 
6.3.5 Correlation of volume in mm3 to Berlin scores –baseline scans 
 
When comparing Berlin scores to volume of lesions in mm
3
, there was a good 
correlation seen at baseline for both scorers (r=0.8 for scorer 1 and r=0.75) (Fig 6.5).  
 
 
 
 
 
 
 
 
 
 
     (a) 
     
 
 
 
 
 
 
 
 
 
 
 
(b) 
Fig 6.5: Correlation between baseline MRI Berlin scores and Volume in mm
3
 for 
scorer 1 (a) and scorer 2 (b). A good correlation was seen for both scorers 
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6.3.6 Correlation of volume in mm3 to Berlin scores at follow up 
 
At follow up, the correlation was still strong for scorer 1 (r=0.8) but not as strong for 
scorer 2 (r=0.59) (Fig 6.6). 
 
 
 
 
 
 
 
 
 
 
 
     (a) 
 
 
 
 
 
 
 
 
 
 
   (b) 
Fig 6.6: Correlation between MRI Berlin score and Volume in mm3 at follow up for 
scorer 1 (a) and scorer 2 (b). A better correlation was seen between scores for scorer 1 
(r=0.8) than for scorer 2 (r=0.59), although p values for both correlations were <0.05. 
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6.3.7 Improvement in volumes and the product of volume in mm3 and mean 
intensity after treatment   
 
When pre and post-treatment volume scores were compared for each scorer, there 
were differences seen between the scorers. While the scores for scorer 1 showed an 
increase in both volume and the product of volume and intensity in both arms of the 
study, the scores for scorer 2 showed a decrease in both these parameters. None of the 
p-values for change were statistically significant (Table 6.1). 
 
When percentage change from baseline was compared for the scorers, the percentage 
change in the volume from baseline was similar in the two groups for scorer 1, with 
both showing an increase. However, percentage change in volume decreased in both 
groups for scorer 2 with a greater decrease in the Apremilast versus Placebo group 
(table 6.2).  
 
Similarly, when percentage change from baseline in the product of volume and 
intensity was compared, an increase was seen in both groups for scorer 1, with the 
increase being higher in the placebo than apremilast arm. On the other hand, scores 
for scorer 2 showed an increase in percentage change from baseline for placebo and a 
decline in percentage change in the apremilast group. None of the p-values for change 
from baseline were statistically significant. 
 
Cumulative distribution plots for percentage change from baseline for volume (total 
spine and SIJ) are shown for scorer 1 in 6.7 (A&B) and for scorer 2 in fig 6.8 (A&B). 
Cumulative distribution plots for percentage from baseline for the product of volume 
and mean intensity for scorer 1 are shown in fig 6.9 A&B and for scorer 2 in fig 6.10 
(A&B). 
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Table 6.1: Change in volume and product of volume and mean intensity with 
treatment 
Volume in mm
3 
 Scorer Baseline Follow up p-value 
Placebo Scorer 1 (EP) 14.95 (18.23) 17.83 (20.16) 0.09 
Scorer 2 (MB) 13.84 (17.07) 11.9 (18.07) 0.88 
Apremilast Scorer 1 (EP) 19.9 (21.1) 25.5 (30.1) 0.3 
Scorer 2 (MB) 25.34 (30.48) 21.9 (25.7) 0.37 
Volume in mm
3
 x Mean Intensity 
 Scorer Baseline Follow up p-value 
Placebo Scorer 1(EP) 10160 (12542) 11647 (13648) 0.5 
Scorer 2 (MB) 10148 (14053) 8580 (12327) 0.6 
Apremilast Scorer 1(EP) 15950 (18733) 22785 (30507) 0.24 
Scorer 2 (MB) 41079 (96524) 19770 (27689) 0.39 
 
 
Table 6.2: Percentage change from baseline in volume as well as the product of 
volume and intensity  
Parameter Scorer Apremilast Placebo p-value 
%Change in 
Vol (mm
3
) 
Scorer 1 (EP) 24.34 (97.48) 25.43 (78.46) 0.7 
Scorer 2 (MB) -14.14 (40.85) -2.06 (62.06) 0.5 
%Change in 
Vol x Intensity 
Scorer 1 (EP) 49.13 (155) 141.1 (469.5) 0.9 
Scorer 2(MB) -12.41 (62.39) 11.08 (76.83) 0.3 
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                                                                 (A) 
Cumulative Distribution Plot - Ejaz_Spine + SIJ Scores_Apremilast
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                                                                (B) 
Fig 6.7: Cumulative distribution plot of percentage change from baseline of 
volume in mm
3
 in placebo (A) and apremilast (B) for scorer 1. While less than 
30% of patients on placebo showed an improvement in volume scores in the 
placebo arm, the figure was almost 50% of patients in the apremilast arm. The 
increase in volume for the placebo arm was much higher than with apremilast. 
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Cumulative Distribution Plot - Mikael_Spine + SIJ Scores_Apremilast
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                                                             (B) 
Fig 6.8: Cumulative distribution plots for percentage change from baseline for 
volume in mm
3
 for whole spine and sacroiliac joints for scorer 2. Fig (A) shows 
plot for placebo group with just above 50% of patients showing an improvement 
in volume scores and Fig (B) showing almost 60% patients receiving apremilast 
showing an improvement. The worsening in volumes was much smaller in the 
apremilast arm as against placebo. 
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                                                                    (A) 
Cumulative Distribution Plot - Ejaz_Spine + SIJ Scores_Apremilast
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                                                                    (B) 
Fig 6.9: Cumulative distribution plots for percentage change from baseline in the 
product of volume and intensity for placebo (A) and apremilast (B) for scorer 1. 
While only 40% of patients receiving apremilast showed an improvement, the 
increase in the product of volume and intensity was much higher in the than 
placebo arm in the 50% that showed worsening. 
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Cumulative Distribution Plot - Mikael_Spine + SIJ Scores_Apremilast
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                                                               (B) 
Fig 6.10: Cumulative distribution plots for percentage change from baseline in 
the product of volume and intensity for placebo (A) and apremilast (B) for scorer 
2. There was an improvement in scores in 60% of patients in both groups with 
the area under the curve being slightly larger for apremilast rather than placebo. 
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6.3.7 Correlation between percentage change in BASDAI versus percentage 
change in volume as well as the product of volume and intensity 
 
When studied as a group, in the START cohort, there were no correlations seen 
between percentage change from baseline in BASDAI versus percentage change in 
volume or percentage change in the product of volume and intensity for either scorer. 
It is however, important to note that the product of volume and intensity in this cohort 
was calculated for individual lesions and then added together. This was in contrast to 
the anti-TNF cohort, where the total volume of all lesions was multiplied by the mean 
intensity of all lesions. When the same procedure was repeated for my scores in the 
START cohort, a similar correlation was seen between percentage change in the 
product versus percentage change in BASDAI (r=0.34, p=0.04 for scorer 1). 
 
When the difference between pre and post-treatment scores for volume as well as the 
product of volume and intensity were compared to the difference in BASDAI scores, 
in the apremilast cohort, a negative correlation was found with change in volume (r = 
-0.5, p=0.02) and change in the product of volume and intensity (r = -0.3, p=0.25) 
only for scorer 2 scores. No correlations were seen in the placebo group. 
 
6.3.8 Correlation between percentage change in MRI Berlin score versus 
percentage change in volume as well as the product of volume and intensity 
 
When percentage change in MRI Berlin scores was compared to percentage change in 
volume as well as the product of volume and intensity, a good correlation was found 
with scores from scorer 2 (r = 0.5, p<0.01 for both parameters). However, the 
correlations were weaker for scores from scorer 1 (r=0.24 for volume and 0.27 for 
volume x intensity, p>0.05).  
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6.3.9 Correlation between percentage change in volume as well as the product 
of volume and intensity versus bone biomarkers 
 
Similar to the anti-TNF cohort, I explored correlations with bone biomarkers. While 
no correlations were seen in the placebo arm of the study, correlations observed in the 
apremilast cohort as shown in table 6.3.  In general, there was a better correlation 
between change in certain biomarkers like plasma sclerostin, Dkk-1, BAP and OPG 
with change in scorer 1 volume and product of volume and intensity. 
 
Table 6.3: Correlation of percentage change in volume as well as the product of 
volume and intensity with percentage change in bone biomarkers in the apremilast 
cohort (p<0.05) 
 % change in 
%Volume 
Scorer 1 
%Volume 
Scorer 2 
%Vol x Int 
Scorer 1 
%Vol x Int 
Scorer 2 
Pl Sclerostin -0.68 -0.22 -0.55 0.04 
Dkk-1 -0.43 -0.40 -0.34 -0.08 
TRAP5b -0.04 0.13 0.16 0.41 
BAP -0.53 -0.20 -0.60 -0.33 
RANKL -0.11 -0.10 -0.24 -0.14 
OPG 0.22 -0.11 0.36 -0.02 
RANKL:OPG -0.19 -0.08 -0.37 -0.12 
MMP3 -0.07 -0.06 0.02 -0.09 
Osteocalcin -0.04 -0.12 0.00 -0.19 
 
6.3.10 Correlation between percentage change in volume as well as the product 
of volume and intensity versus cytokines and growth factors 
 
On comparing percentage change from baseline in cytokines and growth factors to 
percentage change in volume and product of volume and intensity, there was only a 
negative correlation seen with E-selectin levels in the apremilast cohort for scorer 1 (r 
= -0.5 for both parameters). There was also a trend towards correlation between the 
product of volume and intensity for scorer 2 and IP-10 levels. 
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6.4 Discussion 
 
This chapter shows how the volumetric analysis can be applied in the clinical trial 
setting. It highlights the fact that there was a good correlation between Berlin scoring 
and volumetric analysis, hence further validating this against an established scoring 
system. I have shown that two observers independently scoring scans obtained 
acceptable level of agreement for scores at baseline. There were differences between 
the scorers at follow up which are important but can be overcome in order to make 
this method more robust. 
 
Firstly, the two scorers did not have a training session together to agree on how scans 
should be scored. I wrote a standard operating procedure to score the scans and 
calculate results. However, Mikael who had previously used the same software 
modified his approach to the analysis. While I scored multiple lesions on the same 
vertebra separately, he produced a single volume for all lesions on the same vertebra. 
Secondly, as in chapter 5, there were also differences in which scan was used for 
scoring lesions that were common to cervical and thoracic or thoracic and lumbar 
spine scans. The intensities of the lesions on the different scans were very different, 
hence leading to differences between scorers. 
 
Thirdly, as with the anti-TNF data, there were differences between scorers as to the 
number of lesions scored and also the number of slices scored for each lesion. Mikael 
scored a number of lesions in the lateral elements (paravertebral), while I scored only 
lesions in the vertebral body. This was obviously because he was well experienced in 
MRI imaging and was able to detect these lesions. 
 
Similar to anti-TNF data, I scored larger volumes at follow up for both patient groups. 
This probably again reflects the fact that I was less experienced and was not sure of 
whether a lesion was a true lesion or an artefact. It is noteworthy that Mikael’s scores 
were in agreement with MRI Berlin scores produced by 2 other independent 
musculoskeletal radiologists. As with the MRI Berlin score, there was an 
improvement in scores at follow up for both apremilast and placebo arms of the study 
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but a greater improvement in the apremilast arm rather than placebo. The difference, 
as with MRI Berlin scoring, was not statistically significant. It was also important to 
note that when the difference between baseline and follow up scores were compared, 
there was a correlation between difference in BASDAI scores and difference in 
volumetric scores obtained by Mikael. It is not clear why this association was stronger 
for volume of lesions as against the product of volume and intensity, which showed a 
better correlation with the anti-TNF data described in chapter 5. This may be related 
to the way the product of volume and intensity was calculated. In the previous chapter 
by multiplying the total volume by the mean intensity of all lesions, the intensity of 
lesion weighed higher than the volume of the lesion as a factor for this score. This 
would need to be investigated further in larger patient cohorts. 
 
It is not clear why my scores showed a worsening in both patient groups as against 
Mikael’s that showed an improvement. Clearly as he is the more experienced observer 
and as his results mirror those of 2 other musculoskeletal radiologists, they are likely 
to represent true results. One could argue that my scores correlated well with MRI 
Berlin scores although when percentage change from baseline was compared between 
the two scoring system, the correlation was poor. There may have been an element of 
bias here as I was present when the Berlin scoring was carried out by the scorers. 
 
 Even though my scores did not correlate to clinical scores, in the apremilast arm, 
there was a correlation seen with plasma sclerostin, BAP and E-selectin. All of these 
biomarkers showed important change with treatment with apremilast showing 
correlations either with BASDAI or MRI Berlin scores. This may indicate that my 
scores also reflected change in disease activity.  
 
There are three ways of resolving these differences between scorers. The first could 
be to only take into account lesions scored by both scorers. However, given that I am 
not a trained musculoskeletal radiologist, this may exclude some true lesions that I 
have not scored. The second option would be to develop an automated ROI tool and 
apply this to lesions scored by both scorers to minimise differences. This may or may 
not reduce discrepancy depending on whether the discrepancy lies in the size of lesion 
scored or the actual number of lesions. Lastly, a third blinded scorer who is 
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musculoskeletal radiologist, could rescore scans. Clearly, more work is needed before 
volumetric analysis can be used as a tool in clinical research. 
 
6.5 Future work: 
 
Further work needs to be done to standardize scoring using Dynamika. The analysis 
of images for the START study required more than 120 hours to complete as against 6 
hours needed for scoring using Berlin scoring. It would hence need to become more 
user friendly before it can be applied to clinical research. This can be done by 
improving the automatic ROI function which should allow the user to create the ROI 
by drawing a single line through the area of interest with varying intensities on one 
slice. This in turn should draw ROIs on adjacent slices automatically, reducing the 
inter-observer variability between observers who normally differ in the number of 
slices scored. It would also help for the two observers to look at scans together and 
agree before hand as to which lesions need scoring and which ones are artefacts.  
 
 
6.6 Conclusion: 
 
Although this chapter highlights a number of problems with volumetric analysis, the 
correlation of volumetric scores with Berlin scores establishes this as a novel method 
of assessing response to therapy. The correlation to both clinical and laboratory 
biomarkers brings us a step closer to finding an objective biomarker of response to 
therapy in ankylosing spondylitis.  
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Chapter 7: Concluding Discussion 
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7.1 Discussion 
 
Ankylosing Spondylitis (AS) is probably more prevalent than previously realised. It is 
often recognised late but the use of MRI now allows diagnosis early on in the disease. 
The treatment options for the management of AS have largely remained the same, 
exercise, NSAIDs and anti-TNF agents. Although there is emerging interest in some 
therapies such as IL-17 inhibitors [31], newer agents such as IL-6 inhibitors[30] and 
anti-B cell therapy[29] do not work in AS like they do for rheumatoid arthritis. There 
is thus a need for other therapies that are cost effective. Given the lack of effective 
DMARDs in AS, new drugs that maybe positioned between NSAIDs and anti-TNF 
agents would hence be seen as a major advance in the management of this condition. 
This thesis has explored PDE4 inhibition for AS and demonstrated this to be of 
potential clinical benefit. Apremilast has also been shown by others to be effective in 
the management of psoriatic arthritis in clinical trials [155]. 
 
This thesis also highlights the contemporary challenges of clinical trial development 
in AS. The need to demonstrate clinical improvements and also to provide robust 
objective evidence of benefit on imaging in a feasible sized population is a challenge. 
Various semi quantitative scoring methods have been developed to assess MRI and 
these have been discussed. I have also presented exploratory data for alternative 
approaches to MR image assessment in AS. Although semi-quantitative methods do 
take into account both change in volume and intensity of lesions, volumetric analysis 
using Dynamika, is able to objectively quantify this change for the first time. This 
holds promise for further advance in sensitivity to change but some methodological 
issues remain to be resolved.  
 
In this thesis, I have also demonstrated the correlations between clinical, imaging and 
laboratory biomarkers in three AS patient cohorts in an attempt to highlight the role of 
these biomarkers both in routine clinical practice and in the clinical trial setting. In the 
absence of an existing biomarker that provides a clear reproducible measure of 
response, clinical indices of disease activity still dictate what treatment a patient 
should receive.  
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Clinical indices such as BASDAI still remain the gold standard in assessing response 
to therapy, although it is well known that the BASDAI does not differentiate between 
symptoms related to inflammatory or degenerative disease. There were statistically 
significant changes in the BASDAI with anti-TNF therapy where the change seen was 
large. Similar changes were seen with apremilast but given the short duration of 
therapy and slower mechanism of action of this drug, the effects were not statistically 
significant. Also BASDAI showed an improvement in patients treated with placebo. 
 
In contrast, the BASFI has been found to be a better indicator of quality of life than 
BASDAI as indicated by results from studying over 300 patients enrolled in the 
Scotland and Ireland Registry for AS (SIRAS) [162]. In my study, not much change 
was seen in BASFI after treatment in the placebo arm and the improvement with 
apremilast was almost statistically significant suggesting that this may be a better 
marker of disease activity.  
  
The ASDAS was only applied to the START cohort. This showed an improvement in 
both apremilast and placebo groups with the difference between the two not being 
statistically significant. There was a good correlation seen between ASDAS and 
BASDAI in the START cohort with an improvement in BASDAI translating to an 
improvement in ASDAS. Recent reports have shown that improvements in ASDAS 
correlates to improvements in biomarkers of inflammation such as IL-6, angiogenesis 
such as VEGF and bone turnover such as MMP3 and osteocalcin [163]. ASDAS has 
also been shown to correlate better than BASDAI to difference in MRI scores at 24 
and 102 weeks in over 150 patients treated with anti-TNF therapy in the ASSERT 
trial [157]. 
 
MRI Berlin scoring showed significant differences after treatment with anti-TNF 
therapy but not with apremilast. The change in Berlin scores did not correlate with 
change in BASDAI. The volumetric analysis using Dynamika correlated well to 
Berlin scores. The product of volume and intensity of the lesions showed a significant 
change with treatment in the anti-TNF cohort and also correlated to change in 
BASDAI scores. Unfortunately, when applied to the START cohort, there was 
significant inter-observer variability between the two scorers, making it difficult to 
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interpret results. The maximum intensity of the lesion seemed to be most consistent 
between scorers and may hold the key to developing automated ROI function which 
would reduce inter-observer variability. 
 
Inflammatory biomarkers showed a significant change in the anti-TNF cohort but not 
in the other 2 patient groups. There was also no correlation between BASDAI and 
inflammatory biomarkers.  
 
Bone biomarkers showed most promise in terms of change with therapy.  MMP3 has 
already been shown to be an important biomarker of damage in AS. I found a 
reduction in levels of MMP3 in patients treated with anti-TNF although this was not 
statistically significant. Levels of MMP3 have been shown to be elevated in AS 
patients with active disease and have been shown by one group to better reflect 
disease activity than ESR or CRP [164]. It was interesting to note that this correlated 
well with change in the product of volume and intensity in the anti-TNF cohort. 
Others have reported an association between MMP-8 and MMP-9 and increased 
disease activity [165].  
 
Treatment with adalimumab has been shown to be associated with a fall in levels of 
MMP3 and VEGF as well as a rise in levels of BAP [153]. I did not find a statistically 
significant rise in levels of BAP in either the anti-TNF or apremilast cohorts. 
However, there was a statistically significant drop in levels of OPG in the anti-TNF 
cohort and a statistically significant rise in levels of osteocalcin in the apremilast 
cohort, both of which are factors promoting bone formation. Taylan et al showed that 
OPG levels correlated with levels of disease activity in a group of 55 AS patients and 
also found significantly lower levels of OPG in the subgroup of patients receiving 
anti-TNF therapy[166]. Furthermore, an earlier study by Baraliakos that 
retrospectively studied biomarkers of radiographic progression in 159 patients from 
the ASSERT cohort, found higher levels of OPG as the only predictive factor of 
structural radiographic progression over 2 years in this AS cohort treated with 
infliximab [167]. Like OPG, levels of osteocalcin have also been shown to be 
significantly elevated after 12 weeks of treatment with etanercept in a small group of 
26 AS patients from Korea [154]. However, this study did not find any change in 
levels of OPG or RANKL in this group after treatment. 
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RANKL and RANKL: OPG ratio came out as important biomarkers of response to 
treatment. These changed in both the anti-TNF and the apremilast group although the 
relationships in these two treatment groups were different. These have not been 
reported to show change with treatment with anti-TNF therapy by others. There have 
been reports though of the RANKL: OPG being raised in AS patients and higher 
ratios seen in those with low bone density or radiological signs of inflammation [145]. 
It was interesting to see that there was a correlation also between changes in RANKL: 
OPG ratio and change in volume of lesions using volumetric analysis after anti-TNF 
therapy. However, further work needs to be done to better understand the role of the 
RANKL: OPG system in disease pathogenesis and how it changes with treatment. 
 
Another biomarker that showed a close correlation to RANKL: OPG was sclerostin. 
It is well known that TNF α can induce Wnt inhibitors such as Dkk-1[15] and 
sclerostin [168], which in turn are potent inhibitors of osteoblast differentiation. The 
Wnt pathway also controls OPG expression hence blocking the interaction of RANK 
with RANKL. My work demonstrates that the Wnt pathway is modulated by both 
apremilast and anti-TNF therapy, but that there may be differences in how the two 
drugs modulate this system. While a correlation was seen between plasma sclerostin 
and BASDAI in the apremilast group, a different correlation was seen between Dkk-1 
and changes on MRI in the anti-TNF cohort. Studies on AS patients in the German 
spondylarthritis Inception cohort (GESPIC), who were not on anti-TNF therapy, have 
shown that low levels of sclerostin [152]and Dkk-1[169] (as measured by a functional 
assay) at  baseline were predictive of increased disease progression in the form of 
syndesmophytes at 2 years. Moreover, levels of Dkk-1 were found to increase with 
anti-TNF therapy, although the increased levels did not result in increased binding of 
Dkk-1 to its receptor using functional assays [170]. Further work is needed to better 
understand this and correlate changes in these biomarkers to radiological progression 
on X-rays or improvement in bone density on DEXA.  
 
Changes in levels of pro-inflammatory cytokines such as TNF α are also important 
biomarkers of response. Although there was a rise in levels of TNF α after anti-TNF 
therapy, this is unlikely to represent bioactive TNFα. A reduction in levels of TNF RI 
was seen with both apremilast and anti-TNF therapy and may represent valuable 
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marker of response to therapy. A recent study of AS patients undergoing treatment 
with golimumab that evaluated 92 different biomarkers, found a significant change in 
levels of TNF receptor II, along with 15 other biomarkers, after 4 weeks of treatment 
with golimumab [171]. E-selectin was the only other biomarker that correlated with 
change in BASDAI scores, a drop in BASDAI correlating to a drop in E-selectin 
levels. This again has not been reported to change by others [172]. Levels of IL-6 and 
VEGF have traditionally been reported by many previous studies to show change with 
treatment [131, 163, 171]. My results showed that levels of IL-6 only showed a trend 
toward correlation with change in MRI scores but not with BASDAI. Levels of VEGF 
did not show a significant change with treatment, but correlated to change in MRI 
scores in the placebo arm. Levels of VEGF have been shown to correlate to disease 
activity in AS [133]. 
 
Levels of IL-13, IL-17 and IL-23 proved difficult to interpret in this study as levels 
were below the recordable range for a large number of samples. It was hence difficult 
to draw any conclusions from our data although associations were seen in the anti-
TNF cohort suggesting a possible mechanism of action. Levels of IL-12/23 p40 unit 
were reliably measured but only showed a weak association with change in BASDAI 
scores. Similar lack of correlation to disease activity has been described by Wendling 
et al [173] that studied this biomarker in 27 AS patients, 14 of whom were treated 
with anti-TNF therapy. No change was seen in levels of IL-12p40 after treatment and 
no correlations were observed between IL-12p40 and BASDAI, ESR or CRP.  
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7.2 Conclusions:  
This thesis contributes to existing knowledge in spondyloarthritis in three ways. 
Firstly it describes the results of a phase II clinical trial of a novel oral 
phosphodiesterase inhibitor in AS and shows that this drug does modulate bone 
biomarkers. Furthermore, in this population of relatively late stage patients, 
improvements in symptoms and signs were observed in a proportion of those treated 
with apremilast over the short period of exposure investigated in this trial.  
Secondly, it describes a novel technique that allows for objective quantification of 
bone oedema lesions on STIR sequences of MRI, at the same time showing 
correlation to both clinical indices and laboratory biomarkers.  
Lastly, this thesis explores the complex relationships between the various laboratory 
biomarkers and suggests that different drugs may modulate these differently. It also 
highlights the fact that some biomarkers like MMP3 and osteocalcin may correlate 
better with imaging scores while others like RANKL: OPG and plasma sclerostin to 
clinical scores. 
 
7.3 Future directions: 
 
This study leads on to a further phase III study of apremilast in patients with AS over 
a longer duration allowing to better study long term outcome measures such as 
syndesmophyte formation or improvement in bone density. 
Volumetric analysis may provide the most sensitivity to change but at present is too 
prohibitively time consuming to permit routine use. There are also difficulties in 
defining lesions as being of pathological significance. These issues may be resolved in 
the future through development of an automated ROI function and by a better 
understanding of pathophysiological correlates of imaging abnormalities that will 
permit automated identification of pathological tissue and hence reduce inter-observer 
variability.  
Further work needs to be done to better understand the complex relationship between 
RANKL-OPG system and the Wnt pathway and how this is affected by different 
treatments. This in turn will lead to a better understanding of how inflammation leads 
to new bone formation in AS. 
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Appendix 1 Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI)  
Please place a mark on each line below to indicate your answer to each question, relating to the 
past week.  
 
1.  How would you describe the overall level of fatigue/tiredness you have experienced?  
NONE    VERY SEVERE  
0  10  
2. How would you describe the overall level of AS neck, back or hip pain you have had?  
NONE    VERY SEVERE  
0  10  
3. How would you describe the overall level of pain/swelling in joints other than neck,  
back or hips you have had?  
NONE    VERY SEVERE  
0  10  
4.  How would you describe the overall level of discomfort you have had from any areas 
tender to touch or pressure?  
NONE   VERY SEVERE  
0  10  
5.  How would you describe the overall level of morning stiffness you have had from the 
time you wake up?  
NONE    VERY SEVERE  
0  10  
6.  How long does your morning stiffness last from the time you wake up? 
      
 0hrs ½ hr 1hr 1 ½ hr 2 or more hours 
  
Source: Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing 
spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate 
instrument? Rheumatology; 1999; 38:878-882.  
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Appendix 2 Bath Ankylosing Spondylitis Functional Index            
(BASFI)  
 
Please draw a mark on each line below to indicate your level of ability with each of the following 
activities, during the last week. 
  
Note: An aid is apiece of equipment which helps you to perform an action or movement.  
 
1.  Putting on your socks or tights without help or aids (eg sock aids)  
 
     
EASY  IMPOSSIBLE  
 0 10 
 
 
2.  Bending forward from the waist to pick up a pen from the floor without an aid  
 
    
EASY  IMPOSSIBLE  
 0 10 
 
3.  Reaching up to a high shelf without help or aids (eg helping hand)  
 
    
EASY  IMPOSSIBLE  
 0 10 
 
4.  Getting up out of an armless dining room chair without using your hands or any other 
help  
 
    
EASY  IMPOSSIBLE  
 0 10 
 
 
5.  Getting up off the floor without help from lying on your back  
 
    
EASY  IMPOSSIBLE  
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 0 10 
 
6.  Standing unsupported for 10 minutes without discomfort  
 
    
EASY  IMPOSSIBLE  
 0 10 
 
7.  Climbing 12-1 5 steps without using a handrail or walking aid (one foot each step)  
 
    
EASY  IMPOSSIBLE  
 0 10 
 
8.  Looking over your shoulder without turning your body  
 
    
EASY  IMPOSSIBLE  
 0 10 
 
9.  Doing physically demanding activities (eg, physiotherapy exercises, gardening, or sports)  
 
    
EASY  IMPOSSIBLE  
 0 10 
 
10. Doing a full days activities whether it be at home or at work  
 
    
EASY  IMPOSSIBLE  
 0 10 
 
Source: Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A New Approach to Defining 
Functional Ability on Ankylosing Spondylitis: The Development of the Bath Ankylosing Spondylitis Functional Index. J 
Rheumatol. 1994; 21:2281-2285.  
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Appendix 3  Bath Ankylosing Spondylitis Patient Global Score 
(BAS-G)  
 
1.  Please place a vertical mark on the scale below to indicate the effect your disease has had 
on your well-being over the last week.  
 
   
NONE   VERY SEVERE  
0 10 
1  
Source: Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J 
Rheumatol. 1996; 35:66-71.  
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Appendix 4: Bath Ankylosing Spondylitis Metrology Index (BASMI2)  
 
 Score 
 0 1 2 
Tragus to wall < 15 cm 15-30 cm > 30 cm 
 
Lumbar flexion > 4 cm 2-4 cm < 2 cm 
 
Cervical rotation > 70º 20-70º < 20º 
 
Lumbar side flexion > 10 cm 5-10 cm  < 5 cm 
 
Intermalleolar distance > 100 cm 70-100 cm < 70 cm 
 
 
0 = mild disease improvement  
1 = moderate disease improvement  
2 = severe disease improvement  
Results for cervical rotation and lumbar side flexion are the means of the left and right 
measurements.  
Score range 0-10.  
 
Source: Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining 
Spinal Mobility in Ankylosing Spondylitis (AS): The Bath AS Metrology Index. J Rheumatol 
1994; 2 1:1694-1698.  
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Appendix 5 Bath Ankylosing Spondylitis Metrology Index Linear 
(BASMIlin) 
 
Scheme for the assessment of the Bath Ankylosing Spondylitis Metrology Index 
(BASMI) components and graphical conversion into BASMIlin scores. Mark 
measuring results on upper scales read corresponding score on lower scale. For the 
components 1, 2, and 5, the averages of right and left assessments have to be used. If 
a score would lie beyond the range of the scale 0-10, the values 0 or 10 have to be 
used, respectively. 
                                               van der Heijde, D et al. Ann Rheum Dis 2008; 67:489-493 
 
 208 
 
Appendix 6   FACIT-F 
 
By circling one (1) number per line, please indicate how true each statement has 
been for you during the past 7 days. 
 
ADDITIONAL CONCERNS 
 
Not 
at all 
A 
little  
bit 
Some- 
what 
Quite  
a bit 
Very 
much 
I feel fatigued 
………………………………. 
 
0 1 2 3 4 
I feel weak all over 
………………………… 
 
0 1 2 3 4 
I feel listless (“washed out”) 
……………….. 
 
0 1 2 3 4 
I feel tired 
…………………………………... 
 
0 1 2 3 4 
I have trouble starting things because I am 
tired …. 
 
0 1 2 3 4 
I have trouble finishing things because I am 
tired ... 
0 1 2 3 4 
I have energy ……………………………… 
 
0 1 2 3 4 
I am able to do my usual activities 
………… 
 
0 1 2 3 4 
I need to sleep during the day 
……………… 
0 1 2 3 4 
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I am too tired to eat 
…………………………… 
 
0 1 2 3 4 
I need help doing my usual activities 
……… 
 
0 1 2 3 4 
I am frustrated by being too tired to do the 
things I want to do 
…………………………. 
 
 
0 
 
1 
 
2 
 
3 
 
4 
I have to limit my social activity because I 
am tired  
0 1 2 3 4 
 
EMOTIONAL WELL-BEING 
 
Not 
at all 
A 
little  
bit 
Some- 
what 
Quite  
a bit 
Very 
much 
I feel sad 
………………………………………… 
 
0 1 2 3 4 
I am satisfied with how I am coping with my 
illness 
…………………………………………… 
 
 
0 
 
1 
 
2 
 
3 
 
4 
I am losing hope in the fight against my 
illness ….. 
 
0 1 2 3 4 
I feel nervous 
…………………………………… 
 
0 1 2 3 4 
I worry about dying 
…………………………… 
 
0 1 2 3 4 
I worry that my condition will get worse 0 1 2 3 4 
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…… 
 
 
 
FUNCTIONAL WELL-BEING 
 
Not 
at all 
A little  
bit 
Some- 
what 
Quite  
a bit 
Very 
much 
I am able to work (including work at 
home)… 
 
0 1 2 3 4 
My work (including work at home) is 
fulfilling  
 
0 1 2 3 4 
I am able to enjoy life 
………………………… 
 
0 1 2 3 4 
I have accepted my illness 
…………………… 
 
0 1 2 3 4 
I am sleeping well 
…………………………… 
 
0 1 2 3 4 
I am enjoying the things I usually do for 
fun  
 
0 1 2 3 4 
I am content with the quality of my life 
right now... 
0 1 2 3 4 
 
PHYSICAL WELL-BEING Not 
at all 
A 
little  
bit 
Some- 
what 
Quite  
a bit 
Very 
much 
I have a lack of energy 
……………………… 
 
0 1 2 3 4 
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I have nausea 
………………………………… 
 
0 1 2 3 4 
Because of my physical condition, I have 
trouble meeting the needs of my family …… 
 
 
0 
 
1 
 
2 
 
3 
 
4 
I have pain 
……………………………………… 
 
0 1 2 3 4 
I am bothered by side effects of treatment … 
 
0 1 2 3 4 
I feel ill 
………………………………………… 
 
0 1 2 3 4 
I am forced to spend time in bed 
…………… 
 
0 1 2 3 4 
 
 
SOCIAL/FAMILY WELL-BEING Not 
at all 
A little  
bit 
Some- 
what 
Quite  
a bit 
Very 
much 
I feel close to my friends 
……………………… 
 
0 1 2 3 4 
I get emotional support from my family 
……… 
 
0 1 2 3 4 
I get support from my friends 
………………… 
 
0 1 2 3 4 
My family has accepted my illness 
………… 
 
0 1 2 3 4 
I am satisfied with family communication 0 1 2 3 4 
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about my illness 
……………………………… 
 
I feel close to my partner (or the person 
who is my main support) 
…………………………… 
0 1 2 3 4 
Regardless of your current level of sexual activity, 
please answer the following question.  If you prefer 
not to answer it, please check this box and go to 
the next section 
 
     
I am satisfied with my sex life 
……………… 
 
0 1 2 3 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 213 
Appendix 7: Correlations between individual bone biomarkers at 
baseline  
 
When baseline concentrations of various bone biomarkers were compared in 
individual patient groups (tables 7A, B and C), there were some important similarities 
between cohorts but also some differences. RANKL as well as RANKL: OPG ratio 
was positively correlated to serum and to a lesser extent to plasma sclerostin levels in 
all three cohorts. There were positive correlations seen between MMP3 and BAP and 
also between MMP3 and TRAP5b. There was also a negative correlation seen 
between MMP3 and Osteocalcin, though this was a very weak correlation in the anti-
TNF cohort. 
 
There was a strong correlation between plasma and serum sclerostin in the apremilast 
and placebo groups. The anti-TNF cohort showed some correlations that were 
different from the other two cohorts. These included a positive correlation seen 
between Dkk-1 and RANKL as well as serum sclerostin levels. There was also a 
positive correlation between RANKL: OPG ratio and Dkk-1 but a negative correlation 
between RANKL: OPG and MMP3 in this group. 
 
Table 7A: Correlation between bone biomarkers in anti-TNF cohort at baseline (p<0.05) 
Biomarker RANKL OPG RANKL:OPG BAP TRAP5b MMP3 Osteocalcin Sr Sclerostin 
OPG -0.49   -0.62 0.34 0.21 0.27 0.01 -0.27 
RANKL:OPG 0.98 -0.62   -0.33 0.14 -0.67 0.31 0.73 
BAP -0.26 0.34 -0.33   0.31 0.21 0.43 -0.11 
TRAP5b 0.24 0.21 0.14 0.31   -0.19 0.50 0.44 
MMP3 -0.65 0.27 -0.67 0.21 -0.19   -0.11 -0.49 
Osteocalcin 0.37 0.01 0.31 0.43 0.50 -0.11   0.38 
Sr Sclerostin 0.76 -0.27 0.73 -0.11 0.44 -0.49 0.38   
Dkk-1 0.47 -0.33 0.46 0.00 0.48 -0.14 0.22 0.48 
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Table 7B Correlation between bone biomarkers in apremilast cohort at baseline (p<0.05)   
Biomarker RANKL OPG RANKL:OPG BAP TRAP5b MMP3 Osteocalcin 
Sr 
Sclerostin Dkk-1 
OPG 0.08   -0.34 0.20 0.01 -0.69 0.60 0.06 -0.24 
RANKL:OPG 0.87 -0.34   -0.05 0.10 0.13 -0.17 0.56 0.08 
BAP 0.06 0.20 -0.05   0.70 -0.33 0.55 0.31 0.23 
TRPAP5b 0.19 0.01 0.10 0.70   0.10 0.30 0.43 -0.05 
MMP3 -0.16 -0.69 0.13 -0.33 0.10   -0.49 0.12 -0.01 
Osteocalcin 0.00 0.60 -0.17 0.55 0.30 -0.49   0.32 -0.04 
Sr Sclerostin 0.61 0.06 0.56 0.31 0.43 0.12 0.32   0.05 
Dkk-1 -0.09 -0.24 0.08 0.23 -0.05 -0.01 -0.04 0.05   
Pl Sclerostin 0.45 0.16 0.46 0.44 0.52 -0.03 0.43 0.86 0.03 
 
 
 
 
 
Table 7C Correlation between bone biomarkers in placebo group at baseline (p<0.05) 
Biomarker RANKL OPG RANKL:OPG BAP TRAP5b MMP3 Osteocalcin 
Sr 
Sclerostin Dkk-1 
OPG -0.32   -0.59 0.24 -0.15 -0.18 0.12 -0.20 0.41 
RANKL:OPG 0.93 -0.59   -0.65 -0.29 0.09 -0.32 0.73 -0.25 
BAP -0.74 0.24 -0.65   0.29 -0.34 0.36 -0.37 0.18 
TRAP5b -0.38 -0.15 -0.29 0.29   0.15 0.33 -0.30 -0.27 
MMP3 0.12 -0.18 0.09 -0.34 0.15   -0.62 0.12 -0.33 
Osteocalcin -0.30 0.12 -0.32 0.36 0.33 -0.62   -0.27 0.17 
Sr Sclerostin 0.76 -0.20 0.73 -0.37 -0.30 0.12 -0.27   -0.01 
Dkk-1 -0.13 0.41 -0.25 0.18 -0.27 -0.33 0.17 -0.01   
Pl Sclerostin 0.60 -0.22 0.61 -0.25 -0.14 -0.18 0.13 0.85 0.02 
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Appendix 8: Correlations between percentage change in individual 
bone biomarkers with treatment in the three patient groups 
 
When percentage change from baseline in the various bone biomarkers was compared 
post-treatment in the three groups (table 8 A, B and C), different correlations were 
seen in the three different groups. A strong positive correlation was found between 
Dkk-1 and ostoecalcin while a negative correlation was seen between osteocalcin and 
RANKL in the apremilast cohort. There was also a negative correlation seen between 
TRAP5b and RANKL: OPG ratio and a positive correlation between OPG and serum 
sclerostin in this group. In the placebo cohort, a correlation was seen between 
TRAP5b and plasma sclerostin. The correlation between OPG and RANKL: OPG 
ratio remains unchanged in the apremilast and placebo cohort but no correlation was 
seen in the anti-TNF cohort. 
 
 
Table 8A:Correlation between percentage change from baseline in various bone biomarkers in anti-TNF 
cohort (p<0.05) 
Biomarker RANKL OPG RANKL:OPG BAP 
TRAP 
5b MMP3 Osteocalcin Sr Sclerostin 
OPG 0.39   -0.02 -0.12 0.02 -0.21 -0.38 -0.28 
RANKL:OPG 0.81 -0.02   -0.06 -0.18 0.22 -0.18 0.10 
BAP -0.02 -0.12 -0.06   0.07 -0.11 0.41 -0.11 
TRAP 5b -0.29 0.02 -0.18 0.07   -0.06 0.30 0.10 
MMP3 0.02 -0.21 0.22 -0.11 -0.06   0.23 -0.10 
Osteocalcin -0.21 -0.38 -0.18 0.41 0.30 0.23   0.33 
Sr Sclerostin 0.08 -0.28 0.10 -0.11 0.10 -0.10 0.33   
Dkk-1 0.00 -0.05 -0.08 0.25 -0.17 0.14 0.55 0.13 
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Table 8B: Correlation between percentage change from baseline in various bone biomarkers in apremilast cohort 
(p<0.05) 
Biomarker RANKL OPG RANKL:OPG BAP TRAP5b MMP3 Osteocalcin 
Sr 
Sclerostin Dkk-1 
OPG -0.12   -0.60 -0.30 0.31 -0.01 -0.17 0.50 -0.17 
RANKL:OPG 0.83 -0.60   0.31 -0.49 -0.44 -0.32 -0.27 0.26 
BAP 0.22 -0.30 0.31   0.04 0.19 0.12 -0.19 0.42 
TRAP5b -0.38 0.31 -0.49 0.04   0.34 0.39 0.06 0.09 
MMP3 -0.39 -0.01 -0.44 0.19 0.34   0.36 0.07 -0.05 
Osteocalcin -0.52 -0.17 -0.32 0.12 0.39 0.36   0.14 0.15 
Sr Sclerostin -0.06 0.50 -0.27 -0.19 0.06 0.07 0.14   0.21 
Dkk-1 0.17 -0.17 0.26 0.42 0.09 -0.05 0.15 0.21   
Pl Sclerostin -0.21 -0.13 0.02 0.33 0.02 -0.17 -0.09 -0.16 0.43 
 
 
Table 8C: Correlation between percentage change from baseline in various bone biomarkers in placebo cohort 
(p<0.05) 
Biomarker RANKL OPG RANKL:OPG BAP TRAP5b MMP3 Osteocalcin 
Sr 
Sclerostin Dkk-1 
OPG 0.01   -0.56 0.19 0.06 0.02 -0.16 0.13 0.01 
RANKL:OPG 0.73 -0.56   -0.16 -0.32 -0.19 0.09 0.10 -0.14 
BAP -0.14 0.19 -0.16   0.10 -0.27 0.28 -0.19 0.25 
TRAP5b -0.29 0.06 -0.32 0.10   -0.03 0.09 -0.20 0.12 
MMP3 -0.16 0.02 -0.19 -0.27 -0.03   -0.03 -0.04 0.07 
Osteocalcin -0.20 -0.16 0.09 0.28 0.09 -0.03   0.02 0.03 
Sr Sclerostin 0.18 0.13 0.10 -0.19 -0.20 -0.04 0.02   -0.51 
Dkk-1 -0.24 0.01 -0.14 0.25 0.12 0.07 0.03 -0.51   
Pl Sclerostin 0.10 -0.12 0.15 0.11 0.60 -0.12 0.17 0.10 0.09 
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Appendix 9: Methodology for bone biomarker ELISAs 
 
A: RANKL assay 
 
Dilute capture antibody (100 μg of antigen-affinity purified mouse anti-hsRANKL 
reconstituted in 1ml sterile water to give a concentration of 100μg/ml) with PBS to a 
concentration of 1 μg/ml. Add 100μl to each well and incubate overnight at room 
temperature                                         
 
 
 
Aspirate wells and wash plate with 300 μl of wash buffer (0.05% Tween-20 in PBS) 4 
times. Invert plate to remove residual buffer and blot on paper towel. 
                                                              
 
 
Add 300μl blocking buffer (1%BSA) to each well and incubate for at least 1hr at 
room temperature. Then aspirate and wash 4 times. 
                                                             
 
 
Add 100μl of diluted standard (diluted from100 μg/ml to 4ng/ml as top standard) or 
sample to each well in duplicate and incubate at room temperature for 2 hours 
                                                              
 
 
Aspirate and wash plate 4 times. Dilute detection antibody (50 μg of biotinylated 
antigen-affinity purified rabbit anti-hsRANKL reconstituted in 0.5ml sterile water to 
give a concentration of 100μg/ml) in diluent (0.05% Tween 20, 0.1%BSA in PBS) to 
a concentration of 0.5 μg/ml. Add 100μl per well and incubate at room temperature 
for 2 hours                                                 
 
 
Aspirate and wash plate 4 times. Dilute 5.5 μl of Avidin Peroxidase 1:2000 in diluent 
to give a total volume of 11ml. Add 100 μl per well and incubate for 30min at room 
temperature                                         
 
 
Aspirate and was plate 4 times and add 100 μl of ABTS substrate solution to each 
well. Monitor for colour development with an ELISA plate reader at 405nm with 
wavelength correction set at 650nm    
                                                               
 
 
The plate is monitored every 5 min for approximately 30 minutes. Reliable standard 
curves are obtained when either optical density reading do not exceed 0.2 units for the 
zero standard or 1.2 units for the highest standard. 
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B. Sclerostin Assay 
 
 
Dilute capture antibody (anti-human Sclerostin Ab at 500μg/ml produced from a 
hybridoma resulting from fusion of a mouse myeloma with B cells obtained from a 
mouse immunized with purified recombinant human SOST)) in coating buffer 
(NaCO3 1.59 g + NaHCO3 2.93 g + NaN3 0.19 g in 1 litre H2O) to give a 
concentration of 2 μg/ml. Add 100 μl per well and incubate overnight at room 
temperature. 
                                                                
 
Aspirate wells and wash plate with 300 μl of wash buffer (0.05% Tween-20 in PBS) 3 
times. Invert plate to remove residual buffer and blot on paper towel. 
                                                               
 
Block plates by adding 300 μl of blocking buffer (1% BSA) for at least 1 hour at 
room temperature. Then repeat wash step as above to remove all blocking buffer.                                      
 
 
Reconstitute Standard (recombinant human sclerostin) at 200 μg/ml in sterile PBS 
containing at least 0.1% bovine serum albumin. This is diluted further in PBS to give 
a top standard of 10 ng/ml. Serial dilutions in PBS carried out to give a 10 point 
standard curve.                                                                    
 
 
Add 100 μl of standards or samples to the wells in duplicate. Incubate for 2 hours at 
room temperature. Then repeat wash step. 
                                                               
 
 
Reconstitute biotinylated anti-human sclerostin Ab (produced from a hybridoma 
resulting from the fusion of a mouse myeloma with B cells obtained from a mouse 
immunized with purified recombinant human sclerostin) in 0.5ml PBS to give a 
concentration of 500μg/l. Dilute further to produce a concentration of 1μg/ml. Add 
100μl of diluted antibody to each well and incubate for 2 hours at room temperature 
before repeating wash step.                    
 
 
Add 100μl of Streptavadin HRP (diluted1:200) to each well and leave at room 
temperature for 20 min. Avoid direct sunlight. Then repeat wash step. 
                                                                
 
 
Add 100 μl of substrate (equal quantities of Colour reagent A- H2O2 and Colour 
reagent B- TMB). Incubate for 20-30 minutes at room temperature. Avoid direct 
sunlight. Then add 50μl of stop solution (1N H2SO4) to each well. 
                                                                
 
 
Read plate on Mikrowin plate reader at 450nm with wavelength correction at 570nm. 
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C. Dkk-1 Assay 
 
Reconstitute 720μg/ml of mouse anti-human Dkk-1 (capture antibody) with 1ml of 
PBS. Dilute further to a working concentration of 4.0 μg/ml in PBS without carrier 
protein. Add 100μl per well of diluted capture antibody. Incubate overnight at room 
temperature. 
 
 
Aspirate each well and wash with wash buffer (0.05% Tween 20 in PBS), repeating 
the process three times. Invert plate and blot on clean paper towel. 
                                                                
 
Block plates by adding 300μl of Reagent Diluent (1%BSA in PBS) to each well. 
Incubate at room temperature for a minimum of 1 hour. Then repeat wash step. 
                                                               
 
Reconstitute 910ng/ml of recombinant human Dkk-1 with 0.5ml of reagent diluent. 
Allow to sit for 15 minutes with gentle agitation. Then make 2 fold serial dilutions to 
produce a 7 point standard curve using 4000pg/ml as high standard. 
                                                               
 
Add 100μl of sample or standards and incubate for 2 hours at room temperature. 
Then repeat wash step. 
 
 
Add 100μl of detection antibody (9μg/ml of biotinylated goat anti-human Dkk-1 
reconstituted with 1ml of reagent diluent and diluted further in reagent diluent to give 
a working concentration of 50ng/ml). Incubate for 2 hours at room temperature before 
repeating wash step. 
 
 
Add 100μl of working dilution of Streptavadin-HRP to each well and incubate for 20 
minutes at room temperature. Avoid exposure to direct light. Then repeat wash step. 
                                                               
 
Add 100μl of substrate solution (1:1 mixture of colour reagent A- H2O2 and Colour 
reagent B- TMB) to each well. Incubate for 20 minutes at room temperature avoiding 
direct light. Then add 50 μl of stop solution to each well. Gently tap to ensure 
thorough mixing. 
                                                                   
 
 
Measure optical density of each well using micro plate reader set at 450nm with 
wavelength correction at 570nm.  
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D Osteoprotegrin Assay (MicroVue OPG EIA Kit) 
 
Reconstitute the Human OPG standard provided (lyophilised recombinant chimeric 
protein composed of Human OPG and Fc domain of human IgG) with dilution buffer 
provided to prepare stock solution with a concentration of 60pmol/L. Mix gently and 
incubate for 15 minutes at room temperature. Then dilute further in dilution buffer to 
give concentrations of 30, 15, 7.5, 3.75 and 1.875 pmol/L.  
                                                                                                                           
 
Reconstitute high and low controls provided with deionised water. Dilute controls and 
samples 1:3 with dilution buffer.         
 
 
Pipette 100μl of diluted standards, diluted controls and diluted samples into the coated 
assay wells                               
 
 
Incubate shaking at 300rpm for 60±1 minute at room temperature 
 
 
Prepare wash buffer by diluting wash buffer provided 1:10 with deionised water. 
Then aspirate and wash the wells in the plate at the end of 60 minute incubation. 
                                                            
 
Pipette 100μl Biotin labelled polyclonal anti-human OPG antibody provided into each 
well. Incubate shaking at 300rpm for 60±1 min at room temperature. Then aspirate 
and wash the wells.                                    
 
 
Pipette 100 μL Streptavadin HRP Conjugate to each well. Incubate shaking for 
300rpm for 30±1 min at room temperature. Then repeat wash step. 
                                                            
 
Pipette 100μL of substrate solution provided (TMB+ H2O2). Incubate for 10±1 min at 
room temperature.                           
 
 
Pipette 100 μL of stop solution provided (1.96% H2SO4) 
                                                             
 
Read optical density at 450nm. 
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E Osteocalcin Assay (MicroVue Osteocalcin EIA kit) 
 
Prepare wash buffer by diluting 10X wash buffer provided with deionised water. 
Reconstitute standards and controls with 0.5ml of wash buffer within 1 hour of use. 
Allow to stand for 15 minutes.              
 
 
Thaw frozen samples rapidly in a water bath (at 37
o
 C) until just thawed and then 
transfer immediately to ice.                    
 
 
Add 25 μL of standards, control or sample to each well in duplicate. This should be 
completed within 30 minutes.                
 
 
Add 125 μL of  purified murine monoclonal anti-Osteocalcin antibody  to each well 
and incubate for 2 hours at room temperature. Wash wells at the end of incubation 
period. 
                                                                
 
Reconstitute each provided vial of Enzyme conjugate (Lyophilized goat anti-mouse 
IgG antibody conjugated to alkaline phosphatase) with 10ml of wash buffer. Add 150 
μL of reconstituted enzyme conjugate into assay wells. Incubate for 1 hour. Then 
repeat wash step.                                    
 
 
Prepare working substrate within 1 hour of use by adding one tablet (p-Nitrophenyl 
phosphate) per bottle of Substrate buffer provided. Pipette 150 μL of substrate 
solution into each well and incubate at room temperature for 35-40 min. 
                                                               
 
                                          All 50 μL of stop solution  
 
 
                                        Read the optical density at 405nm. 
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F: Tartrate-resistant acid phosphatase isoform 5b (TRAP5b) assay (MicroVue 
TRAP5b EIA Kit) 
 
 
Reconstitute Standards and Controls provided with 400μL of deionised water within 2 
hours of use. Dilute wash buffer provided 1:10 with deionised water. 
                                                                 
 
Pipette 100μL of sample diluent (TRIS buffer) provided into assay wells. Then add 
50μL of reconstituted Standards, Controls and samples into assay wells. Incubate at 
room temperature for 60 minutes on plate shaker shaking at 500rpm.  
                                                               
 
Reconstitute Substrate buffer by adding Substrate Reconstitution buffer provided 
(MES buffer) to the substrate provided (2-chloro-4-nitrophenyl-phosphate powder). 
Prepare this within 30 minutes of use.   
 
 
Aspirate each well and wash with wash buffer prepared earlier, repeating the process 
three times. Invert plate and blot on clean paper towel. Then add 100 μL of 
reconstituted substrate solution into assay wells. Shake for 30 sec at 500-1000rpm and 
incubate for 60 minutes at 37
o
C.           
 
 
Pipette 50 μL of stop solution provided (0.2N NaOH) into assay wells. 
                                                                
 
                                    Read optical density at 405nm. 
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G: Bone Alkaline Phosphatase (BAP) assay (MicroVue BAP EIA Kit) 
 
 
Dilute Wash buffer provided 1:10 with deionised water. Add 125 μL of assay buffer 
provided in the kit into each well.          
 
 
Pipette 20 μL of Standards, Controls (provided) and samples into assay wells. 
Incubate for 3 hours at room temperature. 
                                                                  
 
Wash wells 4 times with wash buffer prepared earlier. Prepare substrate solution 
within 60 minutes of use by adding substrate tablet to Substrate buffer provided and 
shake vigorously.  Then add 150 μL of substrate solution to each well and incubate 
for 30 minutes at room temperature.                   
 
 
Add 100 μL of stop solution provided (0.5N NaOH) to each well. 
 
 
                                        Read optical density at 405 nm. 
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H: Matrix metalloproteinase 3 (MMP3) assay (Quantikine Human Total MMP-3 
Immunoassay 
 
 
Dilute serum samples 10 fold with Calibrator Diluent RD5-10 provided in the kit. 
Reconstitute Standard provided with 1.0ml of deionised water to produce a stock 
solution of 100ng/ml. Allow to stand for 30 min with gentle agitation before preparing 
serial dilutions in polypropylene tubes to give concentrations between 10ng/ml and 
0.156 ng/ml. Use Calibrator Diluent RD5-10 alone as zero standard. 
                                                                
 
 
Add 100 μL Assay Diluent RD1-52 provided to each well. Then add 100 μL of 
Standard, controls and diluted samples to each well. Incubate at room temperature for 
2 hours on a horizontal micro plate shaker (0.12 inches) set at 500±50 rpm. 
 
 
Aspirate and was wells 4 times. Then add 200 μL of MMP-3 Conjugate provided to 
each well. Incubate at room temperature on the shaker.  
 
 
Wash wells as before and add 200 μL of Substrate solution prepared by adding equal 
volumes of colour reagents A and B provided within 15 minutes of use. Incubate for 
30 minutes at room temperature away from light.  
 
 
Add 50 μL of stop solution to each well. Read at 450nm within 30 minutes with 
wavelength correction at 540nm.  
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ABSTRACT 
Objectives  To evaluate the efficacy and safety of an oral phosphodiesterase 4 
inhibitor, apremilast, in the treatment of ankylosing spondylitis (AS) by monitoring 
symptoms and signs in a pilot study including exploratory investigation of effects of 
PDE4 inhibition on blood biomarkers of bone biology. 
Methods  In this double-blind, placebo-controlled, single-centre, Phase II study, 
patients with symptomatic AS with active disease on MRI were randomised to 
apremilast 30 mg BID or placebo over 12 weeks. Bath Indices were monitored 
serially. Patients were followed for 4 weeks after stopping medication. Bone 
biomarkers were assessed at baseline and day 85.  
Results: 38 subjects were randomised and 36 subjects completed the study. Although 
the primary end-point (change in BASDAI at week 12) was not met, apremilast was 
associated with numerically greater improvement from baseline for all clinical 
assessments compared with placebo with mean change in BASDAI (-1.59±1.48 vs -
0.77±1.47), BASFI (-1.74±1.91 vs -0.28±1.61) and BASMI (-0.51±1.02 vs -
0.21±0.67); however, differences did not achieve statistical significance. The clinical 
indices returned to baseline values by 4 weeks after cessation of apremilast.  Six 
apremilast patients (35.3%) vs 3 placebo (15.8%) achieved ASAS20 responses 
(p=0.25). There were statistically significant decreases in serum RANKL and 
RANKL:osteoprotegrin ratio and plasma sclerostin but no significant changes in 
serum DKK-1, bone alkaline phosphatase, TRAP5b, MMP3, osteoprotegrin, or 
osteocalcin.  
Conclusion: Although a small pilot study, these results suggest that apremilast may 
be effective and well tolerated in AS and modulates biomarkers of bone biology. 
These data support further research of apremilast in axial inflammation. 
 227 
INTRODUCTION 
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting the spine 
with or without involvement of peripheral joints. Historically, the mainstay of AS 
treatment was physiotherapy and non-steroidal anti-inflammatory drugs (NSAIDs). 
Although NSAIDs may provide symptomatic relief,[1] they are not always efficacious 
and often poorly tolerated.[2] Traditional disease-modifying anti-rheumatic drugs 
(DMARDs) such as sulphasalazine and methotrexate are ineffective in axial AS[3, 4] 
and not recommended treatments under EULAR guidance for AS management.[5, 6] 
 
Pharmacological management of AS advanced with anti-TNF therapy. Clinical trials 
have shown that 50-70% of AS anti-TNF treated patients have a ≥20% improvement 
in disease activity scores by 24 weeks.[7-9] Furthermore, switching between biologics 
within the class of TNF inhibitors is also effective.[10] However, TNF blockade does 
not prevent radiographic ankylosis over 2 years,[11-13] although a recent study 
suggests that longer-term treatment (8 years) may reduce radiographic progression. 
[14] Despite generally favourable safety, the risk of serious infection remains and 
anti-TNF therapy should only be used with caution in certain patient groups. 
Furthermore, the expense of treatment may restrict use. Therefore, a major unmet 
need exists for alternative and symptomatically effective oral therapies in AS.  
 
Phosphodiesterase 4 (PDE4) is a major phosphodiesterase expressed in leukocytes, and 
keratinocytes, where it hydrolyzes cyclic adenosine monophosphate (cAMP) into AMP, 
leading to production of pro-inflammatory cytokines such as TNFα, IL-23, IL-17, and 
interferon-γ, and suppression of anti-inflammatory cytokines such as IL-10.[15-18] 
Inhibitors of PDE4 cause accumulation of intracellular cAMP, which activates protein 
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kinase A and other downstream effectors, supressing pro-inflammatory cytokine 
transcription and other cellular responses such as neutrophil degranulation, chemotaxis, 
and adhesion to endothelial cells. Furthermore, PDE4 inhibition upregulates anti-
inflammatory mediators such as IL-10 through the cAMP response element-binding 
(CREB) transcription factor.[17, 19, 20]  
 
Apremilast is an orally available, small molecule specific PDE4 inhibitor which, in 
vitro, inhibits spontaneous release of TNF from human rheumatoid synovial 
membrane cultures and lipopolysaccharide-induced TNF production from peripheral 
blood mononuclear cells (PBMCs). It also decreases TNFand IL-23 mRNA levels in 
PBMCs from healthy human donors.[21] Apremilast significantly suppresses arthritis 
in rodent models[22] and has demonstrated efficacy in phase II trials of psoriasis[23] 
and psoriatic arthritis[24] with acceptable safety. Phase III studies for these conditions 
are now ongoing. 
 
Given that cytokines influenced by PDE4 play an important role in spondyloarthritis, 
there is a rationale to explore apremilast use in this condition and we report here the 
findings of the first clinical trial of apremilast in patients with AS. 
 
The aims of this pilot study were to evaluate the efficacy and safety of apremilast in 
patients with AS and to explore the effect of apremilast on biomarkers of bone 
biology. We also assessed the effects of apremilast on MRI imaging of the sacro-iliac 
joints and spine from baseline to 12 weeks and this will be reported separately. 
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PATIENTS AND METHODS 
Study design 
This was a single-centre, randomized, double-blind, placebo-controlled, Phase II, 
investigator-led, pilot study carried out at the Kennedy Clinical Trials Unit 
(Clinicaltrials.gov number NCT00944658) and sponsored by Imperial College 
London. It was conducted in accordance with good clinical practice and received 
ethics committee approval from The Hammersmith Hospital Research Ethics 
Committee. Each patient provided written informed consent. 
 
The study involved a 12-week, double-blind, placebo-controlled period followed by a 
4-week follow-up for safety and clinical assessments. Patients were randomized 1:1 to 
receive apremilast 30 mg BID or placebo in a double-blind fashion. An unblinded 
pharmacist allocated patients to receive either placebo or active drug according to a 
randomization code generated by Celgene. All other study personnel remained 
blinded to treatment until the end of the double-blind period. Patients were started on 
apremilast 10 mg BID or placebo and the dose was titrated by 20 mg every 2 days 
until the maximum dose of 30 mg BID was achieved on day 5. Apremilast/placebo 
was then given daily until day 85 (week 12). Patients were allowed to continue stable 
doses of NSAIDs but were not allowed DMARDs within 8 weeks of randomization or 
corticosteroids in oral/parenteral form within 4 weeks of randomization. 
 
Patients 
Key inclusion criteria included modified New York criteria for AS, disease duration > 
2 years, symptoms of back pain and stiffness confirmed with a score of ≥1 on 
questions 2 and 5 of the Bath Ankylosing Spondylitis Disease Activity Index 
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(BASDAI; spinal pain and stiffness) and presence of active bone oedema either in the 
spine or sacroiliac joints confirmed by magnetic resonance imaging (MRI). Patients 
with prior treatment with TNF inhibitors were permitted to enrol. 
 
Patients were excluded if there were abnormalities on routine blood tests other than a 
raised erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), 
contraindications to MRI scanning, or positive tuberculosis testing (Mantoux and TB 
Elispot). 
 
Evaluation of efficacy 
The primary end point was the mean change in BASDAI score at week 12 compared 
with baseline. Additional efficacy assessments included changes in function using the 
Bath Ankylosing Spondylitis Functional Index (BASFI) and improvement in spinal 
mobility using the Bath Ankylosing Spondylitis Metrology Index (BASMI). The Bath 
Ankylosing Spondylitis Global Score (BAS-G) and night time pain scores were also 
recorded. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) 
questionnaire was used to assess improvement in the quality of life. The Ankylosing 
Spondylitis Activity Score 20 (ASAS20) and ASAS40 responses were calculated. All 
assessments were carried out at baseline (day1) and days 8, 15, 29, 56, and 85 (week 
12) and were repeated at the end of the safety follow-up period (day 113). Post hoc 
analyses of AS disease activity score (ASDAS) changes were undertaken. 
 
Laboratory biomarkers 
Routine biochemistry, including CRP and haematology with ESR, were performed at 
all patient visits. Additional blood samples were centrifuged at 1200 g for 15 minutes 
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within 2 hours of phlebotomy and stored at -80
o
C. The following commercially 
available enzyme-linked immunosorbent assays (ELISA) were used: osteocalcin, 
tartarate-resistant acid phosphatase (TRAP5b), osteoprotegrin (OPG), and bone 
alkaline phosphatase (BAP [MicroVue Bone Health, Quidel Corporation, CA, USA]), 
matrix metalloproteinase 3 (MMP3 [Quantikine , R&D Systems, Abingdon, UK]), 
and human serum receptor activator of NF-κB ligand (sRANKL [Peprotech Inc, NJ, 
USA]). Commercially available DuoSet ELISA development system (R&D Systems) 
was used to measure total DKK-1 levels in serum. A sandwich ELISA protocol was 
developed using R&D Systems’ recombinant human sclerostin, biotinylated anti-
human sclerostin antibody (1:500 dilution), and monoclonal anti-human sclerostin 
antibody (2 μg/ml) to measure sclerostin levels in plasma. 
 
Statistical methods 
Sample size estimation 
This was an exploratory study conducted without prior knowledge of effect size of 
apremilast in AS. The sample size was chosen based on feasibility and on the basis 
that for an effect size similar to that of anti-TNF, a sample size of 18 patients in each 
arm would have 80% power to detect differences between groups at a 95% level of 
significance. 
 
The primary objective was to evaluate the efficacy of apremilast. Analysis of 
covariance (ANCOVA) was used to assess differences between treatment and placebo 
arms for various clinical outcome measures. Baseline values were considered as 
covariates to nullify any differences between groups. 
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Analyses on biomarkers were purely exploratory hence a simpler evaluation of 
unpaired t-tests (ANOVA) or  non-parametric Mann Whitney as appropriate. No 
adjustment for baseline values were explicitly made, however the endpoint evaluated 
was the percentage change from baseline. A p value <0.05 was considered significant. 
 
RESULTS 
Patient demographics and baseline characteristics 
Fifty-five patients were screened (6 failing to demonstrate bone oedema on MRI) and 
38 were enrolled into this study. With the exception of two patients (both receiving 
apremilast), all others completed the study. The two withdrawals discontinued 
treatment within 1 week of commencing due to non-serious adverse events and were 
included in the safety population but not in the efficacy analysis. Hence, the efficacy 
population consisted of 17 patients on apremilast and 19 on placebo.  
 
Patient demographics and baseline characteristics in each group are shown in Table 1. 
The study population was predominantly Caucasian and male (M:F=8:1). The mean 
age was 42.95 years (range 27-67) and disease duration 19.5±11.01 years (range 2-
44). The majority of patients (33/36) were on stable doses of NSAIDs while the 
remaining did not take any concomitant NSAID therapy during the trial period. Three 
subjects had received prior anti-TNF therapy (placebo, 2; apremilast, 1). 
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Table 1  Baseline patient characteristics  
  Placebo* (n=19) Apremilast* (n=17) 
p value 
(ANCOVA) 
Age, years 39.21 (13.3) 44.88 (11.1) 0.17 
Disease duration, years 18.39 (10.17) 20.88 (12.32) 0.51 
BASDAI 4.36 (1.757) 4.79 (2.161) 0.52 
BASFI 3.49 (2.208) 4.55 (2.429) 0.178 
BASMI 3.16 (1.598) 4.48 (1.963) 0.03 
BAS-G 4.13 (2.329) 4.33 (2.850) 0.82 
Night pain 4.03 (2.524) 4.25 (2.940) 0.81 
FACIT-F 110.04 (26.147) 107.75 (25.716) 0.79 
CRP (mg/dl) 6.24 (2.56) 11.37 (12.12) 0.43 
*Data are mean (SD). 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; 
FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue. 
 
Patients assigned to apremilast had higher BASDAI, BASFI, and BASMI scores at 
baseline compared with the placebo arm. The difference in the BASMI baseline 
scores was statistically significant (p=0.03). This was corrected for by using baseline 
values as a covariate in the statistical analysis. None of the p values for the treatment 
by baseline effect were significant (p values not shown). Hence, there was a 
comparable difference in clinical outcome measures in patients with higher or lower 
values at baseline. 
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Clinical response 
Apremilast was associated with numerically larger improvements than placebo at 
week 12 in BASDAI (-1.59±1.48 vs -0.77±1.47), BASFI (-1.74±1.91 vs-0.28±1.61), 
and BASMI (-0.51±1.02 vs -0.21±0.67), although differences did not achieve 
statistical significance (Table 2). The magnitude of improvement from baseline in the 
apremilast group increased over the treatment period and did not appear to reach a 
maximum by week 12. These improvements in all indices were lost by 4 weeks after 
cessation of therapy (Figure 1). Six patients (35.3%) in the apremilast groups vs three 
(15.8%) in the placebo group achieved an ASAS20 response (p=0.25). Similarly, four 
patients (23.5%) in the apremilast group vs one patient (5.3%) in the placebo group 
achieved an ASAS40 response (p=0.17). ASAS 5/6 responses were achieved by 3 
patients in the apremilast group vs one in the placebo group. A post hoc analysis of 
mean (SD) change in ASDAS showed a reduction of 0.46(0.66) in the apremilast 
group vs 0.15(0.71) in the placebo group (p=0.35 by Mann Whitney). ASDAS 
improvements > 1.1 were observed in 4/17 apremilast patients and 1/19 placebo 
patients. 
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Table 2  Mean change from baseline in clinical parameters at week 12 
 Placebo* (n=19) Apremilast* (n=17) p value (ANCOVA) 
BASDAI -0.77 (1.47) -1.59 (1.48) 0.139 
BASFI -0.28 (1.61) -1.74 (1.91) 0.108 (RANK 
ANCOVA) 
BAS-G -0.17 (2.83) -1.36 (2.35) 0.166 
BASMI -0.21 (0.67) -0.51 (1.02) 0.617 
FACIT-F 5.07 (13.44) 9.38 (12.79) 0.358 
Night pain -0.23 (2.75) -0.81 (3.01) 0.587 
*Data are mean change (SD). 
ANCOVA, analysis of covariance; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis 
Metrology Index; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue.  
 
Laboratory biomarkers 
Percentage changes from baseline in bone biomarkers in each study group are shown 
in Table 3. There were no significant differences in baseline bone biomarker 
parameters between the treatment groups. There was a significant reduction in 
RANKL (p=0.04) and RANKL:OPG ratios (p=0.008) in the apremilast group, but not 
in OPG levels which remained relatively unchanged. RANKL levels were below the 
detectable range at both time points in a third of the patients. There was significant 
decrease in plasma sclerostin levels (p=0.02) and a trend towards reduction in levels 
of DKK-1 (p=0.18).  
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Table 3  Mean percentage change from baseline in bone biomarkers 
Biomarker Apremilast* (n=17) Placebo* (n=19) p value 
Serum RANKL, pmol/L -14.7±6.0 3.6±5.47 0.04
†
 
Serum OPG, pmol/L -2.01±4.4 -7.2±4.3 0.4 
RANKL:OPG -12.6±6.4 15.4±7.4 0.008
†
 
Serum DKK-1, pg/ml -11.7±11.1 8.1±9.7 0.18 
Plasma sclerostin, pg/ml -14.3±5.5 18.7±11.3 0.02 
Serum BAP, U/L 2.6±2.4 -6.5±5.1 0.12 
Serum osteocalcin, ng/ml 13.5±5.5 0.48±3.9 0.058 
Serum MMP3, ng/ml -0.08±5.9 7.5±8.4 0.92 
Serum TRAP5b, U/L 7.6±6.5 -2.7±6.3 0.26 
Serum CRP, mg/L 32.6±22.3 28.99±22.7 0.72 
ESR, mm/hr -2.32±8.75 7.34±10.12 0.25 
Serum IgA, mg/dl 0.69±3.0 1.1±2.6 0.91 
*Data are mean±SE (%). 
†
Excludes one outlier that had RANKL levels below recordable range at baseline. 
BAP, bone alkaline phosphatase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
MMP3, matrix metalloproteinase 3; OPG, osteoprotegrin; RANKL, human serum receptor activator of 
NF-κB ligand. 
 
In a post hoc analysis that classified treated patients as responders or non-responders, 
with response being defined as a decrease in BASDAI by > 1 unit, a statistically 
significant fall in sclerostin was only observed in the apremilast-treated responder 
population (Figure 2). 
 
There was a rise in osteocalcin levels in the apremilast group approaching statistical 
significance (p=0.058). There were no significant changes in CRP between treatment 
and placebo groups. At baseline, 8/17 apremilast patients had CRP >5.  Four of these 
patients exhibited decreases in CRP with rebound on stopping medication.  At 
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baseline, 8/19 placebo patients had CRP >5 of which all but two showed little change. 
Of these two, one patient demonstrated a rise in CRP from 5 to 17 corresponding to 
an increase in disease activity and the other showed an increase from 7.4 to 30 
corresponding to an upper respiratory tract infection. 
Safety data 
The incidence of adverse events was similar in the two treatment arms at 17/19 
(94.7%) in the apremilast and 18/19 (89.5%) in the placebo groups (Table 4). The 
majority (68.4%) of all adverse events were classified as “mild” and no serious 
adverse events were observed. Two apremilast patients withdrew from the study after 
two to three doses of medication. The first discontinued due to diarrhoea, which 
settled after stopping medication. The second patient developed poor concentration 
and felt dazed after three doses with resolution on discontinuing treatment. Compared 
with placebo, apremilast patients reported a higher incidence of headaches (26.3% vs 
42.1%) and loose stools (10.5% vs 26.3%). Two apremilast patients developed 
palpitations. One of these had sinus tachycardia and continued treatment with 
spontaneous resolution of symptoms. The other had frequent ventricular ectopics 
which resolved following medication withdrawal on study completion.  
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Table 4  Summary of treatment-emergent adverse events reported by two or more patients 
Coded term Placebo* (n=19) Apremilast* (n=19) 
Any 
severity Mild Moderate Severe Missing 
Any 
severity Mild Moderate Severe Missing 
Patients with AEs 17 (89.5) 13 (68.4) 3 (15.8) 0 1 (5.3) 18 (94.7) 13 (68.4) 4 (21.1) 0 1 (5.3) 
Headache 5 (26.3) 5 (26.3) 0 0 0 8 (42.1) 7 (36.8) 1 ( 5.3) 0 0 
URTI 6 (31.6) 6 (31.6) 0 0 0 6 (31.6) 5 (26.3) 0 0 1 (5.3) 
Loose stools 2 (10.5) 2 (10.5) 0 0 0 5 (26.3) 5 (26.3) 0 0 0 
Nausea 3 (15.8) 3 (15.8) 0 0 0 3 (15.8) 2 (10.5) 1 (5.3) 0 0 
Diarrhoea 2 (10.5) 2 (10.5) 0 0 0 2 (10.5) 1 (5.3) 1 (5.3) 0 0 
Flatulence 0 0 0 0 0 2 (10.5) 2 (10.5) 0 0 0 
Raised serum 
amylase 
0 0 0 0 0 2 (10.5) 2 (10.5) 0 0 0 
*Data are n (%) 
AEs, adverse events; URTI, upper respiratory tract infection. 
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DISCUSSION 
This exploratory pilot study is the first trial to investigate the effect of a PDE4 
inhibitor, apremilast in AS. Although the primary endpoint was not met, Bath indices 
showed trends towards responses over a 12 week treatment period. As expected, the 
improvements in BASDAI, BASFI, and BAS-G were more marked compared with 
the change in BASMI, which may have been due to higher baseline BASMI scores in 
the apremilast group, as well as BASMI scores being generally more resistant to 
change over short periods. It is noteworthy that the magnitude of reduction in disease 
activity continued to increase in sequential measurements over 12 weeks, suggesting 
that the maximal clinical response may not have been reached by that time point. 
Cessation of medication led to rapid loss of improvement in Bath indices. This 
observation may reflect patient bias. However, loss of response in apremilast-treated 
patients was of greater magnitude than placebo patients, suggesting a possible 
symptomatic benefit of apremilast and supporting the view that further studies are 
warranted in AS. Similarly, at 12 weeks the proportions of patients achieving 
ASAS20 (35% vs 16%) and ASAS40 (23.5 vs 5.3%), although greater in the 
apremilast group, were not statistically distinct from placebo.   
 
This study suggested that apremilast was well tolerated in the majority of patients. 
The apremilast dose titration regimen over the first 5 days of treatment was designed 
to optimise tolerability. Commonly observed adverse events were generally mild and 
consistent with those reported for other phosphodiesterase inhibitors and previous 
reports of apremilast,[25, 26] including nausea, diarrhoea/loose stools, and headaches. 
No severe or serious adverse events were reported. There was no significant increase 
in infection risk blood dyscrasias or abnormalities of liver function in the apremilast 
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group. Hence, from this small, short study, apremilast appears to have an acceptable 
safety profile although long-term studies will be required to better characterise this. 
 
Patients with AS may exhibit concurrent effects of bone resorption (eg, vertebral 
osteopenia) and formation (eg, ligamentous ossification). It is therefore interesting to 
note that our study suggests that apremilast may modulate certain biomarkers of bone 
biology. Most published reports have studied bone biomarkers in AS after at least 24 
weeks of treatment so we did not anticipate any statistically significant changes over 
the 12 weeks of our study. This was largely true, except for serum RANKL and 
plasma sclerostin both of which showed significant reduction with apremilast 
treatment. 
 
The binding of RANK to RANKL promotes osteoclast differentiation. RANKL 
inhibition in arthritis models inhibits bone erosion[27] and denosumab, an inhibitor of 
RANKL, has efficacy in osteoporosis.[28] In AS, the RANKL:OPG ratio is increased 
and associated with reduced bone mineral density and radiological findings of active 
inflammation.[29] Hence, successful treatment might be associated with a reduction 
in this ratio and this is in keeping with our findings. However, levels of TRAP5b, a 
marker of osteoclastic activity, did not show a corresponding fall in patients receiving 
apremilast. This might be related to changes in osteoblast and osteoclast populations. 
For example, PDE4 inhibition increases PGE2-induced cAMP production and 
RANKL mRNA expression in murine osteoblasts in a manner directly proportional to 
osteoclast formation in co-cultures of bone marrow cells and calvarial osteoblasts.[30] 
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Previous studies in AS reported low sclerostin levels to correlate with formation of 
new syndesmophytes over 2 years.[31] Further, a recent report suggests that serum 
sclerostin levels rise, but do not normalise, after 6 months of anti-TNF therapy.[32] It 
is not currently known whether low sclerostin expression in AS has a causal 
relationship to syndesmophyte formation or whether it is a response to it. In post-hoc 
analyses, we observed significant reductions in plasma sclerostin in patients 
responding to 12 weeks of apremilast. The clinical significance of this is uncertain. 
 
DKK-1 is an inhibitory molecule regulating the Wnt pathway which controls 
osteoblastogenesis. Blocking DKK-1 prevents inflammatory bone loss in hTNFtg 
mice by stimulating osteoblast function[33] but also promotes ankylosis of sacroiliac 
joints in the same model.[34] In AS patients, anti-TNF therapy is reported to increase 
levels of DKK-1 without evidence of increased Wnt signalling, suggesting that DKK-
1 is dysfunctional in AS.[34] In the present study, there was a trend towards DKK-1 
decrease on apremilast therapy. We also observed trends towards increases in 
osteocalcin and BAP in the apremilast group suggestive of osteoblastic activity, 
consistent with the changes observed in sclerostin and DDK-1 levels. However, the 
longer term correlates of these findings are uncertain with respect to bone density or 
syndesmophyte development. Larger, long-term studies with apremilast measuring 
both bone density and imaging progression would be required to answer this question. 
 
This pilot study has several limitations. Most notably it was likely underpowered to 
detect a significant benefit of apremilast in AS patients because no information on an 
effect size was available to aid in the study design. While the randomization process 
included one unblinded pharmacist, this individual did not disclose any information to 
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investigators or patients, making bias unlikely. The long disease duration (~ 20 years) 
of enrolled patients may have diminished the possibility to demonstrate symptomatic 
improvement. Nonetheless, all subjects had symptomatically active AS and evidence 
of disease activity on MRI. A further limitation was the short treatment duration 
which may not have permitted the maximum therapeutic effect of apremilast to be 
reached, a suggestion consistent with the incremental improvements in BASDAI and 
BASFI during the treatment period. The relatively short nature of our study, together 
with the differential and largely unknown long-term effects of certain bone 
biomarkers, makes interpretation of the observed biomarker changes difficult. Any 
conclusions on the impact of these changes in bone biomarkers should therefore be 
made with extreme caution and further longer term studies with appropriate endpoints 
are required to fully understand their clinical implications. 
 
To summarize, although a small pilot study, these data suggest that apremilast may be 
effective in AS. Given the current lack of effective oral DMARDs in AS, our findings 
support the conduct of a suitably powered study of longer duration to further 
investigate the role apremilast in axial inflammation and the management of AS.  
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Figure Legends 
 
Figure 1. Mean absolute change in BASDAI over 12 weeks in AS patients 
receiving apremilast (n=17) or placebo (n=19). 
 
Figure 2. Study patients were classified as responders or non-responders with 
response being defined as a decrease in BASDAI by at least 1 unit. Individual 
patient change in plasma sclerostin levels over 12 weeks is depicted depending on 
BASDAI response. A statistically significant fall in sclerostin was only observed 
in the apremilast-treated responder population. 
 
 
 
 
 
 
